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ABSTRACT 
Abstract 
The dramatic rise in the incidence of allergic/asthmatic disorders in the past three 
decades has placed a major socio-economic burden on global health care. Exocytosis 
of mediators causing allergic responses follows the binding, and subsequent receptor 
cross-linking by cognate allergen of immunoglobulin (lg) E antibodies to Fe-receptors 
(FcERI), expressed predominantly on mast cells and basophils. 
Fe-receptors have an invariant predominantly hydrophobic ammo acid motif 
(LFAVDTGL) in their transmembrane (TM) domain but contain a hydrophilic 
aspartic acid residue (D194). The function of this potentially energetically unstable 
residue in the TM of the human (hu) Fci,Rla subunit was targeted by transfecting the 
Rat Basophilic Cell line (RBL-2H3.1) with cDNA constructs encoding the gene for 
native and mutant huFcERia subunits and assessing receptor expression and signalling 
events. RBL-2H3 transfected with cDNA constructs encoding a medium-sized polar 
residue hufci,Rla (D194T) demonstrated the formation of a functional rat/human 
chimeric receptor complex which, when activated via hulgE and antigen, supports 
mediator release, intracellular calcium mobilisation and tyrosine phosphorylation of y-
chain and Syk kinase. Transfection with mutant huFci,Rla subunit cDNA constructs 
encoding non-polar Ile (D1941) and V (D194V), larger sized polar Arg (D194R), 
smaller sized polar Ser (D194S) and non-polar Ala (D194A) abrogated surface 
expression of huFcERia and degranulation. An established RBL y-chain deficient cell 
line served as a model for assessing a- and y-chains interactions through the effect of 
mutations introduced into the y-chain. Compared to parental RBL-2H3 cells, the RBL 
y-chain deficient cells supported reduced levels of FcERI expression and mediator 
release. Transfection of RBL y-chain deficient cells with wild-type and mutant (T22A 
and T22S) y-chain cDNA constructs restored FctRI expression to levels observed in 
the parental cell line, but only partially restored mediator release, indicating a 
defective secretory response. 
Collectively this study identifies D194 in FctRia as a potential target for developing 
future anti-allergic drugs that act by inhibiting the FctRI signalling cascade. 
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1.1: The Allergy "Epidemic" 
INTRODUCTION 
Type I hypersensitivity or immunoglobulin (lg) E-mediated allergy is a broad term 
describing undesirable immune responses that follows the encounter with seemingly 
non-pathogenic antigens referred to as allergens. The first historical reference to an 
allergic response dates to 2640B.C and depicts, on a pylon in Luxor, Egypt, the death 
of a Pharaoh from an anaphylactic shock following a bee sting 
[http://www.slideshare.net/inemet/anaphylactic-reactions]. Immunoglobulin E and 
mast cells/basophils are now recognised key players in the allergic response 
(Williams and Galli, 2000). Immune response of the IgE isotype play an important 
role in the response to and elimination of parasites from intestines of the host, a 
function that has been authenticated by various studies in which it has been 
demonstrated that chronic/heavy helminthic infestation, characterised by high levels 
of parasite specific IgE, protects against allergy (Yazdanbakhsh and Matricardi, 
2004). The Viennese paediatrician Clemens von Pirquet in 1906 coined the term 
allergy from the Greek words a//os meaning other and ergon meaning work after he 
noticed the fact that some of his patients were sensitive to apparently innocuous 
entities like dust, pollen and certain foods while the term anaphylaxis was first used 
by Portier and Richard in 1902 to explain an unexpected effect that occurred during 
immunization of dogs. 
The various ailments associated with allergyare atopic dermatitis, urticaria, allergic 
rhinitis, asthma and the potentially fatal condition of anaphylaxis (Corry and 
Kheradmand, 1999). The incidence of allergic diseases is on the · rise globally 
(Pawankar et al., 2008) specially in industrialized countries where 10-30% of the 
population suffer from diverse allergic symptoms (ISAAC Committee, 1998, Sole et 
al., 2001) The rise .has been rapid and started between l 960~ 1970 with an ongoing 
increase witnessed in the 1980s and 90s to levels that have attained almost epidemic 
proportions such that allergic diseases are being labelled as the epidetnic of the 21 st 
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century (lsolauri et al.. 2004). The increase witnessed in westernized societies is in the 
range of 75-100% in cases of asthma (Mannino et al.. 2002) and 150% in atopic 
diseases (Wichmann, 1996). Similar trends are now being observed in the most 
populous continent Asia that is home to fast emerging economies. According to recent 
epidemiological data by ISAAC III (International Study of the Asthma and Allergies 
in Childhood) the incidence of Asthma and allergic rhinitis is also on the rise in low 
and middle income countries (Bjorksten et al., 2008) with incidence for asthma 
increasing from 0.8% to 29% and for allergic rhinitis from 5% to 45% of the 
population in many Asian countries (Pawankar et al., 2008). 
The pathology of allergic diseases is not fully understood but it is believed that both 
genetic and environmental factors have a role to play (Gould et al.. 2003). Genetic 
predisposition is believed to contribute at least to half of the susceptibility to asthma 
(Duffy et al., 1990). The list of allergens includes house dust mite and cockroach 
emanations, pollens, and fungal spores (Machado et al., 1996, Helm et al., 2000). 
Food hypersensitivities which have been documented include cow milk, egg, peanut. 
soya, wheat. shellfish, tree nuts and fish (Sampson, 1999, Sampson, 2004). Allergic 
reaction to latex components now commonly referred to as the 'latex-fruit' syndrome 
are directed against a conserved chitin binding domain in plant host defense proteins 
with diverse enzymatic functions referred to as the hevein symphony. This immune 
response represents a major problem for health professionals, patients and members of 
the general public using latex products (Toraason et al., 2000, Agarwal and 
Gawkrodger, 2002, Pilon and Radman, 2006). 
Most of these environmental allergens have been present for millennia and current 
allergy epidemic even in industrialised countries with genetically stable pool such as 
Japan point to the fact that changes in environmental factors are probably responsible 
for the current epidemic (Cookson and Moffatt, 1997). Diesel exhaust particles 
(DEPs) enhance the production of pro-allergenic cytokines from cells present in nasal 
mucosa and have been held accountable for the increase in airway allergic diseases 
(Diaz-Sanchez et al., 1996). Chronic respiratory diseases are highly prevalent in 
workers who are in employment in motor garages where they are exposed to motor 
vehicle exhaust emission and diesel engine exhausts (Bener et al., 1998). Many 
components in environmental tobacco smoke [ETS] are chemically similar to DEP, 
and have been shown to stimulate ongoing lgE synthesis (Smyth et al., 2000). These 
3 
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chemicals are also implicated in increased airway hypersensitivity and sensitisation to 
common aero-allergens in young children and held accountable for the increased 
incidence in allergy and respiratory symptoms (Magnusson and Johansson, 1986, 
Andrae et al., 1988). 
Reunification of Germany provided a case study of the impact of life style on allergic 
diseases. A study carried out by von Mutius et al (1998) indicated a significant rise in 
the incidence of hay fever amongst children in East Germany who, following the 
reunification of the country adapted to a more Westernized way of life. Likewise 
obesity, a major and ever growing problem in children of industrialized countries, is 
positively linked with the onset of adult-onset asthma (Camargo et al., 1999). The 
"Hygiene Hypothesis" that has been much quoted as a probable cause of increased 
incidence in allergic diseases in affiuent Western societies was originally presented by 
epidemiologist Dr Strachan (1989). The hypothesis stated that there is an inverse 
relationship between family size and allergic diseases (Strachan, 1989). Strachan 
proposed that the increase in atopic disorders might be due to a decreased occurrence 
in early infancy of infections that are commonly transmitted through contact with 
elder siblings. A consensus about this concept is now evolving and it is postulated that 
elementary changes in life style have deprived human beings from developing 
immunoregulatory mechanisms brought about by exposure to certain micro-organisms 
and viral infections thus contributing to increase in the prevalence of allergic diseases 
in the last few decades (Pawankar et al., 2008). 
1.2: Immune System: An Overview 
Immunity is the universal potential of the host to recognize and fight with the aim of 
eliminating the predatory microbes, which are pathogenic to it and, if allowed to live, 
will produce noxious effects on the body. It involves both molecular and cellular 
agents acting in cohesion and involves the coordinated interaction between 
components of the innate and adaptive immune systems. 
Broadly defined, the immune system depends on a combination of the non-specific 
but immediate acting force of innate system and the more target oriented slowly 
responding system of the acquired/adaptive immune system with an extent of overlap 
4 
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present (Basset et al., 2003). The Toll-like receptors (TLRs) expressed by antigen-
presenting cells and mast cells recognize and differentiate self from pathogens and 
bring about the commencement and subsequent steering of adaptive immune 
responses (Orinska et al., 2005, Kaisho and Alcira, 2006). The microbes in their bid to 
gain entry to the body face first resistance in the shape of skin and mucosal membrane 
lining the gastrointestinal, respiratory and urogenital tract, which in addition to acting 
as a physical barrier to the microbes in the external environment, harbour mast cells at 
a position where they are ideally placed to combat any incoming pathogens (Kitamura 
et al., 1977, Metcalfe et al., 1997). The mast cells are thus not only on the interface of 
external and internal environment but form a bridge between both the innate and 
adaptive immunity due to their established place as a component of the innate system. 
At the same time, due to the expression of Fe receptors they mediate responses to 
immunoglobulins, and as a result mediate allergic sensitization. The origin of allergy 
may be found at this interface and better comprehension of the complex mechanisms 
related to the role of mast cells in the immune system may lead to developing more 
efficient intervention strategies to combat the growing menace of allergic diseases. 
1.2.1: The Innate System 
The innate system is comprised of mechanical, chemical and cellular elements. The 
mechanical component includes the physical barrier of intact epidermis and mucosa 
and associated physiological roles such as cilial motility, desquamation and mucus 
secretion (Basset et al., 2003). The initial and all important task of recognising the 
pathogen is carried out by cell surface expressed pathogen recognising receptors 
(PRRs), found on the surface of many cells including epithelial cells, 
macrophages/monocytes, granulocytes, mast cells and dendiritic cells, that identify a 
wide array of pathogen associated molecular patterns (PAMPs) (Janeway and 
Medzhitov, 2002). The PAMPs recognition, which include lipopolysaccharide (LPS), 
peptidoglycan, lipoproteins and oligosaccharides, leads to activation of the 
inflammatory response to a wide variety of the pathogenic stimuli (Iwasaki and 
Medzhitov, 2004). The chemical mediators involved in the innate system can be sub-
grouped into pattern recognition molecules, the proteins and peptides that eradicate 
the micro-organisms and last but not the least depend on cytokines and chemokines 
generated following activation of innate immune responses that have a crucial 
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regulatory role in the steering of adaptive immunity (Hedges et al., 1995, Machado et 
al., 1996, Pitman and Blumberg, 2000, Janeway and Medzhitov, 2002, Wynn, 2009). 
Mast cells, dendiritic cells, NK cells, macrophages and epithelial cells all play a role 
in the innate system (Basset et al., 2003). 
1.2.2: The Adaptive System 
Adaptive immunity. also known as acquired immunity is more specialised than the 
innate system and builds on the work already performed by its more primitive 
counterpart. As the name implies a person has to have had a previous exposure to the 
agent to be able to mount a response against it. The initial encounter with the allergen 
(immunization) brings about a complex and intricate chain of events leading to 
production of antibodies by lymhocytes (Owen. 2007). Any subsequent exposure to 
the same antigen then makes the host capable of combating and eradicating the 
pathogen through the presence of immunological memory. The adaptive system is 
very specific and target oriented as it possesses the sel£'non-self recognition 
mechanism through the expression of T cell receptor (TCR). B cell receptor (BCR) 
and Major-histocompatability complexes (MHC) making it a very well organized 
immune system (Hoebe et al., 2004). The activated T helper cells (Th), through the 
effects of secreted cytokines and by the binding of CD40 on B cells to CD40 ligand 
on T cells, promote the production of immunoglobulins by the B cells (Owen, 2007). 
There are subsets of Th cells. Thl and Th2, derived from Th0, depending on the 
cytokines secreted and the target organisms (Gould et al.. 2003). Thl cells secrete IL-
2 and interferon -y in response to challenge by bacteria and viruses, while Th2 cells 
secrete IL-4, IL-5, IL-6 and IL-10 when challenged by helminth and allergen 
(Finkelman et al., 1997, Romagnani, 2001). It is Th2 phenotype cells which are 
responsible for isotype switching ofB cells to lgE production which is brought about 
by cytokines IL-4. IL-13 via signals through CD40 and CD21 (Gauchat et al., 1993, 
Jeppson et al., 1998). It is interesting to note in this context that activated mast cells 
express a similar cytokine pattern to Th2 cells and via the expression of CD40L have, 
in theory, the capability to induce class-switching to the lgE isotype (Machado et al., 
1996). Another subset T regulatory cell (Treg) mediate self-tolerance and prevent 
autoimmune diseases (Steinke and Borish, 2006). 
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1.2.3: The Immune Cells 
Dendiritic Cells 
The dendiritic cells are antigen-presenting cells, arising from the bone marrow, and 
are generally considered to be the link between innate and acquired immunity due to 
their property of presenting antigens in the tissues and then circulating to regional 
lymph nodes where they mature (Banchereau and Steinman, 1998, Zitvogel, 2002). 
These cells initiate the immune response, have PRRs on their surface that recognise 
P AMPs, and are widely distributed in both lymphoid and non-lymphoid tissues 
making them ideally located to be at the interface of the host and environment to 
perform their role (Janeway and Medzhitov, 2002). 
NK cells 
These cells are also part of the innate system and are derived from the lymphoid cell 
line. They also have an immunomodulatory role as they activate macrophages by 
releasing TNFa and IFN-y and are responsible for killing virally infected and tumour 
cells during cell-to-cell contact by releasing perforin and granzyme (Middleton et al., 
2002). 
The Phagocytic Cells-Neutrophils and Macrophages 
These are effector cells of the innate immunity that destroy the invading pathogens 
before they can carry out their deleterious effects, but these cells also initiate the 
adaptive response by presenting the antigens to T-cells. The first cells to come into 
action are the resident macrophages but they are rapidly joined by the circulating 
neutrophils if the need arises (Zhang et al., 2000). Macrophages and neutrophils 
possess several PRRs that make possible the recognition through direct and indirect 
means of the opsonised micro-organisms (Janeway and Medzhitov, 2002). The 
invading pathogen is then internalised in a phagosome, which fuses with endosomes 
and lysosomes to form phagolysosome leading to killing of micro-organism by using 
oxidative and non-oxidative mechanisms (Burg and Pillinger, 2001). The recruitment 
of the neutrophils to the damaged tissue is brought about through the chemotactic 
action of cytokines such as IL-113, TNF-a, G-CSF, and chemokines such as fMLP and 
LPS and substances from the damaged tissue (Philpott et al., 2001). The neutrophils 
seem to have an immunoregulatory role characterised by the release of certain 
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chemokines, as well as the release of substantial amounts of TNF and IL-I (Chaplin, 
2003). 
1.3: An Overview of Allergic Response 
The symptoms of immediate hypersensitivity are caused by the release of preformed 
and newly synthesized mediators that are released from mast cells and basophils in 
response to a variety of stimuli (Blank and Rivera, 2004). The best characterized 
event involves the sensitization of mast cells and basophils by lgE binding to high-
affinity lgE receptors; subsequent cell activation follows encounter with cognate 
allergen representing currently the best defined route leading to the regulated 
secretion of the pharmacologically active mediators responsible for the symptoms of 
class I hypersensitivity responses (Nadler et al., 2000). It is however known that mast 
cells and basophils can be activated by a number of diverse mechanisms, including 
initial exposure to enzymatically active allergens, which induce the secretion of 
diverse mediators, including IL-4/13; the importance of these processes is only 
beginning to emerge. It still remains to be demonstrated if this is in fact the first in a 
series of steps leading to the synthesis of antibodies of the IgE isotype, although it is 
generally accepted that mast cells and basophils express similar ligands and cytokine 
to Th2 cells known to steer B-cells responses to class-switching to the lgE isotype 
(Dudler et al., 1995, Machado et al., 1996). 
The sequence of events involved in the allergy mechanism involves a complex 
interaction of cells and chemicals. Although the list of allergens is long and varied 
the commonly encountered allergens are pollen grains, house dust mite, cockroach 
emanations, mould spores, latex, soya and nuts (Machado et al., 1996, Helm et al., 
2000). The current generally accepted mechanism proposes that after exposure these 
allergens on entry into the body come in contact with the APCs such as basophils and 
DCs at the mucosa! surfaces (Zitvogel, 2002, Wynn, 2009). The antigenic region of 
these allergens in association with the MHC class II are presented on the cell surface 
after being internalised and processed by the DCs. The presented peptides then bind 
to narve T cells in the lymph nodes leading to Th2-differentiation (Owen, 2007). This 
brings about release of characteristic Th2 cytokines, IL-4, IL-13 causing B cell IgE 
class switching and secretion of antigen-specific IgE into the circulatory system 
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(Platts-Mills, 2001). IgE leaves the circulation and significant amount bind to the high 
affinity IgE receptors (FcsRI) present on the surface of mast cells, basophils, 
eosinophils and other effector cells (Wang et al., 1992, Maurer et al., 1994, Gounni et 
al., 1994, Kinet, 1999). Following this initial priming/sensitisation phase any 
subsequent exposure to allergens causes cross-linking of adjacent FcsRI receptors 
present on the surface of mast cells which initiates a downstream signalling cascade 
culminating in mast cell degranulation causing the rapid exocytosis of pre-formed and 
stored mediators present in the mast cells granules (Theoharides et al., 2007). This is 
labeled as the acute phase of the allergy and is characterised by symptoms such as 
sneezing, coughing, wheezing, itching and tissue swelling that are brought about by 
action of mediators like histamine on tissues, which causes increased vascular 
permeability and smooth-muscle contraction (Galli et al., 1999, Wedemeyer and 
Galli, 2000, Gould et al., 2003). The acute phase is followed by the late-phase that 
occurs 4-6 hours after the initial response and is brought about by other effector cells 
including neutrophils, eosinophils, macrophages, lymphocytes and basophils and may 
last for 1-2 days (Kay et al., 1997, Williams and Galli, 2000). An overview of the 
allergic response is shown in the figure 1.1. 
1.4: Mast Cells 
There is much evidence for the role of mast cells in allergy and asthma (Bradding et 
al., 2006) along with their role in different disease and immunological functions such 
as tissue remodeling, wound healing, pathological fibrosis, arthritis, angiogenesis and 
body response to neoplasia (Benoist and Mathis, 2002). Mast cells were initially 
described by Paul Ehrlich in 1878 as a type of granular cell of the connective tissue 
and the name "Mastzellen" was coined (Riley, 1954). The initial focus of the research 
was on the intracellular granules of mast cells containing histamine (Riley and West, 
19S2, Riley, 1954) and the first role of mast cells to come into attention was their 
involvement with the potentially fatal condition of anaphylaxis (Keller, 1962). Mast 
cells play a prominent role in allergy (Williams and Galli, 2000) and express high 
affinity immunoglobulin (lgE) receptors on their cell surface (Metzger, 1992, Turner 
and Kinet, 1999). It is now established that mast cells are the prime effector cells 
involved in host defence mechanisms against parasitic worms, bacteria and 
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intracellular protozoan parasites by acting in synergy with imrnunoglobulin E 
(Watanabe et al., 1994, Maurer et al., 1998, Marshall, 2004) and are of utmost 
importance to host defence and survival during and after a bacterial infection 
(Echtenacher et al., 1996, Malaviya et al., 1996). Mast cells arise from CD34+ 
pluripotent stem cells in the bone marrow (Nabel et al., 1981) and are not a 
component of the connective tissue as was initially believed (Kitamura et al., 1977). 
They circulate in the blood in immature form and finally reside in the tissues where 
they mature under the influence of stem cell factor (SCF) and their numbers are 
regulated by concentrations of local cytokines like IL-4, IL-6, IL-9, IL-10 and TNF 
(Padawer, 1974). IL-3 is known to stimulate the proliferation and differentiation of 
mast cells (Lantz et al., 1998). 
1.4.1: Mast Cells Activation 
Antigen-mediated aggregation of the lgE bound to its high -affinity receptor on mast 
cells and basophils initiates a downstream signalling cascade leading to exocytosis of 
the preformed and denovo synthesised mediators (Siraganian, 2003). Mediator release 
is influenced by cytokines, growth factors and microenvironmental conditions. IL-4 is 
believed to enhance FceRI-mediated reactions from human mast cells (Bischoff et al., 
1999).The aggregation of FceRI receptors causes phosphorylation, usually by Lyn 
(Siraganian, 2003), of tyrosine residues in imrnunoreceptor tyrosine- based activation 
motif (ITAM) of both the p and the 'Y subunits of FceRI (Reischl et al., 1999, Rivera, 
2002, Siraganian, 2003, Galli et al., 2005). The tyrosine phosphorylated IT AMs then 
act as scaffolds for the binding of the additional signaling molecules with Src 
homology domain 2 (SH2) like the cytoplasmic protein tyrosine kinase Syk, which 
binds mainly to the 'Y subunit of the receptor through its two SH2 domains bringing 
about conformational change of Syk leading to its activation and autophosphorylation 
(Costello et al., 1996, Zhang et al., 1996). The activated Syk kinase through direct or 
indirect means phosphorylates several proteins, including linker for activation of T 
cells (LAT) (Saitoh et al., 2000), SH2 containing leukocyte-specific protein (SLP-76), 
Vav, phospholipase C-yl (PLC-yl) and PLC-y2 (Blank and Rivera, 2004). 
The mast cells and basophils on being sensitised by lgE produced by B cells, release a 
wide array of mediators. These mediators are responsible for immediate 
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hypersensitivity causing acute phase symptoms. Another protein tyrosine kinase, Fyn, 
is also constitutively bound to the ~ chain and following the receptor aggregation 
causes tyrosine phosphorylation of Grb2-associated binder like protein 2 (Gab2), 
which then binds the p85 subunit of phosphatidylinositol 3-kinase (PDK) 
(Parravicini et al., 2002). The PDK then catalyses the conversion of 
phosphatidylinosito-4, 5-biphosphate (PIP2) to phosphatidylinosito-3, 4, 5-
triphosphate (PIP3). The PIP3 in the membrane attracts to the membrane many proteins 
containing pleckstrin homology (PH) domains like BtK, PLC-yl, PLC-y2 and 
phosphoinostide-dependent protein kinase! (Siraganian, 2003). The tyrosine 
phosphorylated PLC-yl and PLC-y2 catalyse the hydrolysis of PIP2 resulting in the 
generation of inositol-1, 4,5-triphosphate (IP3) and 1, 2-diacylglycerol, these second 
messengers then bring about release of Ca+2 from internal stores by binding ofIP3 to 
specific intracellular receptors (Smith et al., 2001) and activation of protein kinase C 
(PKC) respectively. After the initial rise of Ca +2 there is depletion of the Ca +2 stores 
which necessitates the need for entry from the extracellular medium which is brought 
about by activation of calcium release activated channels (CRACS also known as 
store operated Ca channels; SOCCs) on the plasma membranes that allow the 
response to be maintained (Scharenberg and Kinet, 1998). In order to produce signals 
for a sustained Ca+2 influx the tyrosine phosphorylation and activation of Bruton's 
tyrosine kinase (BtK), SLP-76, LAT and PLC-y are mandatory (Siraganian, 2003). 
These early events are followed subsequently by activation of other enzymes and 
adaptors including Vav, She, Grb2 and SOS, which in turn stimulate small GTPases 
such as Rae, Ras and Rho. These pathways lead to activation of the extracellular-
signal-regulated kinase (ERK), Jun amino-terminal kinase (JNK) and p38 mitogen-
activated protein (MAP) kinase pathways, histamine release, phosphorylation of 
transcription factors that induce the synthesis of new cytokines, and activation of 
phospholipase A2 (cPLA2) to release arachidonic acid (Siraganian, 2003). 
lgE-independent activation can take place through complement receptors or the Toll-
like receptor (TLR) and mast cells activators include SCF, complement factors (C3a, 
C5a), neuropeptides (substance P), adenosine, TLR and scavenger receptors (Dawicki 
and Marshall, 2007, Brown et al., 2008). A simplified diagrammatic representation of 
mast cell signalling via FceRI is given in figure 1. 2. 
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The mast cells and basophils on being sensitised by IgE, produced by B cells, release 
a wide array of mediators. These mediators are responsible for immediate 
hypersensitivity causing acute phase symptoms (Adapted from Cain, 1997). 
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Figure 1.2: FctRI Mediated Signalling Pathways in Mast Cells 
A simplified diagrammatic representation of mast cell signalling via FceRI. The 
cross-linking of the high affinity IgE receptor crosslinking in response to appropriate 
antigenic stimuli initiates a downstream signalling cascade. The aggregation of Fe&RI 
receptors cause phosphorylation, usually by Lyn, of the tyrosine residues in 
immunoreceptor tyrosine- based activation motif (IT AM) of both the f3 and the y 
subunits of FceRI. This is followed by recruitment and activation of Syk kinaset 
multiple adaptor proteins are activated leading to mast cell degranulation, cytokine 
Production and arachidonic acid production (Adapted from Siraganian, 2003). 
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1.4.2: Mast Cell Degranulation 
The fundamental step involved in mast cell response in both innate and acquired 
immunity is the exocytosis of the contents of its mediators in response to stimulants 
(Blank and Rivera, 2004). The various symptoms of the atopic phenomena are elicited 
by the profound quantities of the vesicular contents released in a single stimulatory 
episode by a process of compound or regulated exocytosis (where the membranes of 
secretory granules fuse with each other and the plasma membrane) to ensure a 
maximal biological response which is contrary to what is seen in some other secretory 
cells (Blank and Rivera, 2004). Mast cells produce a variety of intra and extra-cellular 
mediators that are produced in response to different stimuli, and they are able to 
control the kind and the strength of response (Theoharides et al., 2007). Mast cells 
secretory mediators have key functions and can be divided into three groups 
(Williams and Galli, 2000) 
1) Preformed substances 
2) Newly synthesized metabolites 
3) Chemokines or Cytokines 
Preformed mediators include a biologic amine, typically histamine, proteoglycans, 
heparin and a wide variety of proteases such as tryptase and chymase (Stevens and 
Austen, 1989, Huang et al., 1998). Newly generated mediators typically produced 
during IgE-mediated activation include arachidonic acid metabolites, principally 
leukotriene C4 (LTC4), leukotrine B4 (LTB4) and prostaglandin D2 (PGD2) 
(Murakami et al., 1995) along with platelet-activating factor (Longphre et al., 1996). 
The leukotrines and prostglandins are responsible for bronchoconstriction and 
vasodilatation in addition to recruiting neutrophils and activating eosinophils 
(Henderson et al., 1996, Rothenberg et al., 1999). Most allergens stimulate mast cells 
degranulation through cross-linking of the lgE sensitised receptors. The local and 
systemic consequences of mast cell degranulation produce the pleiotropic effects 
associated with the diverse allergic manifestations (Costa et al., 1997). Furthermore 
they also regulate the allergic responses thus indicating an immuoregulatory role in 
addition to its effector cell role (Williams and Galli, 2000). 
14 
CHAPTER1 INTRODUCTION 
The wide spectrum of diverse pro-inflammatory mediators released from IgE-
activated target also plays an important role in the up-regulation of MHC class II and 
FceRI molecules and the potential enhancement of lgE synthesis (Williams and Galli, 
2000) by a feedback mechanism that amplifies the response to allergen. The 
chemotactic effect of mast cells mediators in the recruitment of inflammatory cells 
like eosinophils, monocytes, neutrophils and platelets is a hallmark of the late phase 
response, which occurs some 6-12 h after mast cell degranulation (Helm, 1994). 
1.5: Immunoglobulins 
There are nine antibody classes (isotypes) in humans: IgM, IgD, IgGl, IgG2, IgG3, 
IgG4, IgAl, IgA2 and IgE all having similar structure consisting of heavy (H) and 
light (L) chains with variable (V) and constant (C) regions made up of lg domains 
(Gould et al., 2003). H-chains in lgA, lgD and IgG have 3 CH domains each while in 
IgM and IgE there are 4. A pair of identical antigen-binding sites is present in the V 
regions of the L- and H-chains. The Fab region of the antibody is made up of these 
together with the adjacent CH domain pair (Gould et al., 2003). The Fe region, which 
contains the FcR binding sites, of the antibody is comprised of the pair of remaining 
lg domains. 
1.5.1: Immunoglobulin E, IgE 
The discovery of a new antibody isotype called IgE was reported in 1967 by Ishizaka 
and Ishizaka (lshizaka and Ishizaka, 1967). lmmunoglobulin E plays a key role in the 
early-phase allergic inflammation response but may also have a part to play in the 
late-phase allergic response (Williams and Galli, 2000) besides being involved in 
immune response to parasitic infections (Y azdanbakhsh et al., 2001, Maize ls and 
Y azdanbakhsh, 2003). A direct correlation between serum IgE levels and asthma has 
been established (Burrows et al., 1989; Sunyer et al., 1995). Plasma cells in the 
mucosa-associated lymphoid tissue are responsible for the production of IgE (Geha et 
al, 2003). In humans the level of serum IgE is the lowest of all antibodies and is in the 
range of~ 150ng/ml (King et al., 1991 ). The lgG has three heavy chain domains while 
IgE molecule is composed of 4 constant heavy chain domains (Cd - Ce4) and 1 
variable heavy chain domain with the additional domain CE:2 replacing the hinge 
region (Gould et al., 2003). 
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1.6: The High Affinity IgE Receptor, FctRI 
The largest class of Fe receptors belongs to the immunoglobulin superfamily and 
includes IgG specific FcyRI, FcyRII and FcyRIII receptors and lgE specific FcERI 
receptor (Kinet, 1999). FcERI has the highest affinity of all immunoglobulin receptors 
with a binding constant in the 10-9 to 10-10 M range for its ligand, IgE (Daeron, 1997). It 
exists as a tetramer on the surface of human mast cells and basophils consisting of a a-
chain, a P-chain and a disulphide-linked dimer of y-chains, while on Langerhans cells, 
dendritic cells and monocytes the FcERI is present as a trimer and is devoid of the P-
chain and has only one a-chain and two y-chains (Turner and Kinet, 1999). However in 
rodents its expression is limited to the surface of mast cells and basophils and only the 
tetrameric isoform is present (Kinet, 1999). The two isoforms of FcERI are shown in 
figure 1.3. 
FceRI FceRI 
y y y y 
A. B. 
Figure 1.3: Isoforms of FcERI 
The two isoforms of FcERI. The tetramer (aJ3yy) shown in A and trimer (ayy) shown in 
B (adapted from Gould et al., 2003). 
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1.6.1: The Ligand -binding Subunit- FcERla 
The a-chain crosses the cell membrane with a single putative helical segment. The 
extracellular domain of the a-chain binds IgE with high affinity (Hakimi et al., 1990, 
Blank et al., 1991, Ra et al., 1993).The a-chain is comprised of two extracellular 
immunoglobulin-related domains, one transmembrane domain and a short cytoplasmic 
tail (Kinet et al., 1987, Kochan et al., 1988, Shimizu et al., 1988, Ra et al., 1989). The a-
chain is heavily glycosylated and appears as a heterogenous band centered around the 
45-kDa marker when resolved by standard SOS-PAGE; however the weight of the a-
chain protein core is 27kDa (Kinet, 1999). The a-chain has seven N-linked 
glycosylation sites which are thought to interact in the ER with the ER folding machine 
(Letourneur et al., 1995b ); however as part of the ER quality control mechanism these 
glycosylation moieties are trimmed before the subunit can be exported from the ER, 
failing which the receptor may be retained within the ER (Albrecht et al., 2000). 
Another system to differentiate between assembled and non-assembled receptors in the 
ER is the presence of a dilysine ER retention signal in the cytoplasmic domain of the 
FcrRia subunit the steric masking of which is done by the cytoplasmic domain of the 
FcRy subunit to ensure the exportation of the assembled receptor to th~ cell surface from 
the ER (Letourneur et al., 1995a). The human FcrRia subunit has a considerable 
homology with human FcyRIII (Ravetch and Kinet, 1991). 
1.6.2: The Signal Amplifying Subunit- FcRp 
The FcRP. is alsp found as a subunit of the low affinity IgG receptor (FcyRIII) 
(Kurosaki et al., 1992). The P-chain has been computed to span the cell membrane 4 
times and it has been proposed that this subunit amplifies the signal transduction 
tenfolds (Lin et al., 1996, Dombrowicz et al., 1998, Donnadieu et al., 2000a) but is 
not mandatory for a functional receptor complex (Scharenberg and Kinet, 1997, 
Kinet, 1999). FcrRIP. also enhances the cell surface expression bY. early association 
with th~ FcrRI~ subunit during the process of receptor assembly thus ensuring better 
receptor exportation and maturation (Donnadieu et al., 2000b ). This second 
amplification effect when added upon the first amplification make the downstream 
signalling events 12-30 fold greater in tetrameric FceRI. comple?{es compared to the 
trimeric FctRI receptor. The P-chain, like the y-chain has intracellular tyrosine 
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activation motifs (ITAMs) that are phosphorylated immediately following receptor 
cross-linking (Romeo et al., 1992, Samelson and Klausner, 1992, Cambier, 1995, 
Pawson, 1995) and play a pivotal role in activation of downstream signaling from the 
receptor complex which culminates in the exocytic release of the mediators of the 
allergic response. 
1.6.3: The Signal Transducing Subunit- FcRy 
FcR1. is found as a homo and hetro-dimer in association with a number of receptors 
including FccxRI, FceRI, FcyRI (Ernst et al., 1993), FcyRIII, and T-cell receptor 
(TCR) (Orloff et al., 1990). They-chain is an integral membrane protein consisting of 
a short 5 amino acid extracellular domain, a 21 amino acid transmembrane domain 
and a 42 amino acid cytoplasmic domain (Kuster et al., 1990). y-chains have 
intracellular tyrosine activation motifs (ITAMs), which is important in initiating the 
downstream signaling (Romeo et al., 1992, Samelson and Klausner, 1992, Cambier, 
1995, Pawson, 1995) . FcRy_ exists as a disulphide linked dimer with a disulphide 
bond between the cystine residues at the N-terminus region (Varin-Blank and 
Metzger, 1990). It belongs to the same family of molecules as the t.; and T) chains of 
the TCR complex. It has been shown that FcRy an9 ~ chain ofTCR in their capability 
to mediate T cell development and function are interchangeable although the native 
TCR~ subunit is far more efficient (Shores et al., 1997). 
1.6.4: Interaction of IgE with FcERI 
Immunoglobulin E in the body is found mostly bound to FceRI (Geha et al., 2003) and 
the half-life of FceRI bound lgE has been measured to be about 14 days in the skin 
(Tada et al., 1975, Hunt et al., 2005). lgE remains bound to FceRI even in the absence of 
antigens; thus the receptor adopts the antigenic specificity of the prevalent lgE repertoire 
(Gannan et al., 2000). The lgE- FceRI interaction exhibits a 1: 1 stoichiometry (Garman 
et al., 2000). It has been found that monomeric lgE can stimulate mast cell survival 
through signalling pathways distinct from those initiated by receptor cross-linking (Asai 
et al., 2001). In vitro experiments with monomeric lgE and bone-marrow derived mast 
cells have demonstrated that a decrease in the concentration of both free and FctRI -
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bound IgE might lead to a decrease in the mast cell numbers (Kalesnikoff et al., 2001, 
Asai et al., 2001 ). 
Variable regions of heavy and light chains of the immunoglobulin molecules have an 
allergen-binding site. The Ce3 domain of Fe fragment oflgE is able to bind to two types 
of immunoglobulin Fe receptors, the high-affinity lgE receptor (FceRI) and the low 
affinity lgE receptor (FceRII) (Vercelli et al., 1989, Nissim et al., 1993, Presta et al., 
1994). 
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Model of tetrameric high affinity receptor first suggested by Blank et al (1989) and 
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according to their hydrophobicity/hydrophilicity score (see scale). The putative 
transmembrane domain is predominantly hydrophobic, with the FceRia subunit 
transmembrane domain containing a hydrophilic aspartic acid residue (D 194, shown 
in blue) 
1.7: The Role of Conserved Charged Residues in 
Transmembrane Domains of Immunoreceptors on 
Receptor Assembly, Expression and Function 
The importance of conserved charged residues in the transmembrane domains (TMs) 
of the immune receptors on receptor subunit assembly, expression and function has 
been highlighted in various studies over the last two decades. 
1.7.1: The Role ofTransmembrane Charged Residues ofFccRI 
Varin-Blank and Metzger (1990) carried out mutations in a, ~. and y subunits of 
FcsRI and analysed the effects of these genetically engineered modifications on FcsRI 
surface expression. The study concluded that transmembrane domains are crucial for 
!he accurate receptor assemblage and transport to the cell surface while the 
cytoplasmic domains affect the surface expression of the receptors although their role 
is not mandatory. The COS-7 cell line was used by Varin-Blank and Metzger for 
transient transfections of the mutated subunits ofFcsRI. A conserved charged aspartic 
acid residue is present in both the a and y subunits of FcsRI of rat, mouse and human 
and the , chain of TCR of mouse and human (Kuster et al., 1990). This arrangement 
of a charged hydrophilic residue in a predominantly hydrophobic environment of lipid 
bilayer is energetically unstable. The mutations introduced in this residue by Varin-
Blank and Metzger were D195A in the FcsRia subunit and D1 lA in the FcR-y 
subunit. They were then co-transfected with the appropriate wild-type rat FcsRI 
subunit cDNAs. The results indicated a decrease in the cell surface expression with 
the most adversely affected being the double mutation D195ND11A. The importance 
ofy-subunit in the surface expression of the FcsRia subunit was highlighted when the 
mutation D1 IA lead to complete abrogation of the human FcsRia (wild-type) cell 
surface expression. The conserved nature coupled with the presence in the 
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transmembrane region where the subunits of the receptor interact with each other 
make this residue a potential target for studies to elucidate the mechanisms involved 
in receptor subunits interactions . 
1.7.2: The Role ofTransmembrane Charged Residues oflgA 
Receptor 
The transmembrane lgA immunoglobulin receptor (FcaRI, CD89) is expressed alone 
or in association with FcR-y subunit on the surface of monocytes, macrophages, 
neutrophils and eosinophils. Studies carried out on this receptor to understand the 
relationship of the FcaRI and FcR-y subunit, by introducing site directed mutations, 
revealed that the positively- charged arginine residue at position 209 within the FcaRI 
TM domain is needed for the functional association with the FcR-y subunit (Morton et 
al., 1995). Another mutation (Y25F) in the FcR-y subunit located at the 
cytoplasmic/transmembrane interface had no affect on the FceRI-FcR-y expression 
but did show pronounced affects on FcaRI-FcR-y arrangement by substantially 
decreasing ( ~ 10%) the cell surface expression, subunit association and signal 
transduction capability in the mutant transfected cell line as compared to the wild-
type FcaRI-FcR-y transfected cell line (Wines et al., 2004). 
1.7.3: The Role of the Transmembrane Charged Residues of T cell 
Receptor (TCR) 
The TCR is a multi-subunit complex having 8 transmembrane proteins each of which 
has a charged residue in the transmembrane region (Weiss, 1991). TCR consists of 
two heterodimeric glycoproteins (TCRa and TCRP) which together with CD3y, -B, -e, 
and -l; form the CD3 complex. The CD3B, CD3e, and CDl; subunits have an aspartic 
acid residue while the TCRa subunit has conserved positively charged lysine/arginine 
residues, TCRP subunit has lysine residue and CD3y has glutamic acid residue. TCR 
assembly takes place in the ER (Minami et al., 1987) and only intact TCR complexes 
are efficiently transported to the plasma membrane (Sussman et al., 1988). TCR has 
been widely studied and it was found that charged TM residues of a and p subunit are 
needed for TCR subunit interaction. Studies involved transfection of both a or p 
subunit cDNA in a or P deficient T cell lines which do not express TCR on their cell 
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surface. One of these studies showed that the a. and P subunits do form heterodimers 
and were unable to associate with CD3 (Alcover et al., 1990). When the lysine residue 
of P subunit was mutated the cell surface expression of TCR did not take place even 
when the mutation introduced was of the same charge/structure (Alcover et al., 1990, 
Morley et al., 1988). A study by Blumberg et al (1990) on TCRa. TM residues by 
carrying out single and double mutations showed abrogation of cell surface 
expression in case of double mutations (Rl 18G/K123I). The importance of polarity of 
the transmembrane residues in signal transduction in TCR was highlighted in a study 
by Fuller-Espie et al (1998) where four polar residues located within the TCRP CART 
(conserved antigen receptor transmembrane) motif were replaced by non-polar 
residues of similar size and shape. Polar to non-polar TM mutations of the conserved 
tyrosines within the TCRP subunit greatly reduced the expression level and functional 
capability of TCR indicating the importance of polar TM residues (Kunjibettu et al., 
2001). 
1.7.4: The Role of the Transmembrane Charged Residues ofB Cell 
Receptor (BCR) 
BCR is composed of a membrane-bound ligand-binding immunoglobulin (mlg) and 
signal transducing heterodimer, Ig-a./lg-p. Any mlg that fails to become associated 
with the Ig-a./Ig-p heterdimer is retained by ER due to the presence of an ER retention 
signal in the TM domain of mlg. mlg has 26 amino acid a. helical transmembrane 
domains with 13 out of these residues being conserved in 7 out of the 8 isotypes of 
mlg and 10 of the 26 having a hydroxyl residue. Those residues predominantly 
present on one side of the a. helix were targeted for mutation studies. Various studies 
(Shaw et al., 1990, Grupp et al., 1993, Sanchez et al., 1993, Stevens et al., 1994) 
showed that single mutations had no affect on the receptor expression and function 
but double mutations affect the lg-a./lg-p heterodimer association with Y 465 and 
S466 TM residues identified as playing significant function in lg-a./lg-p association 
and receptor expression/function. 
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1.8: Current Therapeutic Strategies for Treatment of 
Allergy 
Traditionally people have been advised to avoid exposure to the allergens, something 
that is not always possible. Currently available therapeutic strategies available for 
combating allergic diseases are inefficient and are frequently associated with 
debilitating side effects. It is hoped that advances in gene therapy vaccines and drug 
delivery will provide the basis for the development of more efficient therapeutics 
using a more target oriented approach that will produce less undesirable side-effects. 
1.8.1: Conventional Therapies 
The various medications currently available are not effective on their own and are 
usually used in combinations that provide symptomatic treatment rather than targeting 
the underlying immunological pathology. The first-line of treatment conventionally 
has been the administration of oral antihistamines that act by countering the effects of 
histamine released by the mast cells (Meltzer, 1998). These drugs are however 
associated with side effects the most significant of which has been sedation, which 
necessitated the introduction of non-sedating antihistamines. Topical corticosteroids 
that reduce the inflammation are the most effective treatment for asthma and rhinitis 
and are extensively being used worldwide. Corticosteroids reduce inflammation by 
increasing the transcription of anti-inflammatory genes and more decisively 
suppressing the transcription of inflammatory genes (Pawankar et al., 2008). Another 
drug, which is time tested in treating the life-threatening situation of anaphylaxis, is 
epinephrine (Kemp et al., 2008). 
Allergen immunotherapy introduced in 1911, targets the specific allergen to which a 
person is sensitised and has proven to be a potent long-term therapeutic tool capable 
of reducing the symptoms of allergic rhinitis and asthma, and in children treated for 
allergic rhinitis decreases the subsequent development of asthma (Barnes, 1999). 
Demerits associated with this strategy include multiple injections over a period of 
months and associated risk of anaphylaxis or additional sensitisation (Lewis, 2002). 
Recently success has been declared by a Cambridge group using this approach for 
desensitisation to peanut flour (Clark et al., 2009). The drugs used for treating asthma 
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may be grouped as either relievers or controllers. The relievers or the bronchodilators 
include P2 - agonists, theophylline and anticholinergics while the controllers or the 
anti-inflammatory treatments include corticosteroids, sodium cromoglycate and anti-
leukotrines. p2 -agonists produce bronchodilation by acting directly on the p2 
receptors in smooth muscles lining the airways (Barnes, 1999). 
1.8.2: lmmunomodulators 
An ideal therapeutic strategy for allergic and immunological diseases would be one 
that can bring about induction of immune tolerance by changing the aberrant immune 
response and thus provide a long-lasting cure with minimal side effects. For this 
purpose as the knowledge of pathogenesis of allergic and immunological diseases 
improve and the underlying molecular mechanisms are elucidated, novel therapeutic 
agents called immunomodulators are being developed (Casale and Stokes, 2008). The 
therapies included in this category are Toll like receptor (TLRs) 4 and 9 agonists, 
immunosimulatory oligodeoxynucleotides, oral and perenterally administered 
cytokine blockers, and specific cytokine receptor antagonists. 
TLRs play an important role in activating the APCs of the immune system; agonists 
acting on TLRs can alter the allergic phenomena by changing the Thi and Th2 
~ytokine balance thus raising concerns about risk/benefit ratio of such broad spectrum 
therapies. CXR-675 (aqueous formulation of monophosphoryl lipid A) is a TLR4 
agonist currently under trials for treating seasonal allergic rhinitis, (Casale et al., 
2006) which acts by binding with LPSs and endotoxins present on the cell surface, 
while TLR9 agonists such as Tolamba act by binding to unmethylated cytosine 
phosphate guanine (CpG) motifs, most commonly found in bacterial pathogens 
(Krieg, 2006). In order to develop targeted therapies with lesser side-effects, the Th2 
cytokines have emerged as potential targets with strategies targeting single or multiple 
related cytokines. Therapies against IL-4, IL-5, and IL-13 are at various stages of 
evaluation. Similarly, oral cytokine (IL-4 and IL-5) synthesis inhibitors are being 
developed with A VP-13358 showing suppression of lgE, CD23 and Th2 cytokine 
responses in ex vivo and in vitro mouse and human assays (Richards et al., 2004). 
Other strategies that are currently explored include inhibition of Syk kinase, although 
these may be associated with severe side-effects since syk is an almost ubiquitous 
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signal transducer (section 1.4.1). Various syk-inhibitors, Rl 12 and R-343, are under 
evaluation for efficacy and side-effects (Casale and Stokes, 2008). 
Another drug category to combat asthma is the leukotrine receptor antagonists group 
of drugs which has proven to be less effective than the inhaled corticosteroids in the 
control of asthma (Capra et al., 2006). Cysteinyl-leukotrines (cys-LTs) are potent 
bronchoconstrictors to counter the effects of which cys-LT1 receptor antagonists, 
montelukast and zafirlukast have been developed (Israel et al., 1993). 
1.8.3: Mast Cell Therapeutics 
Mast cells are now known to play a crucial part in the pathogenesis of allergic 
diseases by not only inducing an immediate response but also contributing towards 
the late-phase reaction (Williams and Galli, 2000). As the understanding of the 
mechanisms underlying mast cell signalling and release of mediators increase, novel 
therapeutic modalities are being developed. The drugs devised to combat allergic 
diseases by acting on mast cells as the target can be broadly grouped into those 
directed at the cell membrane targets (membrane receptors), to intracellular targets 
( cell signalling, gene expression) or to extracellular targets. These drugs are in 
various stages of development (Table 1.1) and the treatment options might depend on 
using them in combination as there is variable response in patients and allergic 
diseases. One drug which has shown promise is passive immunisation with the anti-
lgE humanized monoclonal antibody, omalizumab which targets the binding domain 
of circulating lgE thus blocking its binding to FcERI on the inflammatory cells leading 
to the indirect down-regulation of FcERI expression on the cell membrane (Beck et 
al., 2004). 
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St1ge of 
Mast cell target Therapeuric d~s Mecha~m of :rrion developmem 
Cell membrane Chromones Potenrial disruption ofCa2• intlux,chloride ion 1ranspo1t andexocyric Clinical use 
processes 
Pi agonisis Increase cytoso lie cAMP levels through bi!Kli ng of P2 receptors Clinical use 
Omalizumab Monoclonal antibody to free fgE resulting in decreased foil membrane Clinical use 
expression 
CCRl antagonisrs Block chemotaxis and degranuliion Clinical trials 
ct• and t• channel Jlguption of ion influx with anenuarion of degrangularion and Pre-clinical 
antagonists chemoraxis 
Anri-CD63 anribody Monodonal antibody to ~3 which interferes with cellula- adhesion to Pre-clinical 
~I imegrins and blocks FccRI-induced degranularion via impairment 
of Gab2-Pllk pathway 
lnll':rell ula- Glucocorticoids Regulate tmscriprion of numerous inflammatory genes Clinical use 
Syk kinase inhibitors Block IgE-FccRI-mediied dov.nstream signaling lphosphorylarion) Clinical trials 
MAPK inhibitois Block phosphoryliion of muhi~e intracellular proteim ftnduding Clinical trials 
1ra1scriprion factors) that are involved in cellular proliferarion, 
differenriiion, survival and chronic int1ammarion 
PDE4 inhibitors Block hydrolysis of cAMP to S' AMP Clinical trials 
Extracellular S-L0 inhibitor Blocks the conversion of arachidonit acid to LTA. which subsequendy Clinical use 
prevenis CytT formarion 
Tiyptase inhibitors Block dte prote~e activity of riyptast Pre-d inical 
CytTRI ant1gonists Block the binding to and cffeclS of Cyst! on t1rget cells Clinical me 
Hi-, rerepror anragonislS Block the binding to and cffeclS of hisramine on target cells H,nti: Clinical use 
H3: Clinical trials 
"4: Pre-dinical 
PAR-2antagonisrs Block PAR-2 receptor signaling following activiion by proteases Pre-dinical 
le.g.. nyptast) 
IF and Cmf-2 receptor Block the binding to and cffeclS of PGD2 on target cells Pre-dinical 
antagoni1s 
*Representative strategies in each iarget class are pr~nred. 
MAPK, mitogen-activared protein kin~; POK, phosphoinosiride-3 kina\e; PDE, ph~hodieste~e; S-LO, S-lipoxygenase; PAR-2, proteinast• 
irrivated receptor 2; CRTH-2, chemoartractant receptor homologue on T helper type 2 cells; IF, D p~ianoid. 
Table 1.1: Mast Cell and Mast-product Directed Therapeutics 
The drugs devised to combat allergic diseases by acting on mast cells as the target can 
be broadly grouped into those directed at the cell membrane targets (membrane 
receptors), to intracellular targets (cell signalling, gene expression) or to extracellular 
targets (Adapted from Brown et al., 2008). 
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1.9: Aim of Study 
Our group is exploring the relationships between the structure of the FctRI and its 
ability to mediate transmembrane signalling. The methodology employed was to carry 
out site-directed mutations in the alpha and gamma subunits of the FctRI. When 
compared to other multisubunit membrane receptors the FctRI is characterised by 
weak subunit interactions (Kinet et al., 1985) so that even minor modifications of one 
or more of the subunits can lead to significant overall changes. Immunoreceptors have 
conserved transmembrane motifs that are believed to play a crucial role in receptor 
assembly, expression and function. 
Transmembrane domains of FctRia and FcyRIIIa subunits have an invariant eight 
amino acid motif (LFAVDTGL), which has been shown to be conserved in mice, rats 
and humans. This predominantly hydrophobic motif has a hydrophilic aspartic acid 
residue (Dl94) that in theory is energetically unstable (Ravetch and Kinet 1991). The 
aim of the present study was to examine the role of the D 194 residue within the TM 
domain of the huFctRia subunit on cell surface expression and FctRI -mediated 
signaling. Rat Basophilic Cells (RBL-2H3.1) originating from rats treated with ~-
ethylamine were chosen for the study due to their identical phenotype to the immature 
human mast cells (Eccleston et al., 1973). The RBLs are functionally homologous to 
human mast cells in FctRI cell surface expression, granular content and mediator 
release and represent an accepted model system to study mast cell/basophil 
physiology. The ligand-binding domain of the rodent FctRI complex does not 
recognise primate or human IgE. Previous studies have shown that in RBL-2H3 cells 
the transfected huFceRia subunit forms a functional chimeric rat/human receptor 
complex with endogenous FcR-y and FcR-~ subunits. These rat/human chimeric 
receptors can be specifically activated via a human IgE (hulgE) mediated cross-
linking stimulus to mediate cell secretion (Gilfillan et al., 1992, Wilson et al., 1993) 
and conclusions to be drawn from the outcome of these experiments are more relevant 
to the assessment of mast cell signaling pathways than earlier studies based on COS 
cell transfection (Varin-Blank and Metzger 1990). The outcome of preliminary 
mutagenesis studies by Iodice (2006) led to the proposal of a model structure for 
FctRI by Professor P.Artimyuk (UoS), which proposed an interaction between the 
D 194 residue of the alpha subunit and Thr22 residue of the gamma chain as shown in 
figure 1.6 (Iodice, 2006). This model differed significantly from the one proposed 
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from the one proposed previously by (Farber and Sears, 1991) which suggested an 
interaction between positively charged K29 (FcR-y) which corresponds to K30 in 
FcR-y subunit, with negatively charged D203 (rat FcyRIIIa) homologous to D194 in 
huFceRia. In the model proposed by our group there is a 2:1 stoichiometry between 
the FcR-y and FceRia subunits rather than a 1:1 association predicted in the earlier 
model (Farber and Sears, 1991). The other difference between the two models 
predicted that K29, found in a relatively hydrophilic sequence RLKIQV, is located in 
the cytoplasmic rather than the TM region, as proposed by Farber and Sears (1991). 
Thus our model considered only the interaction between the minimal essential 
receptor subunits ofFceRia and y involved in FceRI-mediated signalling. 
In order to assess the proposed model and to elucidate the FceRia and FcR-y subunits 
interactions it was necessary that mutations be carried out in the FcR-y subunits. For 
this purpose a subline of RBL-2H3, which was reported to be defective in the 
expression of FceRI, RBL y-chain deficient cell line (RBL-y-) (section 2.2), a gift 
from Professor Draber, was used to make a distinction between cells responses 
mediated by the endogenous FcRy from those of FcERI. The RBL y-chain deficient 
cell line was prepared (Draberova and Draber, 1995) using chemical mutagenesis 
suppressing y-chain expression. The y subunit, is essential for the cell surface 
expression of FceRI and FcyRIII (Kinet, 1992) and the resultant y-chain deficient cell 
line expresses a lower level of the lgE receptor. Following transfection of y-chain 
deficient RBLs with an expression plasmid encoding the rodent gamma construct 
demonstration of cell surface expression of the receptor complex could be 
demonstrated in the y-chain transfected cells. The cells could be sensitized with 
mouse lgE and challenged with antigen to assess the release of mediators (Bocek et 
al., 1995). This suggested that the RBL y-chain deficient cell line could be employed 
as a host for the transfection of native and mutant y-chain constructs for the 
assessment of a structure/function relationship in FceRia/y interaction. This 
investigation formed the basis for the second part of the project since transfection of 
gene construct encoding native and mutant forms of FceRiy should facilitate, through 
site-directed mutagenesis, an investigation into the role of Thr22 in supporting surface 
expression and lgE mediated, antigen induced cell activation. 
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TM 
Figurel.6: Modeling of Transmembrane Helices 
INTRODUCTION 
The transmembrane regions of both the FcaRia and FcR-y subunits were identified 
from NCBI annotations and confirmed by hydropathy plots (Kyte and Doolittle, 
1982). The proposed model envisages two FcR-y subunits linked at Cys7 residue by 
disulphide bond and a central located single FcaRia helix all with inter-helical angles 
of approximately -25°. The aim was to expose most of the hydrophobic side chains on 
the side to permit a favorable interaction with lipid tail groups in the membrane. The 
model positioned D194 of the FcaRia subunit in the hydrogen bonding distance from 
the Thr22 residues present in the both FcR-y subunits (indicated by arrows). The 
model was subjected to energy minimization using the X-PLOR program (Brunger et 
al., 1987) in order to improve stereochemistry and to optimize contacts from the 
original model (adapted from Iodice, 2006). 
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Another approach employed was to create a chimera (humanayy) usmg the 
extracellular (EC) domain of the human high affinity lgE receptor alpha subunit 
(huFcERla) spliced onto the rodent gamma TM and cytoplasmic domain (CD) and 
transfect them into the RBL cell line in order to assess the possibility of selectively 
activating cells transfected with this single pass construct for antigen induced 
mediator release. This strategy might facilitate assessment of the surface expression of 
the huF cERla ligand binding domain independent of the endogenous rodent F cERla. 
As mentioned earlier the rodent FcERI requires a ~ subunit in addition to two y 
subunits for its expression in contrast to the human, which can exist as a trimer on the 
surface of some but not all cells (Section 1.6). The yTM and CD contain important 
residues that warrant investigation by site directed mutagenesis which can be 
activated independent of the endogenous expressed subunits by stimulating through 
hulgE and antigen as the hulgE is specific for the huFcERla chain. Repetto et al 
(1996) prepared chimeric receptors of the EC and cytoplasmic (CT) domains of the 
FcERI and the IL-2R p55 subunit (I) were constructed and stably transfected into 
RBL-2H3 cells. The two constructs prepared by Repetto et al were o./y/y and 1/y/y and 
results demonstrated that FcERla EC and FcERy CT domains are mandatory for 
signalling process leading to the response characteristically seen after the receptor 
aggregation {Repetto et al., 1996). 
This ongoing study should provide significant information regarding the importance 
of conserved polar amino acids in the TM domain of multi-subunit cell surface 
receptors. Identification of molecular interactions that occur at contact sites between 
TM domains of the subunits of the high-affinity lgE receptor by mutational analysis 
may reveal targets for the development of therapeutic agents aimed specifically at 
inhibition of FcERl-mediated cell signaling. The identification of TM amino acid 
residues implicated in the down stream signalling may reveal useful targets in the 
treatment of the IgE-mediated hypersensitivity through the introduction of a peptide 
sequence which contains the amino acid which has the ability to inhibit 
transmembrane interaction in receptor complexes thus interrupting the downstream 
signalling cascade at an early stage. This approach has been successfully applied to 
the development of "molecular wedge" anti-cancer drugs, by developing TM-derived 
peptides that inhibit neu oncogene receptor aggregation thus retarding growth of neu-
transformed cells in monolayers and tumors in nude mice (Lofts et al., 1993). This 
31 
CHAPTER1 INTRODUCTION 
approach was also used to modulate the T-cell receptor signaling and may have wider 
applications for the development of selective inhibitors of T cell-mediated diseases. 
Manolios et al (1997) showed that a specific synthetic peptide (core peptide), based 
on a conserved motif present in the TM region of TCRa. subunit which contained 
positively-charged residues interacting with similarly negatively-charged residues of 
the CD3 complex (Clevers and Ferrier, 1998), entered and suppressed T cell function. 
This novel therapeutic agent has shown promise in inhibiting T cell functions in vitro 
in T cell hybridoma (2B4. l l) and in reducing clinical signs of three T cell mediated 
diseases in in vivo studies in animal models of immunoreceptor-mediated pathologies 
(Manolios et al., 1997). These core peptides are not only anchor proteins but appear to 
function by inhibiting downstream signalling by blocking receptor subunit 
interactions in the membrane. The most interesting aspects of these peptides is their 
ability to internalize to many cell types without any complications (Huynh et al., 
2003). 
The current study aimed at a better comprehension of mast cell and lgE receptor 
complex signalling to pave the way for development of efficient proactive preventive 
measures and therapeutic tools to combat allergic disease thus relieving the sufferings 
of millions of human beings world wide. 
32 
CIIAPTER2 MATERIALS AND METHODS 
CHAPTER2 
MATERIALS AND METHODS 
33 
CHAPTER2 MATERIALS AND METHODS 
Chapter 2 
Materials and Methods 
2.1: Materials and Equipment 
All chemicals were purchased from SIGMA unless stated otherwise. Deionised water was 
used as solvent. 
All solutions were formulated as described by Sambrook (2001). 
2.1.1 Cell Culture Reagents 
1.2 ml Cryogenic Vials 
50 ml Polypropylene tubes 
100 mm tissue culture dishes 
CDS 
DMEM 
DPBS 
FCS 
Geneticin (G-418 sulphate) 
Pencillin/streptomycin solution 
Trypsin/EDT A 
Universal tubes 
2.1.2: Protein Manipulation 
Acrylamide/Bis (30%) 
Bradford protein assay reagent 
Bovine serum albumin (BSA, Fraction V) 
Developer/fixer solution 
Nalge Nunc Inc. 
Greiner Bio-One 
Iwaki 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Autogen Bioclear 
Invitrogen 
Sigma-Aldrich 
Sigma-Aldrich 
Bibby Sterilin 
Sigma-Aldrich 
Bio-Rad 
Fischer Scientific 
Kodak 
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Dried semi -skimmed milk 
Enhanced Chemiluminescence detection kit 
Full Range molecular weight marker 
Low Range molecular weight marker 
Nitrocellulose membrane (HybondC+) 
Protease Inhibitor Cocktail Tablets 
Protein A agarose, fast flow 
MATERIALS AND METHODS 
TEMED (N·N·N·N·-tetra methyl ethylenediamine) 
X-ray film 
Somerfield 
Amersham Biosciences 
Fermentas 
Amersham Biosciences 
Amersham Biosciences 
Roche 
Chemicon 
Bio-Rad 
Kodak 
2.1.3: Antibodies Used 
Anti-phosphotyrosine( Clone 4G 1 0,mouse) 
DNP-specific mouse IgE (mlgE) 
Upstate 
SPE-7 supernatant developed 
at The Antibody Resource Centre,University Of Sheffield 
Goat anti-human IgE biotinylated 
Goat anti-mouse IgE FITC-conjugated 
HumanigE (Chimeric NIP-specific) 
Mouse anti-syk-[01] 
NIP-specific human IgE (huigE) 
Rabbit anti FcR-y 
Rabbit anti-syk 
Streptavidin R-phycoerythrin 
Swine anti-rabbit HRP-conjugated 
Vector Laboratories 
Bethyl Laboratories 
Serotec 
Abeam 
JW8 developed at The Antibody 
Resource Centre, University Of Sheffield 
Upstate 
Santa Cruz Biotechnology 
Sigma-Aldrich 
Dakocytomation 
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2.1.4: Molecular Biology Reagents 
Agar (Bacto) Difeo 
Agarose (SeaKem) FMC 
Ampicillin Roche 
Calf Alkaline Phosphatase Autogen Bioclear 
DNA Markers ( 1 Kb) Fermentas 
Plasmid Midi Kit Qiagen 
METAFECTENE™ PRO Biontex 
Restriction enzymes Promega 
T4 DNA Ligase Promega 
Tryptone Unipath 
DNA gel extraction kit Bio-Rad 
Plasmid miniprep kit Qiagen 
Yeast extract Difeo 
2.1.5: Buffers 
Dulbecco 's phosphate buffered saline (DP BS) was purchased from Sigma and 
sterilization was done by autoclaving. 
Tissue culture Trypsin/EDTA solution (0.5% trypsin, 0.2% EDTA) was prepared by 
diluting the Trypsin-EDT A (TE) 1 Ox stock (Sigma-Aldrich). 
Tissue culture DMEM was supplemented with 10% FCS. Media used for transfected cell 
lines was further supplemented with Geneticin (G-418) 400µg/ml, was initially 
reconstituted in 20ml of DMEM and then added to FCS supplemented media via a 0.2µm 
filter. 5ml of 1 00u/ml penicillin and I 00µg/ml streptomycin solution (Sigma-Aldrich) 
was added to both types of media. 
NIP-HSA was prepared according to manufacturer,s protocol. 
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2.1.6: Equipment 
37° C Incubator 
37° C Incubator (Galaxy R CO2) 
Agarose gel electrophoresis equipment 
Balances (AE200, P 13000) 
96- Well plate reader (Milenia Kinetics Analyser) 
Centrifuge (Minispin, <2ml) 
Centrifuge (Centaur II, <50ml) 
Cryomed liquid nitrogen container 
FACSVantage flow cytometer 
FACSCalibur flow cytometer 
F ACSMoFlo flow cytometer 
F ACSCyan ADP cytometer 
FACSort flow cytometer 
Electrophoresis (Mini Protean II) 
Electroporator-Gene pulse 
Fluorchem ™ Imaging System 
Haemocytometer 
Heat block 
Microwave 
Laminar Flow cabinets 
pH Meter ( Toledo 320) 
Pipettes (p 10, p20, p200, p 1000) 
Pipettes multichannel 
Wheel Rotator 
Spectrophotometer (PU 8625) 
UV Transilluminator 
. 
Vortexer (whirlmixer) 
Water Bath 
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LEEC 
SLS 
Bio-Rad 
Mettler 
Diagnostic Product Corporated 
Eppendorf 
MSE 
Forma Scientific 
BD Biosciences 
BD Biosciences 
Dakocytomation 
Dakocytomation 
Dakocytomation 
Bio-Rad 
Bio-Rad 
Alpha Innotech Corporation 
Weber Scientific 
Grant 
Goodmans 
BioMat 
Mettler 
Gilson 
Anachem limited 
Stuart Scientific 
Philips 
UVP 
Fisions 
Clifton/ Nickle electrode 
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2.2: Cell Lines 
Rat Basophilic Leukaemia (RBL) cell line RBL-2H3. l employed in the study was 
derived from rats treated with P -<:hlorethylamine that developed basophilic leukaemia 
(Eccleston et al., 1973). The cell line has been extensively used in high affinity JgE 
receptor studies due to its identical phenotype to immature human mast cells. The RBLs 
have similarities to immature human mast cells in FcERI cell surface expression, granular 
content and mediator release and thus represent an easily maintained mast cell-like model 
for the study of IgE-mediated, antigen induced mediator secretion (Blank and Varin-
Blank, 2004). 
The other cell line used was RBL gamma chain deficient, a subline of RBL-2H3, which 
was defective in the expression of FcERI and was a gift from Professor Draber of 
University of Prague. RBL y-chain deficient cell line was isolated from RBL-2H3 cell 
chemically mutagenised by 5 successive cycles of negative immunomagnetic separation 
followed by cloning of FcERI deficient cells using limiting dilution (Draberova and 
Draber, 1995) causing it to have an FcERI, which is devoid of the y subunit, a subunit 
which is essential for the cell surface expression of FcERI and FcyRIII (Kinet, 1992). 
2.3: Mammalian Cell Culture Techniques 
2.3.1: Culturing RBL Cell Line 
RBL-2H3. l cells were grown at 37° C in a humidified atmosphere of 5% CO2, as 
monolayer cultures in I 001145mm plates in DMEM supplemented with I 0% FCS. The 
transfected cell lines were grown in media supplemented with Geneticin (G-418). The 
cells on reaching a confluency of 80-90% were harvested by trypsinisation. The media 
was aspirated and cells washed in DPBS to remove FCS. Trypsin/EDT A was added to 
each plate and incubated at 37° C for 5 minutes. Cells were lifted from the plate by gentle 
washing with a PIO00 Gilson and added to an equal volume of media containing FCS 
. 
(inactivating the trypsin). Cells were recovered by centrifugation (180g for 3 minutes) 
and re-suspended in 1ml of the appropriate media. Aliquots according to the size of tissue 
culture plates were added to the appropriate volume of media allowing confluency 2 days 
later. 
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2.3.2: Cryogenic Preservation 
For long-term storage of cell lines, a sub confluent monolayer of cells was harvested by 
trypsinisation. Proceeding recovery of cells by centrifugation, the pellet was resuspended 
in FCS (90%) and transferred to a cryogenic storage vial. After the addition of DMSO 
(10%), cells were placed in vapour phase of liquid nitrogen in a modified holder for the 
nitrogen storage bank for I hour before being catalogued and placed in liquid nitrogen. 
2.3.3: Thawing of Cells 
After removal from the liquid nitrogen storage bank the cells were re-suspended in 20ml 
of appropriate media pre-warmed to 37° C. Cells were recovered by centrifugation (180g 
for 3 minutes) and re-suspended in 1ml of the appropriate media. Aliquots according to 
the size of tissue culture plates were added to the appropriate volume of media and left 
overnight. The following day the cells were checked for adhesion and media was 
replaced. 
2.4: fl -Hexosaminidase Assay: Measurement of Secretory 
Output from RBL Cell Lines in Response to an 
Immunological Stimulus 
Reagents: 
Buffered Solution (BS): 
(pH7.4) 
120mM NaCl, 5mM KCI, 25mM PIPES, 
.04mM MgCh, lmM CaCh 
Substrate: p-nitrophenyl N-acetyl ~-D-glucosaminide 
Stock solution (50mM) in DMSO 
Protocol: 
Cell lines were harvested by trypsinisation as described previously (section 2.3.1). 
Viable cells numbers were counted on a haemocytometer (lx104 volume). Cells were 
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resuspended at a cell density of 0.5x 106 /ml and sensitized with DNP-specific mlgE 
(SPE-7 1/500) or NIP-specific hulgE (JW8 1/500). Aliquots (100µ1) were plated out in 
triplicate on 96-well plates and incubated at 37°C for 16 hours. All solutions from this 
point were pre-warmed to 37°C. Next day, 96 well plates were examined for cell 
confluency before the media was removed and cells washed twice with DPBS. DNP-
HSA and NIP-HSA dilutions (0.1-lO000ng/ml) and Triton -Xl00 (1%) were prepared in 
BS. BS (100µ1) was added to the first set of three wells (blank), followed by 100µ1 of 
Triton-Xl00 (total) to the last set of triplicate wells, and addition of DNP-HSA/NIP-HSA 
dilutions to the remaining wells as appropriate. Following incubation for 20-30 minutes 
at 37°C, 50µ1 of supernatant from each well was transferred to an identically labelled 96-
well plate. Substrate solution was diluted in 0.2M citrate buffer (pH4.5) to a final 
concentration of 2mM. 50µ1 of substrate solution was added to each well containing 
supernatant prior to 2-3 hours incubation at 37°C allowing time for the reaction to take 
place. The reaction was terminated by the addition of 150µ1 lM Tris-HCI (pH 9.0). Plates 
were analyzed using an ELISA reader set at 405nm. Analysis of plates allowed 
percentage release for each DNP-HSA / NIP-HSA dilution to be calculated using the 
following equation. 
(Average of test triplicate)- (average of blank triplicates) x 100 
(Average of total triplicates) 
2.5: Cell Lysate Preparation for 1D- PAGE 
2.5.1: Sample Preparation 
Reagents: 
RIPA Lysis buffer 150mMNaCl 
1 % lgepal CA-630 (Nonidet P-40) 
0.5% Sodium deoxycholate 
0.1 % SDS, 50mM Tris-HCI (pH 8) 
All lysis buffers were supplemented with protease inhibitor cocktail tablets (Roche), I 0-
100 µl PMSF and lmM Sodium orthovanadate. 
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Protocol 
Cells were cultured as monolayer on 145 mm plates and sensitized for 16 hours with 
either DNP specific mlgE (SPE-7, 1/500) or NIP specific hulgE (JW8), 1/500) at 37°C. 
Solutions and universal tubes were all pre-warmed to 37°C. The following day cells were 
washed with pre-warmed PBS and harvested in pre-warmed CDS. This was followed by 
recovery by centrifugation (180g for 3 minutes). The cell pellet obtained was 
resuspended in I ml of pre warmed BS. Cell numbers were determined and re-suspension 
was carried out at 5 x 106/ml. The cells were divided equally into universal tubes 
dependent on the number of samples required. The appropriate sample was activated for 
2 minutes with the corresponding cross-linking agent (IOOng/ml, optimal concentration 
determined from ~ -Hexosaminidase assay). The reaction was halted by addition of I 0ml 
of ice cold PBS to each universal tube and the tubes were then kept on ice for 2 minutes. 
The cells were recovered by centrifugation (180g for 3 minutes) followed by re-
suspension in I ml ofDPBS and centrifugation (180g for 3 minutes) at room temperature. 
The pellets were resuspended in 1ml RIPA Lysis Buffer (to which sodium 
orthovanadate and I 0-100µ1 PMSF was added) transferred to cooled micro centrifuge 
tubes, vortexed and left on rotating for 60 minutes at 4°C. From this point onwards all 
procedures were carried out at 4°C. The tubes were then centrifuged (10000g for 15 
minutes) and cell lysate obtained transferred to new micro centrifuge tubes and assayed 
for protein content employing Bradford's method. 
2.5.2: Bradford's Method for Protein Estimation 
The need for carrying out protein quantification prior to immunoprecipitation is to ensure 
uniform protein concentrations in all samples under study. The principle of Bradford 
Assay is that binding of Coomassie Blue G-250 dye in the Bradford reagent to protein 
causes a shift in absorption from 465 to 595 nm. A standard curve was prepared using 
BSA. 900µ1 of Bradford Reagent (1/4 dilution, Bio Rad), 95µ1 dH2O and 5µ1 of cell 
lysate were mixed in a 1.5ml cuvette to achieve a final volume of I ml. After a lapse of 5 
minutes readings were taken on spectrophotometer set at 595nm. 
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2.5.3: Immunoprecipitation 
Protein A Agarose beads (Chemicon) were used in all immunoprecipitations. All pipette 
tips were cut off when working with protein A to avoid bead degradation. All steps were 
performed at 4 °C unless otherwise stated. 
Protocol: 
Protein A was prepared following the manufacturer's instructions (Chemicon). Cell 
lysate was incubated with protein A (I 00µ1) of 50% slurry for 30 minutes ( end-to-end 
rotation). This process is known as pre clearing which reduces any non-specific binding 
by proteins within the sample, which may interfere with later analysis. Lysates were 
centrifuged (10000g for 15 minutes) and the supernatant was transferred to new micro-
centrifuge tubes being careful not to disrupt protein A pellet. Protein estimation of sample 
was carried out using the Bradford protein assay allowing sample normalisation. At this 
point, 15-25µ1 of cell lysate was taken from the samples to be used in anti-
phosphotyrosine immunoprecipitation for the later purpose of FcR-y quantification. An 
equal amount of appropriate antibody was added to each sample following the 
manufacturer's instructions. Lysates were incubated overnight with end-to-end rotation to 
allow antigen-antibody complex formation. The following day, protein A (100µ1) was 
added to each sample as appropriate prior to 2-4 hour incubation with end-to-end rotation 
allowing immune complex capture. Immunoprecipitates were pulsed in a centrifuge 
(10000g), the supernatant removed and washed three times with appropriate ice-cold lysis 
buffer. After the last washing all of the supernatant was removed from the 
immunoprecipitates using a Gelsaver pipette microtip. Immunoprecipitates were 
resuspended in 60µ1 of Laemmli's 1-D SDS-PAGE loading buffer (50mM Tris-HCI, pH 
6.8, 2% SDS, I 0% Glycerol, I OOmM DTT) and boiled for 5 minutes. Samples were 
centrifuged ( 10000g for 5 seconds) and resolved on a 12.5-17% SDS-P AGE gel. 
2.5.4: One-dimensional Polyacrylamide Gel Electrophoresis 
ProJeins were resolved by polyacrylamide gel electrophoresis using the Mini-Protean II 
electrophoresis system (Bio-Rad). Acrylamide gels (12.5-17%) were made using a multi-
gel casting chamber following the manufacturer's instructions. Discontinuous acrylamide 
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gels were used consisting of a stacking gel (5% acrylamide in Tris-HCI pH 6.8) allowing 
uniform entry of sample into the gel followed by a separating gel (12.5 -17% acrylamide 
in Tris-HCI pH 8.8) for the resolution of proteins according to molecular weight. 
Following the addition of 60µ1 of 1-D SDS sample buffer, samples were boiled for 5 
minutes and were pulsed in a centrifuge (10000g). The samples were then allowed to cool 
to room temperature prior to loading in parallel with a molecular marker (Fermentas) to 
allow estimation of relative molecular weights of the resolved proteins. Electrophoresis 
was performed in a Tris-Glycine buffer (2SmM Tris, 250mM Glycine pH 8.3, 0.1 % 
SDS). Proteins were resolved at SOY for 20 minutes to allow proteins to enter the 
stacking gel followed by I 00-120V until the dye front reached the end of separating gel. 
On the completion of electrophoresis, gels were used for Western transfer to PVDF 
membrane. 
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2.5.5: Western Transfer of Proteins to PVDF Membrane 
. 
Electrophoretic transfer of proteins to PVDF (Amersham Biosciences) was performed 
using the Mini Trans-Blot system (Bio-Rad) according to the manufacturer's instructions 
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in a Tris-Glycine buffer 25mM Tris, 250mM Glycine pH 8.3, 20% methanol). The PVDF 
membrane required a pre-soaking step in methanol for I minute followed by washing in 
distilled water for 5 minutes before transfer buff er equilibration for IO minutes. The 
assembly consisted of the gel and membrane in direct contact, sandwiched between two 
sheets of filter paper and sponge on either side and held together in a transfer cassette. 
The cassette was placed in the Trans-Blot System checking for correct orientation. 
Electrophoretic transfer was carried overnight at 30V ( 4 °C). 
2.5.6: Immunodetection of Transferred Proteins 
Membranes were removed from the Mini Trans Blot system and placed in universal 
tubes/50ml polypropylene tubes depending on the size of membrane (protein side facing 
the lumen). All steps were carried out on a roller platform mixer (Denley Spiramix) to 
ensure even distribution of solution across the membrane and minimize antibody usage. 
Depending on the primary antibody used blocking of the non-specific binding sites on the 
membrane was carried out by immersing the membrane either in 3% Bovine serum 
albumin (anti-phosphotyrosine, clone 4G I 0) or 5% dried semi-skimmed milk (all other 
antibodies) in DPBS-Tween (lxDPBS supplemented with 0.1% tween-20, Sigma-
Aldrich) for 60-90 minutes at room temperature (alternatively it may be left overnight in 
blocking solution in refrigerator at 2-8°C). The prepared blocking solutions were kept 
aside for antibody dilutions. The membranes were rinsed three times in DPBS-Tween. 
Membranes were incubated for 45-60 minutes at room temperature with the appropriate 
primary antibody diluted in appropriate blocking solution. Following primary antibody 
incubation the membranes were rinsed three times and washed in DPBS-Tween in four 
steps of lxl5minutes and 3 x 05minutes. Dilution of the secondary horseradish-
peroxidase (HRP) antibodies was made in appropriate blocking solution and the 
membranes were incubated for 45-60 minutes. Membranes were washed as described 
previously and prepared for protein detection using Enhanced Chemiluminescence (ECL) 
according to manufacturer's instructions. 
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2.5.7: Detection of Proteins with Enhanced Chemiluminescence (ECL) 
Membranes were drained of excess DPBS-Tween and incubated with equal volumes 
(enough to cover the membrane) of both ECL reagents for 1 minute at room temperature. 
Membranes were placed in a photographic cassette (protein side up) and covered with 
cling-film and taken to dark room. A sheet of autoradiography film was placed on top of 
the membrane in the cassette and exposure of film for varying lengths of times dependent 
on signal strength was carried out followed by developing and fixing of the film 
(KODAK). 
2.6: Assessing FceRI Expression in Transfected Cell lines 
by Flow Cytometry 
Reagents: 
Wash buffer 
Primary antibody 
Secondary antibody 
Flurochrome antibody 
DPBS suplemented with 1% FCS (4°C) 
Mouse IgE (migE) (UoS)/ human IgE (Serotec) 
Biotinylated goat anti human IgE (Vector Laboratories) 
Streptavidin R-phycoerythrin (Sigma-Aldrich) 
Goat anti-mouse lgE FITC-conjugated (Bethyl Laboratories) 
Protocol: 
Transfected cell lines were grown in 100mm tissue culture plates to cell confluency for 
the days of FACS analysis. Cells were washed with pre-warmed PBS and harvested in 
pre-warmed CDS. This was followed by recovery by centrifugation (180g for 3minutes). 
The cell pellet obtained was washed twice in 10ml wash buff er and resuspended at a 
density of 5X106 cells/assay in ice-cold wash buffer. 50µ1 of cell suspension was added to 
non-sterile polypropylene FACS tube as un-labelled negative control and placed on ice 
till cell analysis. Another 50µ1 cell suspension was added to appropriately labelled non-
sterile polypropylene FACS tube as labelled control. The appropriate 1 ° antibody {mlgE / 
. 
hulgE , 1 µg) was added to 100µ1 cell suspension in appropriately labelled non-sterile 
polypropylene F ACS tube labelled as sample and incubated on ice for 30 minutes. After 
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the 30 minutes incubation period the polypropylene F ACS tubes containing the labelled 
control and the sample were washed two times with ice cold wash buffer before finally 
resuspending the pellet in 1ml cold wash buffer. Biotinylated goat anti human IgE (1/400 
dilution in wash buffer) / goat anti-mouse IgE FITC-conjugated (1/500) was added and 
mixed to each tube and left on ice for 30 minutes. The cells were recovered by 
centrifugation and washing as described above. Streptavidin R-Phycoerythin antibody 
(1/50 dilution in wash buffer) was added (RBL transfected cells) and mixed to both tubes 
(labelled control and sample) and again incubated on ice for 30 minutes. Two final 
washes were carried out to remove excess Streptavidin R-Phycoerythin / goat anti-mouse 
lgE FITC-conjugated antibody as described above and the cells were resuspended in 
200µ1 wash buffer and kept on ice till the analysis. Samples were analysed using a 
FASort or a FACS™ CY AN ADP flowcytometer (Dakocytomation). 
2.7: FACS Cell Sorting of Transfected Cell Lines by Flow 
Cytometry 
Reagents same as above. 
Transfected cell lines were grown in 1001145mm tissue culture plates to cell confluency 
(~12X106cells/plate) for the days of FACS sort. Cells were washed with pre-warmed 
PBS and harvested in pre-warmed CDS. This was followed by recovery by centrifugation 
(180g for 3minutes). The cell pellet obtained was washed two times in 10ml wash buffer 
and resuspended in 1 ml ice-cold wash buffer. Cell suspension (50µ1) was added to non-
sterile polypropylene FACS tube as unlabelled negative control and was placed on ice till 
cell sorting. Another 50µ1 cell suspension was added to non-sterile polypropylene F ACS 
tube as labelled negative control and was placed on ice. Human lgE / mlgE (IOµg) was 
added and mixed to the remaining cell suspension (sample) which was incubated on ice 
for 30 minutes. Labelled control and sample were centrifuged (180g for 3minutes) at 
4°C; the supernatant was removed and two washes with ice cold wash buffer were carried 
o~t before finally resuspending the pellet in 1ml cold wash buffer. Biotinylated goat anti 
human IgE (1/400 dilution in wash buffer) / goat anti-mouse lgE FITC-conjugated 
(1/500) was added and mixed to each tube and left on ice for 30 minutes. The cells were 
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recovered by centrifugation and washed as described above. Streptavidin R-Phycoerythin 
antibody (1/50 dilution in wash buffer) was added (RBL transfected cells) and mixed to 
both the tubes (labelled control and sample) and were kept on ice for 30 minutes. Final 
two washes were carried out as described above to remove excess Streptavidin R-
Phycoerythin I goat anti-mouse lgE FITC-conjugated antibody and cells were 
resuspended in 200-500µ1 of wash buffer and were kept on ice till the time of cell sorting. 
Samples were F ACS cell sorted using a F ACSAria or a F ACS Mo Flo flowcytometer 
(Dakocytomation). The sorted cells were collected in the appropriate media and plated in 
100mm plates in the appropiate media (supplemented with Penicillin lO0U/ml and 
streptomycin 1 00µglml to avoid contamination) as described in section 2.3.1. 
2.8: Assesment of Intracellular Calcium Mobilisation 
Intracellular Ca2+ mobilization brought about by antigenic stimulus {NIP/DNP) was 
assessed using the Ca2+ indicator Fluo-3AM , 4-( 6-Acetoxymethoxy-2, 7-dichloro-3-oxo-
9-xanthenyl)-4 • -methyl-2,2'( ethylenedioxy) dianiline-N' ,N' ,N' ,N' - tetraacetic acid 
tetrakis (acetoxymethyl) ester. Developed by Minta et al (1989), Fluo 3 remains non-
fluorescent until bound with Ca2+ resulting in a 40-fold increase in mean fluorescence. 
Analysis was carried out in the visible light range with excitation at -488nm and 
emission at~ 525nm. Acetoxylmethyl ester was added to give an uncharged molecule that 
can diffuse across the cell membrane allowing entry into the cell cytoplasm. 
Acetoxymethyl ester is hydrolysed by action of cytoplasmic esterase yielding Fluo 3 
within cell {Tsien, 1981 ). 
Reagents: 
Balanced Salt Solution (BSS) 
Fluo-3-AM 
fonomycin 
l 48mM NaCl, 49mM KCL, 63mM 
D-sorbitol, 2.63mM K2HPO4, 
lmM KH2PO4, 10.lmM HEPES 
Sigma-Aldrich, 500 µM stock in DMSO 
Sigma-Aldrich, lmglml stock in DMSO 
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Protocol: 
Cells were cultured as a monolayer on 145mm plate and passively sensitized for 16 hours 
with either DNP-specific mlgE (SPE-&, 1/500) or NIP-specific hulgE (JW8, 1/500) at 
37°C. The cells were washed in DPBS and harvested with CDS and centrifuged (180g for 
3 minutes). Cells were counted and resuspended in BSS at lxl06/ml. For the purpose of 
background reading 0.5 ml of each cell suspension was taken. This was followed by 
addition of Fluo 3-AM (5µM) and incubation at room temperature for 30 minutes was 
carried out in the dark. Cells were pelleted and resuspended in DPBS (containing no 
additional CaCii or MgCb) at a density of 2xl06/ml. IgE sensitized cells loaded with 
Fluo-3AM were analyzed using a FACSort flow cytometer preset for Fluo-3AM studies. 
Data was recorded in the form of a density plot of mean fluorescence against time. After 
an initial background reading of 30-50 seconds, samples were activated with the 
appropriate cross-linking agent (NIP/DNP I 00ng/ml). In the event where no calcium 
mobilization was witnessed ionomycin (IOµM) (a calcium ionophore) was used as a 
positive control to ensure that the sample has been loaded with Fluo-3AM. 
2.9: Molecular Biology Methods 
2.9.1: Bacterial Strain 
All cloning work was carried out using the XL I-blue E.coli strain (Stratagene). 
Genotype - recAI end AI gyrA96 thi-1 hsdR17 supE44 re/AI lac [F'pro AB /acfl 
ZM115 Tn IO (Tet1)]. 
2.9.2: E.Coli Growth Media 
Bacterial cultures were grown in LB-broth or LB-agar as required supplemented with the 
antibiotic (Ampicillin I 0µg/ml). 
LB Broth- MQ water, Tryptone (IOg/L), Yeast extract (5g/l), Sodium Chloride (IOg/L). 
LB Agar: LB Broth; Bacteriological Agar (15g/L). 
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2.9.3: Vectors 
pEE6 (Celltech) 
This vector was used previously to generate the RBLhuFcERia transfected cell line 
(Section 1.11) (Wilson et al., 1993). The vector confers resistance to ampicillin and 
neomycin, allowing selection of transformants in E.Coli and mammalian cells using 
G418. 
pUC18 
pUC18 is a 2686bp vector. The vector has a J3-lactamase resistance gene conferring 
ampicillin resistance and lacZ operon, which allows selection of the successfully ligated 
clones. 
2.9.4: Preparation of Competent Bacterial Cells 
Buffers 
TFBJ- 30mM KCH3COO, IOmM CaCh. 50mM MnCh, IO0mM RbCh, 
15% Glycerol pH 5.8 with CH3COOH 
TFB2-10mM PIPES, 75mM CaCh. 50mM MnCh, lOmM RbCh.15% Glycerol. 
pH 6.5 with KOH 
Protocol: 
A single colony from a freshly streaked LB plate was cultured overnight in 2.5ml LB 
medium at 37°C with shaking (approximately 225rpm). The following day the entire 
culture was used to inoculate 250ml LB medium containing 20mM MgSO4 in a 1 L flask. 
Cells were cultured at 37°C with shaking until the OD was between 0.4 and 0.6 (upto 6 
hours). Cells were centrifuged (4500g for 5 minutes) at 4°C and the pellet was gently 
resuspended in 100ml ice-cold TFBl. After incubation on ice for 5 minutes at 4°C, the 
c~lls were centrifuged as before and gently resuspended in 10ml TFB2. After incubation 
on ice for 15-60 minutes the cells were divided into aliquots (200µ1) and quick-frozen in 
a dry ice/ isopropanol bath for storage at -80°C. 
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2.9.5: Transformation of Competent Bacterial Cells 
Competent cells were thawed slowly on ice. Approximately 1 Ong plasmid DNA was 
added to 200µ1 cells and mixed by swirling with a pipette tip. After incubation on ice for 
30 minutes, cells were heated in a water bath at 42°C for 45-60 seconds then cooled on 
ice for 2 minutes. LB medium (3ml) was added and the cells were incubated for 45 
minutes with shaking (approximately 150rpm) at 37°C. 50- 200µ1 of mix was spread on 
plates containing the selection antibiotic (ampicillin). The plates were incubated 
overnight at 37°C and examined for colony growth the next day. 
2.9.6: Isolation of Plasmid DNA 
2.9.6.1: QIAprep Spin Miniprep Kit 
The QIAprep miniprep kit was employed when small amount of DNA was required. The 
kit contained all the required solutions and the protocol provided with the kit ~as 
followed. Cells were isolated from a 3ml overnight culture by centrifugation. The kit is 
based on alkaline lysis of bacterial cells followed by adsorption of DNA onto silica in the 
presence of high salt. The procedure consists of following three basic steps 
• Preparation and clearing of a bacterial lysate 
• Adsorption of DNA onto the QIAprep membrane 
• Washing and elution of plasmid DNA 
Plasmid yield with the QIAprep miniprep system was variable and dependent on plasmid 
copy number per cell, the individual insert in the plasmid, factors that affect growth of 
the bacterial culture, the elution volume, and the elution incubation time. A 1.5ml 
overnight culture yielded between 5 and 15µg of plasmid DNA. 
2.9.6.2: QIAGEN Plasmid Midi Kit 
When large quantities of high purity plasmid DNA were required for mammalian cell 
transfection the QIAGEN plasmid Midi Kit was used allowing upto 100-200µg of DNA 
to be isolated. This kit is also based on the modified alkaline lysis procedure, followed by 
binding of plasmid DNA to QIAGEN Anion-Exchange Resin under appropriate low-salt 
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and pH conditions. Cells were isolated from a 50ml overnight culture by centrifugation. 
RNA, proteins, dyes, and low-molecular weight impurities were removed by a medium-
salt wash. Plasmid DNA was eluted in a high salt buffer and then concentrated and 
desalted by isopropanol precipitation and subsequently washed with 70% ethanol. The 
DNA was eluted in a microcentrifuge with 100-1000µ1 water or TE buffer as specified in 
the protocol provided with the kit. 
2.9. 7: Agarose Gel Electrophoresis 
T AE agarose gel electrophoresis was employed to visualise isolated plasmids, restriction 
enzyme digests and PCR products. A 6x loading buffer (MBI) was added to the DNA 
before loading on I% agarose gel containing 0.Sµg/ml ethidium bromide. Electrophoresis 
was performed using a Biorad subcell at 1 00V, 80mA for 1 hour. A molecular weight 
standard of lKb ladder (Fermentas) was loaded onto the gel. The DNA was visualised 
and photographed under UV light on the Fluorchem TM 8000 imaging system. 
bp 
1000 
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lKb DNA Ladder (Fermentas) 
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2.9.8: DNA Manipulation 
2.9.8.1: Restriction Enzyme Digests 
Restriction enzymes digests were typically carried out in a 20µ1 volume, with 2µ1 1 Ox 
buffer and lOunits of enzymes (lµl). The quantity of DNA used was dependent on the 
application (typically 0.5-1.0µg for test digest and up to 5µg for cloning) and the 
remaining volume made up to 20µ1 with sterile MQ water. The temperature and time for 
digestion depended on the specific restriction enzyme but was commonly 37°C for 1-2hr. 
The optimal 1 Ox buff er for the specific enzymes was used according to the 
manufacturer's recommendation. 
2.9.8.2: Dephosphorylation 
To prevent religations without insertion of the desired fragment, 5' phosphate ends of 
pEE6 vector were removed prior to ligation using calf intestinal phosphatase. Digestion 
of pEE6 was performed to provide linearised rlasmid for ligations. This was followed by 
adding 1µ1 alkaline phosphatase, 2µ1 lOx phosphatase buffer and 17µ1 sterile MQ water 
to the 20µ1 digest mixture followed by incubation at 37°C for 1 hour. 
2.9.8.3: Ligation 
Ligation of DNA fragment was typically carried out in 30µ1 total volume. The reaction 
mixture contained 1µ1 T4 DNA ligase, 3µ1 of lOx ligase buffer, varying ratios of 1:2 or 
1:3 of vector (pEE6) to insert DNA and water to make up the volume. Generally a ratio 
of 1 :2 or 1 :3 of vector to insert was aimed for as generally a 2-3x molar excess of insert 
DNA gives optimal ligation. A plasmid re-ligation control was always set up along side 
whereby an identical reaction was set up having MQ water in place of DNA. The reaction 
was incubated at 16°C overnight. 
52 
CHAPTER2 MATERIALS AND METHODS 
2.9.8.4: DNA Purification from Agarose Gel 
DNA gel extraction from agarose gel was carried out by using Quantum Prep™ Freeze N 
Squeeze DNA gel extraction spin columns kit (BIO-RAD). This kit purifies via filtration 
in a spin column format. The DNA band was excised from an agarose gel, and the gel 
slice cut into small pieces and placed in filter cup. The cup plus gel piece was put in a -
20°C freezer for 5 minutes, then removed and immediately centrifuged (13,000g for 3 
minutes) at room temperature. The agarose debris was retained within the filter cup and 
the bottom of the tube contained the recovered DNA. 
2.9.8.5: Site Directed Mutagenesis 
In vitro site-directed mutagenesis was carried out using Stratagene QuickChange® Site-
Directed Mutagenesis Kit which allows site specific mutation in a double-stranded 
plasmid. This is a rapid four step procedure generating mutants with more than 80% 
efficiency. Miniprep plasmid DNA was used to make point mutations. QuickChange® 
Site-Directed Mutagenesis Kit was performed using PfuTurbo® DNA polymerase and a 
temperature cycler. The procedure utilizes a supercoiled double-stranded DNA (dsDNA) 
vector (pUC18) with the insert of interest and two synthetic oligonucleotide primers 
containing the desired mutation. The primers each complementary to opposite strands of 
vector are extended during temperature cycling by PfuTurbo® DNA polymerase. This 
generates a mutated plasmid containing staggered nicks. This is followed by treating the 
product with Dpn I. The Dpn I endonuclease is specific for methylated and 
hemimethylated DNA and is used to digest the parental DNA tempelate and to select for 
mutation-containing synthesised DNA. DNA isolated from almost all E. Coli strains is 
dam methylated and therefore susceptible to Dpn I digestion. The nicked vector DNA 
containing the desired mutations is then transformed into XLI-Blue supercompetent cells 
(Stratagen). 
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2.9.8.6: DNA Sequencing 
The DNA was sequenced by Cogenics and then analysed using ALIGN, CHROMA and 
CLONE computer programmes to compare the sequence with genomic huFcsRia 
subunit. The primers used for the sequencing were Ml3-48REV and Ml3For-40 to read 
the DNA from both ends. Clones with additional or no mutations were rejected. 
M13-48REV GGGATAACAATTTCACACAG 
M13For-40 GTTTTCCCAGTCACGAC 
2.10: Transfection Mammalian Cells 
Stable transfection in the mammalian cells was obtained by using the technique of 
electroporation. Cells were grown to 50-60% confluency and harvested as already 
described then washed with DMEM containing no FCS or antibiotics, to remove FCS so 
as to prevent sparking during electroporation. The cells were counted and resuspended in 
DMEM to give I 07 cells/0.8ml. The cell suspension was added to electroporation cuvette 
(0.4cm electrode gap) in 0.8ml aliquots. Plasmid DNA prepared by using the Qiagen 
midiprep kit (section 2.9.6.1) was mixed with the cells, and a control prepared using 50µ1 
MQ water in place of DNA. The cuvettes were then incubated on ice for IO minutes. 
Each cuvette was given a single pulse of 250V, 960µF using a Gene Pulser (Bio-Rad) 
then incubated on ice for further IO minutes. The cells were then plated out after 
resuspending in 20ml of appropriate fresh complete medium. After 24-48 hours recovery 
period the medium was aspirated and selection medium was introduced. The cells were 
maintained with change of medium being carried out every 2-3 days. Cells in the control 
died by 7-10 days and the successful transfected cells were grown as normal and selected 
using flowcytometry (section 2. 7). 
Another technique employed for carrying out transient transfection in RBL-2H3. l was by 
using the commercially available METAFECTENE™ PRO transfection reagent as part 
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of collaboration with the manufacturer (Biontex). This reagent uses the Biontex' RMA-
Technology (Repulsive Membrane Acidolysis) with new toxicity optimisation module 
(TOP-technology), which regulates the lipolex release of genetic material. The protocol 
provided by the manufacturer was followed. 
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CHAPTER3 
Mutagenesis of Human Higli Affinity IgE Receptor Alplia 
Cliain subunit 
3.1: Conserved Motif-Fc1:Rla 
Previous studies have demonstrated the presence of an invariant eight amino acid motif 
(LFAVDTGL) within the transmembrane domain of FcsRia and FcyRIIIa subunits, 
shown to be conserved in many species including rat, mice and humans. The conserved 
motif contains a polar aspartate residue at position 194 within a predominantly non-polar 
setting (Ravetch and Kinet, 1991) (Section 1.11). 
3.1.1: Residues Targeted for Site Directed Mutagenesis 
Protein activity can be transformed by using the protein engineering technique of site 
directed mutagenesis thus providing the researchers with an insight into the structure 
function relationship leading to a better understanding of the cellular responses. This 
technique was employed to assess the functional consequences of site-specific 
mutagenesis replacing the D 194 residue of human FcsRia subunit (huFcsRia) to obtain 
an improved understanding of the role of this residue within the transmembrane domain 
in FcsRia-mediated signalling. The mutations introduced previously included asparagine 
(D194N), leucine (D194L), alanine (D194A), glutamic acid (D194E), and lysine 
(D194K) (Iodice, 2006). The RBL-2H3.l cells transfected with mutant huFcsRia 
constructs D194E, D194A, and D194K failed to support cell surface expression (Iodice, 
2006) while the wild type (D194) and mutant variant D194N expressed the huFcsRia 
subunit at the cell surface in association with the endogenous FcR-P and FcR-y subunits 
(Iodice, 2006). The transfected cell lines D194 and D194N demonstrated FcERI 
aggregation, tyrosine phosphorylation of FcR-y and Syk kinase, intracellular Ca +2 
mobilisation and mediator release in response to antigen-mediated activation, analogous 
to that observed in parental RBL-2H3. l cell line (Iodice, 2006). However the RBL-2H3.1 
-cell line transfected with mutant D194L gene construct, although supporting cell surface 
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expression, showed absence of FcERI-mediated signalling in response to antigenic 
stimulus, but the pattern of cell surface expression was suggestive of constitutive receptor 
pre-clustering irrespective of antigenic stimuli (Iodice, 2006). 
In order to gain a more comprehensive understanding of the role of the aspartate residue 
5 new mutations were carried out in the present study which included replacing the D194 
residue with polar residues threonine (D194T), serine (D194S), arginine (D194R) and 
non-polar residues valine (D194V) and isoleucine (D1941). The idea was to replace D194 
with amino acids of different sizes and polarity and assess the effect of these mutations 
on the huFcERla expression and FcERla-mediated signalling. 
The construct verification of the mutations carried out is shown in figure3.1.a and 3.1.b. 
3.1.2 Primer design 
Primers were designed to carry out single point mutation in the D 194 domain with the aid 
of computer software. An additional silent mutation in the form of Stu I was also 
incorporated to aid in assessing the presence of mutation with the help of restriction 
digestion with Stu I and running on TAE agarose gel. The sequence of the primer was 
necessitated by the fixed position of the domain in which the point mutation was to be 
carried out. Primers were based on approximately 20bp sequence around the mutation. 
The mutagenic primers show the altered bases in bold and the altered codons are 
underlined while the silent mutation is shown in bold green. The primers are shown as 
below. 
D194T (Threonine) 
S' 5'GGTGATTCTGTTTGCTGTGACCACAGGCCTA TIT ATCTCAACTCAGCAG 3' 
3 5' CTGCTGAGTTGA GAT AAA TA<; (;CCTGTGGTCACAGCAAACAG AATCAC C 3· 
D194V (Valine) 
S' 5' G GTG A TT CTG TIT GCT GTG GTC ACA GGC CTA TIT ATC TCA ACT CAG CAG 3 • 
3' 5' CTG CTGAGTTGA GAT AAA TAf; GCCTGTGACCACAGCAAA CAG AATCACC 3' 
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D1941 (Isoleucine) 
5' 5' G GTG A TT CTG TIT GCT GTG ATC ACA GGc < TA TIT ATC TCA ACT CAG CAG 3 · 
3' 5' CTGCTGAGTTGA GAT AAA TA<; <:CCTGTGATCACAGCAAA CAG AATCAC C 3' 
Silent mutation- Stu I s· s· AGG CCT 3· 
3· 5'TCC GGA 3' 
The mutations encoding the replacement of Asp with threonine and valine were 
successful but problems were encountered with the isoleucine mutation. This necessitated 
the design of a new primer and successful mutation was introduced by altering the bases. 
D1941 (lsoleucine new primer) 
s· 5' G GTG ATT CTG TIT GCT GTG ATT ACA GGC < TA TIT ATC TCA ACT CAG CAG 3 · 
3' 5· CTG CTG AGTTGA GAT AAA TA<; <;CCTGT A:i!CACAGC AAA CAG AATCACC 3· 
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huFcERla TI 111 TATCCCATTGTTGGTGGTGATTCTGTITGCTGTG~ACAGGATTATTTATC 
FF IP LLV VI --------= 1 F 
D194 Aspartic acid Polar Negatively-charged 
IIIIITATCCCATTGTTGGTGGTGATTCTGTTTGCTGTG~ACAGGATTATITATC 
FF P LLV VI \\ IF 
D194N Asparagine Polar Non-Charged 
TITTTTATCCCATTGTTGGTGGTGATTCTGTTTGCTGTGAM£ACAGGATTATITATC 
FF P LL V V FAV F 
D194L Leucine Non-Polar Non-Charged 
TlllTTATCCCATTGTTGGTGGTGATTCTGTTTGCTGTG.QEACAGGATTATITATC 
FF P LL V VI 1 <i F 
Figure 3.la-Sequence Verification of transmembrane domains of Wild 
type (D194) and mutant (D194N and D194L) huFcERia constructs. 
These variants were generated in a previous study (Iodice, 2006). 
The constructs were sequenced by Lark (Cogenics) Technologies Ltd. The sequence of 
transmembrane domain of huFceRla subunit was obtained from www.cxpasy.org. 
Translated amino acids are shown beneath each sequence. Green shaded area indicates 
the invariant motif with the mutations in bold underlined and in different colours: Dl 94 
(red), D194N (pink) and D194L (yellow). 
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Dl94T Threonine Polar Non-Charged 
TTIITTATCCCATTGTTGGTGGTGATTCTGTTTGCTGTG~ACAGGATTATTTATC 
F F P L L V V I I· V 'I 0 F 
D194V Valine Non-Polar Non-Charged 
TTTTTTATCCCATTGTTGGTGGTGATTCTGTTTGCTGTG.QEACAGGATTATTTATC 
FF Ip LL V vr r V TG F 
D194I Isoleucine Non-Polar Non-Charged 
TTTTTTATCCCATTGTTGGTGGTGATTCTGTTTGCTGTGATTACAGGATTATTTATC 
F F P L L V V I I A V T G F 
D194R Arginine Polar Charged 
TlTTTTATCCCATTGTTGGTGGTGATTCTGTTTGCTGTG,grrACAGGATTATTTATC 
FF P LLY VI V TG F 
D194S Serine Polar Non-Charged 
TTTTTTATCCCATTGTTGGTGGTGATTCTGTTTGCTGTG~ACAGGATTATTTATC 
F F P L L V V I F 'I G F 
Figure 3.lb-Sequence Verification of transmembrane domains of 
mutants (D194T, D194I, D194V, D194R, and D194S) huFctRia 
constructs. These variants were generated in the current study. 
The constructs were sequenced by Lark (Cogenics) Technologies Ltd. Translated amjno 
acids are shown beneath each sequence. Green shaded area indicates the invariant motif 
with the mutations in bold underlined and in different colours: D194T (orange), D194V 
(blue), D194I (lavender), D194R (plum) and D194S (grey). 
61 
CHAPTERJ Mutagenesis of Human High Affinity lgE Receptor Alpha Chain subunit 
3.2: Vectors 
3.2.1: pUC18 
The cloning vector used for carrying out site directed mutagenesis and subsequent 
sequencing of the mutation was pUC18 (figure3.2) which is a relatively small, high copy 
number vector having '3-lactamase gene conferring ampicillin resistance which allows 
selection of successfully ligated clones by growing them on LB media to which 
ampicillin has been added. 
3.2.2: Mammalian expression vector 
pEE6 (figure 3.3) has been used previously by our research group for expression of the 
wild type and mutant huFcERla subunits in the RBL mammalian cell line. The vector 
comprises the gene conferring resistance to ampicillin and neomycin thus allowing 
selection of successfully ligated clones using G4 l 8. 
3.3: Cloning into pUC18 
The huFcERla construct was introduced into the pEE6 expression vector. It was 
necessary to subclone the construct into pUC18 cloning vector to carry out subsequent 
site-directed mutagenesis and sequencing. The pEE6 vector with huFcERia subunit DNA 
construct and pUCl 8 vector were digested using the EcoRI and HindIII restriction 
enzymes (Section 2.9.8.1). The pUC18 vector was dephosphorylated to prevent re-
ligation of the digested linearised vector (Section 2.9.8.2). The digested vector pUC18 
and pEE6 with huFcERla were resolved in parallel on I% T AE agarose gel (Section 
2.9. 7). The representative results are shown in the figure 3.4a. The desired bands i.e. 
794bp (huFceRla) and 2686bp (pUCJ 8) were excised from the agarose gel and purified 
using Quantum Prep™ Freeze N Squeeze DNA gel extraction spin columns kit (Bio-Rad) 
(section 2.9.8.4). The purified bands of pUC18 and huFcERla were ligated together 
(Section 2.9.8.3) The ligation reactions were set up overnight at 16°C, including a 
negative control (water), to rule out any re-ligations. Ligation reactions were 
subsequently transformed into XU-Blue supercompetent cells (Section 2.9.5). The 
transformed cells were plated out onto LB ampicillin plates for selection and incubated 
overnight at 37°C. Next day the plates were examined for colony, numbers of which was 
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highly variable but were below 50. The variability in the number of colonies could be due 
to multiple factors namely competence of cells used for transformation, the quality of 
purified DNA, quantity of DNA agarose bands excised and the ratio of the vector to DNA 
insert. 
Six colonies were picked from the plate into 3ml LB media and incubated overnight on 
shaker at 250rpms in 37°C room. Next day Qiagen DNA miniprep kit was employed for 
small scale DNA extraction (Section 2.9.6.1). Test digestion of 10µ1 miniprep plasmid 
DNA was carried out using the EcoRI and Hind III restriction enzymes (Section 2.9.8.1) 
followed by resolving on T AE gel to confirm the presence of the desired fragment 
(figure 3.4b ). 
3.4: Site-Directed Mutagenesis 
Quickchange Site- Directed Mutagenesis Kit (Stratagene) was employed to introduce the 
point mutations (Section 2.9.8.5). The nicked vector DNA, containing the respective 
desired mutations, was than transformed into XLI-Blue supercompetent cells (Section 
2.9.5). The transformed cells were plated out onto LB ampicillin plates for selection and 
incubated overnight at 37°C. Six colonies were picked from the plate into 3ml LB media 
and incubated overnight on shaker at 250rpms in 37°C room. Next day Qiagen DNA 
miniprep kit was employed for small scale DNA extraction (Section 2.9.6.1). Test 
digestion of 1 OµI miniprep plasmid DNA was carried out using the Stu I, EcoRI and Hind 
III restriction enzymes (Section 2.9.8.1) followed by resolving on TAE gel to confirm the 
presence of the desired mutation (figure 3.5). Miniprep plasmid DNA samples were sent 
for sequencing to check the integrity of the mutations. 
3.5: Sequencing 
The DNA was sequenced by Cogenics and the results were then analysed using ALIGN, 
CHROMA and CLONE computer programmes to compare the sequence with genomic 
huFccRia subunit. The primers used for the sequencing were Ml3-48REV and M13For-
40 to read the DNA from both ends. Clones with additional or no mutations were 
rejected. 
M13-48REV CGGATAACAA TTTCACACAG 
MlJFor-40 GTITTCCCAGTCACGAC 
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Bsm8151 
BsmB:111rd1qr EcoO109l2674 Ndol 183 
Alll 112617 J Nar 1/Kas 1235 
Ssp 12501._____ : J .J" Bgll 245 
~ . • -::;.__Fsp1256 
Eco57 I 27PBI "'-•-Pvu 1276 
,,!--....Pvu Xmn I 2294 . 11306 
Bcg/2215 r 
SCA 12177 
Poly/inker 
cloning sites 
396-454 
Pvu 120661 Pvu II 628 Aval/2059 . + Tll164f 
BsrD 11935 Sap I 6B3 
Fspl 1919 
Avail 1837-
BQll 1813 
B"'lJ;,}~8: 779 
Bsa 11766 
BsrDI 1753 
Ahcl I 1694 EcoS7 I 1333 AtwN 11217 
Figure 3.2 Bacterial expression vector pUC18 
This vector was used previously to introduce site directed mutations in the huFcsRia 
subunit. pUC18 is a 2686bp vector. The vector has a J3-lactamase resistance gene 
conferring ampicillin resistance and lacZ operon that allows selection of the successfully 
ligated clones through blue and white screening procedure. The successful ligations 
appear as white E.Co/i colonies grown in ampicillin-enriched agar plates. Adapted from: 
http://web.bio.utk.edu/peter on/BCMB%205 I 5/pUC I 8map.htm. 
pff 6 plasmid DNA 
6200bp 
Figure 3.3 Mammalian Expression Vector pEE6 
pEE6 is a 6200bp expression vector. It has the bacterial ampicillin resistance gene 
(ampR) and polylinker site for the insertion of the regulatory gene which allows gene 
expression. Modified from Stephens and Cockett (1989). 
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The digested (EcoRT and HindIJI restriction enzymes) vector pUC 18 (Lane2) and pEE6 
with huFceRla gene construct (Janel) were resolved in paral1el on 1% TAE agarose gel 
(figure3.4a). The desired bands i.e. 794hp (huFceRla) and 2686bp (pUCJ 8) were excised 
from the agarose gel and purified using Quantum Prep™ Freeze N Squeeze DNA gel 
extl'action spin columns kit (Bio•Rad) (section 2.9.8.4). The purified bands of pUCl 8 and 
huFcsRJa were ligated together (Section 2.9.8.3). In figure 3.4b ptJC I 8 with huFceRla 
clone digest show the correct appearance of two bands 2686bp pUC18 and 794bp 
huFccRJa in lane 1 while lane M is the 1 Kbp DNA marker (Section2. 9. 7). 
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Test digestion of 10µ1 miniprep plasmid DNA was carried out using the Stu I (Janel) 
andEcoRI /Hind III (lane 2) restriction enzymes followed by resolving on l¾TAE gel to 
confirm the presence of the desired mutation. Lane 1 shows bands at 313bps and 3066bps 
after digestion of PCR product with Stu I, which was according to the incorporated silent 
restriction site of Stu I. Lane M, is the lKbp DNA marker (Section2. 9. 7). 
3.6: Subcloning to pEE6 
After sequencing the clones, with the successful mutation, were employed to subclone the 
mutant cDNA construct into expression vector pEE6 for subsequent transfection into 
mammalian cells (RBLs). 
The p,UCI 8 vector with mutant huFceRla. subunit DNA construct and pEE6 vector were 
digested using the EcoRI and HindlII restriction enzymes (section 2.9.8.1). The pEE6 
vector was dephosphorylated (section 2.918.2) to pre.vent re~ligation of the digested 
linearised vector. The digested vector pEE6 and pUCl8 with mutant huFceRJa were 
resolved in parallel _on 1 % TAE agarose gel (section 2.9.8.4).The representative results 
are shown in the figure 3.6a. The desired bands i.e. 794bp (huFceRla.) and 6200bp 
(pEE6) were excised from the agarose gel and purified using the Quantum Prep TM Freeze . 
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N Squeeze DNA gel extraction spin columns kit (Bio-Rad) (section 2.9.8.4). The purified 
bands of pEE6 and mutant hufcERla were ligated together (section 2.9.8.3) and a 
negative (water) control was also set up to rule out any re-ligations. The ligation reactions 
were set up overnight at l6°C and then were transformed into XU-Blue supercompetent 
cells (section 2.9.5). The transformed cells were plated out onto LB ampicillin plates for 
selection and incubated overnight at 37°C. Next day the plates were examined for colony 
numbers, which were highly variable but were below 50. Six recombinant colonies were 
picked from the plate into 3ml LB media and incubated overnight on shaker at 250rpms 
in 37°C room. Next day Qiagen/Wizard DNA miniprep kit was employed for small scale 
DNA extraction (section 2.9.6.1). Test digestion of 10µ1 miniprep plasmid DNA was 
carried out using the EcoRI and Hind III restriction enzymes (section 2.9.8.1) followed 
by resolving on TAE gel to confirm the presence of the desired fragments (figure J.6b). 
The miniprep plasmid DNA was transformed into XLI-Blue competent cells (section 
2.9.5). The transformed cells were plated out onto LB ampicillin plates for selection and 
incubated overnight at 37°C. Next day the plates were examined for recombinant 
colonies. Two colonies were picked from the plate into 5ml LB media in universals and 
incubated for 8 hours in 37°C room with continuous shaking at 250rpms. After the 
passage of 8hours the contents of the universals were shifted to 50ml LB media in 250ml 
conical flasks for overnight incubation in 37°C room with continuous shaking at 
250rpms. Next day QIAGEN DNA midiprep kit was employed for large scale DNA 
extraction (section 2.9.6.2). Test digestion of 02µ1 midiprep plasmid DNA was carried 
out using the EcoRI and Hind III restriction enzymes (section 2.9.8) followed by 
resolving on T AE gel to confirm the presence of the desired fragments (figure 3. 7). 
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The digested vectors pEE6 and pUC18 with huFceRJa were resolved in parallel on 1% 
TAE agarose gel (3.6a). The desired bands i.e. 794bp (huFceRJa) and 6200bp (pEE6) 
were excised from the agarose gel and purified using the Quantum Preprn Freeze N 
Squeeze DNA gel extraction spin columns kit (Bio•Rad) (section 2.9.8.4). The purified 
bands of pEE6 and mutant huFceRJa were ligated together (Section 2.9.8.J). Tn figure 
3.6b pEE6 with huFceRJa clone digest show the correct appearance of two bands 6200bp 
pEE6 and 794bp huFceRJa in lane 1 while Jane M is the 1 Kbp DNA marker 
(Section2.9. 7). 
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Figure 3. 7 Test Digestion of Midiprep Plasmid DNA 
Test digestion of 02 µl midiprep plasmid DNA was carried out using the Eco RI and Hind 
III restriction enzymes (Section 2.9.8.1) followed by resolving on TAE gel to conftnn the 
presence of the desired fragments. In Lane 1 two bands are visible 6200bp (pEE6) and 
794bp (human alpha chain gene) while lane Mis the lKbp DNA marker (Section2. 9. 7). 
3.7: Expression of the cDNA huFceRia Constructs 
3.7.1: Transfection into Rat Basophilic Leukemia Cell line (RBL-2H3.1) 
The RBL-2H3. I cell line was chosen as the host for gene constructs coding the mutant 
huFceRia subunit constructs (D194T, D194I, D194V, D194S and D194R). It has been 
shown previously that transfection of huFceRla CDNA construct into RBL-2H3 resulted 
in expression of huFceRla by forming a functional chimeric rat/human receptor complex 
with endogenous FcR-'3 and FcR-y subunits (Section 1.11) (Gilfillan et al., 1992, Wilson 
et al., 1993). These stably transfected RBL-2H3.1 cells with huFceRia provided a model 
system to elucidate the mast cell signalling by investigating the huFceRI -mediated cell 
signalling using NIP-specific huJgE (Section 2.4). 
Initially transient transfection using METAFECTENE PRO (Section 2.10) was attempted 
but failed to provide viable cell lines. Subsequently stable transfections were carried out 
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out using electroporation (Section 2.10). In each case a negative control using water in 
place of DNA was set up alongside. The cells in control plates started dying by end of 
first week and died off before the end of second week. At the same time in the plates set 
up for transfection the un-transfected cells also started dying and the successful 
transfectants started forming colonies. When the transfected cells appeared crowded or 
attained confluence they were spread out and split (Section2.3.l). The cells were then 
used to carry out flowcytometric studies (Section 2.6) to ascertain the presence of the 
desired huFcsRia. receptors on the cell surface of RBLs. Following repeated rounds of 
flowcytometric studies stocks of the transfected cells were prepared by cryogenic 
preservation (Section 2.3.2). The cells with the highest levels of cell surface expression 
were selected to create frozen stocks or employed for release assays (Section 2.4), 
flowcytometric and intracellular calcium mobilisation studies (Section 2.8). 
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Chapter4 
Identification of huFceR/a Expression and Assessment of 
Mediator Release via the Transfected Receptor 
4.1 Introduction 
The RBL-2H3. l cells transfected with the wild type and mutant huFceRia cDNA 
constructs (O194T, D1941, O194V, D194S and D194R) (Section]. 7.1) were assessed for 
the cell surface expression of the huFceRia subunit and cellular responses following a 
receptor-mediated cross-linking stimulus by measuring phosphorylation of the y-subunit 
and Syk kinase, intracellular Ca2+ mobilisation, and the exocytic release of mediators. 
These rat/human chimeric receptor complexes can be specifically activated via a human 
IgE (hulgE) mediated cross-linking stimulus to mediate cell secretion (Gilfillan et al., 
1992) leading to release of histamine, inositol phosphate production, intracellular Ca2+ 
mobilisation, and tyrosine phosphorylation of endogenous FceRIW FceRI-y subunits in 
response to anti human IgE cross-linking. Similar studies were carried out in our 
laboratory by Wilson et al (1993) and a stably transfected cell line with huFceRia (D 194) 
was obtained which on being sensitised with the human lgE (JW8) and challenged by 
model antigen NIP-HSA confirmed the formation of a functional receptor complex as 
seen by SHT (5-hydroxy tryptamine) release (Coleman, 1988). Transfection of RBLs 
with huFceRia allowed the independent manipulation of the transfected receptor subunit 
with human IgE, which does not recognize the endogenous rodent receptor (Eccleston et 
al., 1973). 
4.1.1 RBL-2H3 cell line 
The research into understanding of the immunological processes is often difficult due to 
multiple factors involving isolation and primary culturing of the degranulating cells like 
mast cells and basophils (Passante et al., 2009). Tissue mast cells and blood basophils 
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obtained from peripheral blood progenitors require elaborate and lengthy protocols for 
primary culturing and differentiation (Saito et al., 2006). Peritoneal mast cells are 
comparatively easier to obtain by peritoneal lavage of small animals like rats but tend to 
loose their response to antigenic stimuli during the purification process ( Coutts et al., 
1980) and are difficult to maintain in primary culture for long periods of time (Horigome 
et al., 1994). The rat cell line, RBL-2H3, which can be maintained in continuous culture, 
has served as an established model system for the study of secretory events due to their 
ease of culture, and property of adherence to plastic surfaces thus making available in 
short time of a great number of monoclonal cells by simple cell culture techniques (Blank 
and Varin-Blank, 2004). RBL-2H3 cell line was developed in 1973 by inducing 
leukaemia in rats fed with the chemical carcinogen, P-chlorethylamine (Eccleston et al., 
1973). Since then the cell line has been extensively used for studying IgE-FceRI 
interactions, as it bears FceRI receptors, (Ortega et al., 1988) and receptor cross-linking 
activates signalling pathways that culminate in degranulation of multiple mediators ( 
histamine, 5-HT, P-hexosaminidase) almost identical to those observed in primary mast 
cells and basophils (Barsumian et al., 1981, Funaba et al., 2003). This cell line has also 
been employed in assessment studies for mast cell stabilisers (Ikawati et al., 2001). The 
RBL model is expected to continue to serve in future as the model system for studying 
the biological characteristics of mast cells together with an additional potential role in 
clinical research (Blank and Varin-Blank, 2004). 
4.2: Results 
4.2.1: Flow Cytometric Analysis ofTransfected Mutant huFcsRla 
Receptor Subunits 
Flow cytometry is a technique which provides information about various parameters like 
cell size, granularity and degree of flouresence associated with cells under investigation. 
Flow cytometry is a technique that combines optic, fluidic and electronic systems. On 
exposure to the laser system cells scatter the light, which is then picked up by multiple 
sensors located at various angles. The light scattered in the forward direction (Forward 
scatter, FS) provides information about the cell size whilst light scattered in a side 
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direction (Side Scatter, SC) is proportional to the relative granularity of the cell while 
separate fluorescence channels detect any fluorescence associated with the cell. 
Populations of huf cERla expressing cells were sorted on the basis of granularity, size and 
fluorescence and collected and used for preparing stocks of cells with the aim of using 
them to assess the cells capacity to release mediators or support calcium mobilisation. 
RBL-2H3 cells transfected with the mutant huf cERia cDNA constructs were assessed for 
clonal stability and highest huFCERla expressing cells were selected by employing flow 
cytometry (Section 2.6). The transfected cell lines D194 (wild-type) D194T, D194V, 
D1941, D194R and D194S were subjected to repeated rounds of FACS cell sorting 
(Section 2. 7) and analysis. Cells were labelled in series with a combination of human IgE 
(JW8), biotinylated anti-human IgE and streptavidin R-phycoerthrin antibodies. Data 
from the F ACS analysis of the transfected cell lines is shown in figures 4.1 and 4.2. 
The data clearly demonstrate the presence of D194 (wild type used as reference control) 
and D194T receptors on the cell surface of respective transfected cell line (figure 4.lb 
and d respectively). The cell population histogram (figure 4.1 b and d) shows the shift 
to right compared to the unlabelled control (figure 4.la and c) indicating the expression 
of the transfected receptor (human FcERia subunit) on the cell surface of the transfected 
RBL-2H3 cells. 
In figure 4.lf no shift to the right is visible as compared to the unlabelled control (figure 
4.le) indicating the absence of the D1941 receptors on the cell surface oftransfected cell 
line. 
Similarly in figure 4.lh no shift to the right was witnessed as compared to the unlabelled 
control in figure 4.lg thus indicating the failure of D194V receptors to reach the cell 
surface of RBL-2H3 cell line following transfection. 
In figure 4.2b again no shift to the right was observed compared to the unlabelled 
control in figure 4.2a thus demonstrating the absence of D194R receptor expression on 
the cell surface of transfected RBL-2H3 cell line 
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In figure 4.2b again no shift to the right was observed compared to the unlabelled 
control in figure 4.2a thus demonstrating the absence of D l 94R receptor expression on 
the cell surface of transfected RBL-2H3 cell line 
Similarly In figure 4.2d no shift to the right was observed as compared to the unlabelled 
control in figure 4.2c indicating a failure of the transfected cell line to support cell 
surface expression of genes encoding huFci:;RJa D 194S. 
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Figure 4.1: Assesment of cell Surface Expression in D194 (wild type), D194T, 0194V 
and D194I Transfected Cell Lines by Flow Cytometry 
RBL-2H3 cells transfected with the wild and mutant huFceRla cDNA constructs were 
harvested and labelled in series with a combination of human IgE, biotinylated goat anti-
human IgE and streptavidin R-phycoerthrin. Figures 4.1 a, 4.1 c, 4.1 e and 4.1 h show the 
control histogram for D194, D194T, D1941 and D194V transfected cell lines 
. 
respectively. While figure 4.1 b, 4.1 d, 4.1 f and 4, 1 h show the cell population histograms 
of samples of Dl 94, D194T, 01941 and D194V transfected cell lines respectively which 
were assessed for huFcsRfo receptor expression. 
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Figure 4.2: Assesment of Cell surface Expression In D194S and D194R 
Transfected Cell Lines by F.lowcytometry RBL-2H3 cells transfected with the mutant 
huFceRla cDNA constructs were harvested and labelled in series with a combination of 
human JgE, biotinylated goat anti-human IgE and streptavidin R-phycoerthdn. Figures 
4.2a and 4.2c show the control histogram for 0194Rand DI 94S · transfected cell lines 
respectively. Figure 4.2b and 4.2d show the cell population histograms of samples of 
0194R and D194S transfected cell lines respectively which were assessed for huFceRfo 
receptor expression. 
77 
CHAPTER4 huFceR/a expression and assessment of mediator release via the transfected receptor 
4.2.2 f3-hexosaminidase Release Assays 
Following IgE receptor cross-linking by cognate antigen mast cells release inflammatory 
mediators, which play a pivotal role in the allergic disease pathology. Mast cell activation 
initiates downstream intracellular signaling cascades, which cause the fusion of 
preformed secretory granules with plasma membrane and culminate in the release of 
pharmacologically active mediators into the local environment. In view of their similar 
granular content to mast cells RBL-2H3 cells are commonly chosen as a reliable and 
convenient model to study lgE mediated degranulation of mast cells, although in other 
aspects they have similarities to basophils rather than other histamine-releasing cell types 
(Passante et al., 2009). This provides a tool to monitor the presence or absence of 
response of RBL-2H3 cells to antigenic stimulus and level of cellular degranulation, 
which indicates the ability of the parental, and transfected receptors to convert the 
receptor mediated stimulus into a secretory response (Section 2.4). 
The parental RBL-2H3, transfected cell lines D194 (wild-type), D194T, D1941, D194R, 
D194S and D194V were monitored for f3-hexosaminidase release through endogenous 
and huFcERia transfected receptors by challenging them with mlgE specific DNP-HSA 
and human IgE specific NIP-HSA model antigens respectively (Gilfillan et al., 1992, 
Wilson et al., 1993, Aketani et al., 2001, Dearman et al., 2005). The response through the 
endogenous mouse FcERla in parental RBL-2H3 and all the transfected cell lines (D194, 
D194T, D194I, D194V, D194S and D194R) demonstrates release in response to mlgE 
specific DNP-HSA (figure 4.3). D194T cell line exhibited release in response to human 
lgE specific NIP-HSA (figure 4.3). The parental RBL-2H3, D194I, Dl94R, Dl94S and 
D194V transfected cell lines failed to release above background readings in response to 
human lgE specific NIP-HSA (figure 4.3) as the endogenous rodent FcERia specifically 
binds and responds only to rodent but not primate IgE antibodies (Eccleston et al., 1973). 
On being stimulated by monoclonal or polyclonal antibodies the RBLs exhibits a marked 
prozone effect (bell shaped dose-response curve) (Dearman et al., 2005) similar to the 
response in freshly isolated peritoneal murine mast cells (Coleman, 1988) and human 
basophils (Hoffmann et al., 1999). 
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Figure 4.3: Release of 13-hexosaminidase through FcsRia transfected receptors in 
RBL-2H3 and RBL-2H3 transfected cell lines D194 (wild-type), D194T, D194Rl 
D19412 D194S and D194V cell lines in response to antigenic stimulus 
CeJls were cultured, harvested, re-suspended at 0.5x 106/ml in appropriate media with 
DNP-specific mlgE (SPE-7, 11500) I NIP-specific hulgE (SPE, 1/500) and plated into 96 
well plates. After 16h, cells were washed and activated with DNP-HSA / NIP-HSA cross-
linking agent (0.1-1 0000ng/ml) for 20 minutes prior to incubation with P-hexosaminidase 
substrate for 2 hours. 
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4.2.3: Intracellular Calcium Mobilisation 
The exocytosis in mast cells is a calcium concentration- dependent process (Beaven et 
al., 1984a, Beaven et al., 1984b, Costa et al., 1997) which causes the intracellular 
secretory granules to fuse with the plasma membrane and release the preformed 
inflammatory mediators into the local environment in response to IgE FcERI-mediated 
activation brought about by cross-linking of the FcERis with multivalent agents (Metzger 
et al., 1986). The RBL-2H3 cell line has similar properties to mast cells and has been 
used for studying the intracellular mobilization of calcium in response to antigenic 
stimulus (Bingham et al., 1994, Aketani et al., 2001 ). 
Intracellular Ca2+ mobilization in parental RBL-2H3 and tranfected cell lines D194T 
' 
D194V, D194I, D194R and D194S brought about by antigenic stimulus (NIP/DNP) 
(Aketani et al., 2001, Dearman et al., 2005) was assessed using the Ca2+ indicator Fluo-
3AM (Section 2.8). IgE sensitized cells loaded with Fluo-3AM were analysed using a 
FACSort flow cytometer preset for Fluo-3AM studies. Data were recorded in the form of 
a density plot of mean fluorescence against time. After an initial background reading of 
30-50 seconds, samples were activated with the appropriate cross-linking agent 
(NIP/DNP 1 OOng/ml) and in the absence of calcium mobilization the samples were 
challenged with a calcium ionophore (ionomycin) to ensure that the cells had been loaded 
with Fluo-3AM. 
The cells sensitized with mlgE exhibited an increase in mean fluorescence peaking at 
26seconds after being activated by mlgE-specific DNP-HSA (figure 4.4A). Similar 
results were obtained for D194 (wild-type used as a reference control) and Dl94T cell 
line when sensitized with hulgE and activated by hulgE-specific NIP-HSA (figure 4.4B 
and C respectively). However in case of D194I, D194V, D194R and D194S cell lines, 
no calcium mobilization was observed when the cells were sensitised with hulgE and 
activated by hulgE-specific NIP-HSA (figures 4.4 D, E, F and G respectively). The 
same cell lines (D1941, Dl94V, D194R and. D194S) that failed to elicit calcium 
mobilization with hulgE-specific NIP-HSA were activated by ionomycin (calcium 
ionophore) and exhibited an immediate increase in mean fluorescence which was 
maintained until a slow decrease occurred due to a depletion of intracellular Ca2+ (figures 
4.4D, E, F and G respectively). 
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Figure 4.4: Assessment of Intracellular calcium level of RBL-2H3 transfected cell 
lines D194 {wild-type), D194T, D194V, Dl 941, D194R and D194S transfected cell 
lines following activation in the absence of extraceJJular calcium 
RBL·2H3 cells transfected with the wild•type (D 194) and mutant huFcaRJo: cDNA 
constructs were sensitised with (Figures A) DNP-specific migE (SPE-7, 1/500) or 
(Figures B, C, D, E, F) NIP-specific hulgE (JW8, 1 /500) for 16 hours. lgE sensitised cells 
were washed in BSS and harvested with CDS. Cells were loaded with Fluo 3-AM (5µM) 
for 30 minutes at room temperature in the dark. Samples were washed and re-suspended 
at 2x 106 /ml in DPBS (without CaCI2 or MgC}i). After an initial background reacting the 
cells were activated with appropriate cross-linking agent DNP (Figures A) and NIP 
(Figures B, C, D, E, and F) at a concentration of lOOng/ml. Following excitation at 
488nm emitted fluorescence was recorded at 525nm using a FACSort flow cytometer 
(BD biosciences). D194I, D194V, D194R and D194S celJs were then activated witli 
. 
ionomycin (1 OµM, Figures C, D, E, and F). Results are representative of three separate 
experiments. 
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4.2.4: FcR-r and Syk Kinase Phosphorylation 
The activation of protein tyrosine kinases (PTKs) (Reth, 1989) is a mandatory step in 
signal transduction from immune receptors (IRs) including the T cell receptor (TCR), B-
cell receptor (BCR), FcERI, and IgG-Fc receptors. The IRS lack intrinsic kinase activity 
but have immunoreceptor tyrosine- based activation motif (ITAM) (Romeo et al., 1992, 
Samelson and Klausner, 1992, Cambier, 1995, Pawson, 1995) which play a pivotal role 
in cell activation. 
The cross-linking of the high affinity IgE receptor in response to appropriate antigenic 
stimuli causes activation of PTKs within seconds leading to phosophorylation of various 
substrates including IR subunits (Benhamou et al., 1990, Paolini et al., 1991). Toe 
aggregation of FcERI receptors causes phosphorylation, usually by Lyn, of the tyrosine 
residues in ITAMs of both the j3 and the r subunits offceRI (Reischl et al., 1999, Rivera, 
2002, Siraganian, 2003, Galli et al., 2005). Current evidence suggests that tyrosine 
phosphorylated ITAMs then act as scaffolds for the binding of the additional signaling 
molecules with Src homology domain 2 (SH2) like the cytoplasmic protein tyrosine 
kinase Syk, which binds mainly to the r subunit of the receptor through its two SH2 
domains. This is followed by conformational change of Syk leading to its activation and 
autophosphorylation (Section I. 4.1). 
Syk family has two members syk and ZAP-70 which are essential for lymphocyte 
development and signal transduction via IRs (Turner et al., 2000, Latour and Veillette, 
2001). Syk kinase has 8 tyrosine residues and is responsible for signal transduction in 
FceRI (Siraganian, 2003) and BCR (Dal Porto et al., 2004). Syk kinase expression has 
been demonstrated in RBL-2H3 cell line and is a rapid process preceeding calcium 
mobilization, tyrosine phosphorylation being detected within 1 minute after receptor 
stimulation (Benhamou et al., 1990). Other studies with RBL-2H3 cell line are suggestive 
of preferential binding of Syk SH2 domains with FcR- 'Y IT AMs and activation of Syk 
kinase proceeding tyrosine phosphorylation of the FcR- 'Y (Shiue et al., 1995). Studies 
with RBL-2H3 Syk-deficient variant (TB1A2 cells) and Syk deficient mast cells 
demonstrated the presence of j3 and 'Y chain phosphorylation but downstream events are 
abrogated (Costello et al., 1996, Zhang et al., 1996). There was reinstatement of 
intracellular signaling and degranulation on reconstitution of Syk kinase expression in 
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TB 1A2 cell line and Syk deficient mast cells (Costello et al., 1996). Syk kinase inhibitors 
have been shown to inhibit signaling and degranulation by selectively inhibiting FcERI-
mediated activation (Oliver et al., 1994, Moriya et al., 1997). 
Studies by Paoilini et al (1991) demonstrated a rapid(< 30sec) in vivo phosphorylation of 
FcR- y (tyrosine and threonine) and FcR- ~ subunits (tyrosine and serine) following 
engagement of FcERI receptor. FcR- y subunit belongs to the same family as TCR{; 
subunit and in their capability to mediate T cell development and function are 
interchangeable although the native TCR{; subunit is far more efficient (Shores et al., 
1997) (Section 1.6.3). Further studies (Paolini et al., 1995) using {;-deficient T cell line 
demonstrated the requirement of FcR- y IT AMs in FcERI-mediated signalling. Studies 
where mutations were introduced in the tyrosine residues of ~ and y chains IT AMs 
abolished signalling (Letourneur and Klausner, 1991, Jouvin et al., 1994, Lin et al., 
1996). Similarly it was found that the downstream signaling cascade can be initiated by 
attaching IT AM sequence of y-chain to unrelated extracellular domains (Letourneur and 
Klausner, 1991, Romeo and Seed, 1991). However it is the ITAM sequence of y-chain, 
which alone can initiate downstream signaling in FcERI (Letourneur and Klausner, 1991, 
Romeo and Seed, 1991) while ~-chain serves as amplifier of they-chain signaling (Lin et 
al., 1996, Dombrowicz et al., 1998). 
4.2.4.1: Immunoprecipitation Studies Results 
The tyrosine phosphorylation status of FcR- y and Syk kinase was investigated by 
immunoprecipitation studies (Section 2.5.3). The parental RBL-2H3.1 and the 
RBL.2H3.l cells transfected with the mutant huFcERia cDNA constructs D194T cell 
lines exhibited tyrosine phosphorylation of FcR- y subunit at ~ 12-1 SkDa (Bingham et al., 
1994, Iodice, 2006) and Syk kinase at ~ 72kDa (Hutchcroft et al., 1992, Iodice, 2006) 
once they were sensitised with hulgE and activated by hulgE-specific NIP-HSA antigen 
system. The level of tyrosine phosphorylation was reduced in case of D194T cell line as 
compared to the parental RBL-2H3.1 cell line probably due to lower huFcERla receptor 
numbers as also seen in other previously transfected cell lines (D 194, D 194N and 
D l 94L) which expressed huFcERla receptors (Iodice, 2006). 
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Figure 4.5: Phosphorylation state of FcR-y in parental RBL-2H3.J and 
RBL-2H3.1 cells transfected with the mutant huFcERla cDNA 
constructs (pl94 (wild-type), D194T) 
Parental RBL-2H3.1 and RBL-2H3.1 cells transfected with the mutant huFceRla cDNA 
constructs were cultured and sensitised overnight with DNP-specific migE (SPE-7, 
1/500) or NIP-specific hulgE (JW8, 1/500) respectively. Cells were cultured, harvested, 
resuspended at 5x106/m1 in appropriate media and activated with appropri~te cross-
linking agent (1 00ng/ml) for 2 minutes. Cells were Iysed using RIPA buffer foJ1owed by 
immunoprecipitation using a mouse monoclonal anti-phosphotyrosine antibody (clone 
4010, Millipore). Immunoprecipitates were resolved by SOS-PAGE (12.5% acrylamide). 
Electrophoretic transfer of proteins to PVDF (Amersham Biosciences) was carried out 
overnight at 30V (4°C). Western blots were probed with rabbit polyclonal FcR-y 
(Millipore) antibody and protein bands were visualised using ECL. 
FcR-y quantification w~s carried out on aliquot removed from samples prior to 
immunoprecipitation and probed with rabbit polyclonal FcR-y (Millipore) antibody. 
Results are representative of at ]east 5 separate experiments. 
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Figure 4.6: Phosphorylation state of Syk kinase in parental RBL-283.1 
and RBL-2H3.1 cells transfected with the mutant huFcERla cDNA 
constructs (D194 (wild-type) and D194T 
Parental RBL-2H3.1 and RBL-2H3.1 cells transfected with the mutant huFceRJa cDNA 
constructs were cultured and sensitised overnight with DNP-specific mlgE (SPE-7, 
1/500) or NIP-specific hulgE (JW8, 1/500) respectively. Cells were cultured, harvested, 
resuspended at 5x106/ml in appropriate media and activated with appropriate cross-
linking agent (lO0ng'ml) for 2 minutes. Ce11s were lysed using RIPA buffer followed by 
immunoprecipitation using a rabbit polyclonal anti-Syk antibody (Santa Cruz). 
Immunoprecipitates were resolved by SDS~PAGE (12.5% acrylamide). Electrophoretic 
transfer of proteins to PVDF (Amersham Biosciences) was carried out overnight at 30V 
(4°C). Western blots were probed with mouse monoclonal anti-Syk (Abeam) and mouse 
monoclonal anti-phosphotyrosine antibody ( clone 4G 10, Millipore) antibodies. Protein 
bands were visualised using ECL. 
Syk kinase quantification was carried out on aliquot removed from samples prior to 
immunoprecipitation. 
4.3: Sum,mary of Results 
The RBL.2H3. I cells transfected with the mutant huFceRfo, cDNA constructs (DJ 94T, 
D1941, O194V, D194S and D194R) (Section3.7.J) were assessed for the cell surface 
expression of the huPceRJa subunit and the response to the antigenic stimulus by looking 
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for degranulation, intracellular Ca2+ mobilisation, and phosphorylation of the y-subunit 
and Syk kinase. 
D 194T transfected cell line expressed the huFcERia as shown by tlowcytometric studies 
(figure 4.ld) and in response to antigenic stimulus degranulation was affected as seen by 
P-hexosaminidase release assay (figure 4.3) and intracellular calcium mobilisation 
(figure 4.5d). The immunoprecipitation studies on D194T cell line showed 
phosphorylation of y-chain (figure 4.6) and Syk kinase (figure 4. 7) on being stimulated. 
These results indicate the presence of functional huFcERla subunit in D 194T transfected 
cell line working in synergy with the endogenous rodent P and y chains. These results are 
comparable to those seen following transfection of RBL-2H3. l cell line with huFceRia 
(D194)(Wilson et al., 1993) and mutant huFceRia cDNA constructs (0194N) (Iodice, 
2006). 
D1941, D194V, D194S and D194R transfected cell lines did not express the huFceRia 
receptor (figures 4.lf,h and 4.2b,c) and no degranulation in response to antigenic 
stimulus as seen in f3-hexosaminidase release assay (figure 4.3) and intracellular calcium 
mobilisation (figure 4.Sc,d, e and f). Simifar results were obtained when RBL-2H3.1 cell 
line was transfected with mutant huF cERia cDNA constructs (D 194 E, DI 94 K and 
D194A) (Iodice, 2006). This data indicates that mutations introduced at the position 
D 194 have significant effects on receptor expression and downstream signalling thus 
highlighting the importance of this residue. 
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Chapters 
High Affinity IgE Receptor a and r Subunit 
Interactions 
5.1: Introduction 
The high affinity lgE receptor (Fci::RI) belongs to the immunoglobulin superfamily 
(Metzger 1992; Kinet 1999) and as the name suggests possess the highest affinity of 
all immunoglobulin receptors with a binding constant in the 109 to 1010 M"1 range for 
its ligand, lgE (Metzger 1992; Daeron 1997; Kinet 1999) compared to 6.3xl07M ·1 in 
the low affinity receptor, Fci::RII also referred to as CD23 (Spiegelberg, 1984). CD23 
is distributed on several different cell types namely B lymphocytes, macrophages, 
eosinophils, platelets, some T cells, and follicular dendiritic cells and has diverse roles 
including antigen presentation and regulation of lgE synthesis (Delespesse et al., 
1991, Delespesse et al., 1992, Bonnefoy et al., 1997). Fci::RI exists as a tetrameron 
the surface of mast cells and basophils (Section 2. 6). The tetramer comprises the 
ligand binding subunit or a-chain, a P-chain and a disulphide-linked y-chain dimer. In 
contrast, in Langerhans cells, dendiritic cells and monocytes Fci::RI is present as a 
trimer and is devoid of the P-chain comprising only one a-chain and two y-chains 
(Turner and Kinet 1999). However in rodents only the tetrameric isoform is present 
and the P-chain is essential to facilitate cell surface expression of the receptor 
complex (Kinet, 1999). 
Since the minimal signalling complex depends on Fci::Rla and FcR-y subunits 
interaction, it was necessary that mutations designed to shed light on a and y- chain-
mediated signalling be carried out in the Fci::R-y subunits on the same lines as those 
carried out in the a-subunit (Chapter 4). 
5.2: Human art Construct 
The subunits (a, p, and y) of FcsRI are composed of three domains: extracellular 
(EC), transmembrane (TM) and cytoplasmic (CT) domains (Ravetch and Kinet, 
1991, Beaven and Metzger, 1993). The EC domain FcsRia subunit is responsible for 
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ligand binding through its high affinity lgE Fe binding domain (Kuster et al., 1990). 
The cytoplasmic domain of they-subunit ofFcERI is responsible for steric masking of 
dilysine ER retention signal in the cytoplasmic domain of the FcERia subunit to 
ensure the exportation of the assembled receptor to the cell surface from the ER 
(Miller et al., 1989, Letourneur et al., 1995a). In order to investigate the role of y TM 
and CD in inter subunit interactions it was necessary that site directed mutagenesis 
studies be carried out in these two domains . However these mutated y dimers need 
activation independent of the endogenous expressed subunits for which an 
extracellular label, EC domain of huFcERla, was chosen. This allowed the ligand 
binding domain of the receptor complex to be stimulated through hulgE and antigen 
as the endogenus rodent FcERia specifically binds and responds to the murine, but not 
primate lgE antibody (Eccleston et al., 1973). 
A chimeric construct composed of the extracellular (EC) domain of the human high 
affinity IgE receptor alpha subunit (huFcERla) spliced onto the rodent gamma TM 
and cytoplasmic domain (CD) was generated. In the present study this chimera was 
transfected into the RBL-2H3 cell line, a cell line which has already been shown to 
form a functional rat/human chimeric receptor complex on being transfected with 
huFcERla (Gilfillan et al., 1992, Wilson et al., 1993). 
The earliest studies aimed at the identification of a structure function relationship in 
FcERI used non-mast cell lines like COS7, CHO and P815 (Kuster et al., 1990, Varin-
Blank and Metzger, 1990, Miller et al., 1990, Blank et al., 1991) which were 
transfected with receptor subunits. These cell lines do not produce granules containing 
mast cell mediators and as a consequence only the effects of various FcERI domains 
on cell surface expression could be analysed in these studies. It was found that the rat 
FcERla requires both the p, and y subunits for its expression but the huFcERla could 
be transiently expressed even in the absence of the P subunit in COS 7 cell line. 
Although deletion of CDs decreases the efficiency of membrane insertion, these were 
not mandatory for receptor surface expression (Varin-Blank and Metzger, 1990). 
Various studies have been conducted using chimera made up of the CD of the y 
subunit FcERI or TCR~ and the EC domain of CD4 (Romeo and Seed, 1991) or Tac, 
the interleukin 2 receptor(Letourneur and Klausner, 1991 ). In the study by Letourneur 
et al ( 1991) a chimeric receptor consisting of EC domain of a chain of the interleukin 
receptor (Tac) and CT domain of either c; or y when expressed in T cells or RBLs 
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could be activated leading to release of interleukin 2 in T cells and serotonin in RB Ls. 
A chimera made up of EC and TM domains of CDS to the CT domain of the s chain 
was prepared and used in a study by Irving et al (1991) suggested that CDS can 
activate the appropriate signal transduction pathway in the absence of CD3. Chimeric 
proteins containing EC and TM domains of Tac receptor and CT domains of either s 
or y suggested that FcERI-y is responsible for some but not all the changes in 
downstream signalling that are observed following receptor cross-linking (Eiseman 
and Bolen, 1992). In a study by Wilson et al (1995) where RBLs were transfected 
with chimera made up of EC domain of Tac joined to the CT domains of y and p 
subunits {TTP and TTy) the level of signalling activities differed between the two 
chimeras with TTy exhibiting a full range of signalling activity to no signalling 
response in TTf3. Repetto et al (1996) constructed chimeric receptors of the EC and 
CT domains of the FcERI and the IL-2R p55 subunit (I) and stably transfected them 
into RBL-2H3 cells. The two constructs prepared by Repetto et al were alyly and 1/y/y 
and results demonstrated that FcERia EC and FcERy CT domains are mandatory for 
signalling process (Repetto et al., 1996). 
5.2.1: Results 
The already established huFcERiaJy/y construct was present in pUC18 cloning vector. 
Three 10µ1 miniprep plasmid DNA samples were sent for sequencing to check the 
authenticity of the construct. Cogenics sequenced the DNA and results were then 
analysed using ALIGN, CHROMA and CLONE computer programmes. The primers 
used for the sequencing were M13-4SREV and M13For-40 to read the DNA from 
both ends. The huFcERla/y/y construct was found to contain two unwanted mutations. 
These spurious mutations were corrected using site-directed mutagenesis. 
5.2.1.1: Primer Design 
Two primers were designed to carry out single point mutation with the aid of 
computer software to correct the unwanted mutations in the huFceRia/y/y construct. 
The sequence of the primers was necessitated by the position of the mutations which 
needed to be corrected. The primers are shown on the next page with the altered bases 
in bold and the altered codons are underlined. 
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Correction 1 
5' 5'CACAATGGCAGCCTTTCAGAAGAGAC 3' 
3' 5 'GTCTCTTCTGAAAGGCTGCCATTGTG 3' 
Correction 2 
5' 5'TGCCCTAGGAGAGCCGCAGCTCTGCTATATC 3' 
3' 5'GATATAGCAGAGCTGCGGCTCTCCTAGGGCA 3' 
5.2.1.2: Site-Directed Mutagenesis 
Quickchange Site- Directed Mutagenesis Kit (Stratagene) was employed to carry out 
the point mutations (Section 2.9.8.5) one at a time. The nicked vector DNA containing 
the respective desired mutations was than transformed into XLI-Blue supercompetent 
cells (Section 2.9.5). The transformed cells were plated out onto LB ampicillin plates 
for selection and incubated overnight at 37°C. Six colonies were picked from the plate 
into 3ml LB media and incubated overnight on shaker at 250rpm in the 37°C room. 
Next day Qiagen DNA miniprep kit was employed for small scale DNA extraction 
(Section 2.9.6.1). Test digestion of 10µ1 miniprep plasmid DNA was carried out using 
the EcoRI and Hind III restriction enzymes (Section 2.9.8.1) followed by resolving on 
TAE gel (figure 5.1). Miniprep plasmid DNA samples were sent for sequencing to 
Cogenics to check for the correction of first mutation. On confirmation of the 
correction the same technique as mentioned above was employed to correct the 
second mutation. Miniprep plasmid DNA samples were again sent to Cogenics for 
sequencing to check the correction of the second mutation and absence of any other 
unwanted mutation. 
5.2.1.3: Subcloning to pEE6 
After sequencing, the clones, with the corrected mutations, were used to subclone the 
cDNA construct (huFceRia/-y/-y) into expression vector pEE6 for subsequent 
transfection into mammalian cells (RBLs). Vectors pEE6 and pUC18 with 
huFceRia/-y/-y were digested using the EcoRI and Hind III restriction enzymes 
(Section 2.9.8.1). The digested vector pEE6 and pUC18 with huFceRia/-y/-y were 
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resolved in parallel on 1 % T AE agarose gel (section 2. 9. 8.4). The desired bands 
i.e.1117bp (b.uFcERialy/y) and 6200bp (pEE6) were excised from the agarose gel and 
purified using the Quantum Prep™ Freeze N Squeeze DNA gel extraction spin 
columns kit (Bio-Rad) (section 2.9.8.4). The purified bands of pEE6 and 
huFcERla/y/y were ligated together (section 2.9.8.3) and a negative (water) control 
was also set up to rule out any religations. The same procedure as described 
previously in section 3.6 was employed. The ligation reactions were transformed into 
XLI-Blue supercompetent cells (section 2.9.5). Qiagen/Wizard DNA miniprep kit was 
employed for small scale DNA extraction (section 2.9.6.1). Test digestion of 10µ1 
miniprep plasmid DNA was carried out using the EcoRI and Hind III restriction 
enzymes (section 2.9.8.1) followed by resolving on TAE gel to confirm the presence 
of the desired fragment. The miniprep plasmid DNA was transformed into XLI-Blue 
competent cells (Section 2.9.5). QIAGEN Plasmid Midi Kit was employed for large 
scale DNA extraction (section 2.9.6.2). Test digestion of 10µ1 midiprep plasmid DNA 
was carried out using the EcoRI and Hind III restriction enzymes (section 2.9.8.1) 
followed by resolving on T AE gel to confirm the presence of the desired fragment 
(figure 5.2). 
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pUC 18 (2686bp 
art construct 
(1117bp) 
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Figure 5.1 Test Digestion of Mini prep Plasmid DNA 
Test digestion of I OµI miniprep p.lasmid DNA was carried out using the EcoRI and 
Hind III restriction enzymes (Section 2.9.8.1) followed by resolving on TAE gel to 
confirm the presence of the desired fragment. In Lane l two bands are visible 2686bp 
(pUCl8) and l 117bp (huFceRia!yly construct) while lane Mis the lKbp DNA marker 
(Section2.9. 7). 
8000b 
6000b 
M 1 
Figure 5.2 Test Digestion ofMidiprep Plasmid DNA 
Test digestion of 10µ1 midiprep plasmid DNA was carried out using the EcoRI and 
Hind III restriction enzymes (Section 2.'9.8.1) followed by resolving on TAE gel to 
confirm the presence of the desired fragment. In Lane 1 two bands are vis.ible 6200bp 
(pEE6) and 1 l 17bp (huFceRia./y/y construct) while lane Mis the IKbp DNA marker 
(Section2. 9. 7), 
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5.2.1.4: Transfection into Rat Basophilic Leukaemia Cell 
line (RBL-2H3.1) 
The RBL-2H3.l cell line was employed as the host for the huFcERla/y/y construct. 
Stable transfections were carried out using electroporation (Section2. J 0). In each case 
a negative control using water in place of DNA was setup alongside. The same 
procedure as described previously in section 3. 7.1 was employed. The transfected 
cells were then used to carry out flowcytometric studies (Section 2. 6) to ascertain the 
presence of the desired huFcERla receptors on the cell surface of RBLs. Following 
flowcytometric studies stocks of the transfected cells were prepared by cryogenic 
preservation (Section 2.3.2) and employed for release assays and intacellular calcium 
mobilisation studies (Section 2.8). 
5.2.1.5: Flow Cytometric Analysis of Transfected RBL-2H3 
Cells for huFcERla Receptor Subunits 
The RBLs cell lines transfected with the huFcERla/y/y cDNA constructs were 
assessed for surface expression of huFcERla by employing the flow cytometry 
technique which provides information about various parameters like cell size, 
granularity and degree of flouresence associated with cells under investigation 
(Section 2. 6). Cells were labelled in series with a combination of human IgE (JW8), 
biotinylated anti-human IgE and streptavidin R-phycoerthrin antibodies. Data from 
the FACS analysis of the transfected RBLs is shown in figures 5.3. 
The data demonstrates the absence ofhuFcERla receptor subunit on the cell surface of 
transfected RBLs (figure 5.3b). The cell population histogram (figure 5.3b) shows no 
shift to right compared to the unlabelled control (figure 5.3a) indicating the absence 
of the transfected receptors (human FcERla subunit) on the cell surface of the 
transfected RBL-2H3 cells. 
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Figure 5.3: Assessment of cell surface expression of huFceRia 
transfected receptors in RBL-2H3 cells transf ected with 
huFceRla/y/y construct by flowcytometry 
RBL-2H3 ceJls transfected with the huFcsRia/y/y cDNA constructs were harvested 
1abe1led in series with a combination of human IgE, biotinylated goat anti-human JgE 
and streptavidin R-phycoerthrin. Figures 5.3a shows the control histogram whj]e 
figure 5.3b shows the cell population histograms of sample of huFcsRia/y/y 
transfected cell lines which were assessed for huFceRia receptor expression. 
5.2.1.6: ~-bexosaminidase Release Assays 
The RBL-2H3 transfected ce11 line with the huFceRia/y/y cDNA constructs was 
monitored for P-hexosaminidase release through endogenous and huFcsRia. 
transfected receptors by chaJlenging them with mlgE specific DNP-HSA and human 
IgE specific NIP-HSA model antigens respectively (as described previously in Section 
4.2.2) (Aketanj et al., 2001, Dearman et al., 2005). The RBL-2H3 transfected cell line 
with the hu.FcsRia/y/y cDNA constructs demonstrates release in response to mlgE 
specific DNP-HSA (figure 5.4). The RBLs transfected with huFceRia/y/y cDNA 
constructs when sensitised with human IgE and subsequently challenged with human 
IgE specific NIP-HSA model antigen failed to release ~bove background readings 
(figure S.4). 
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Beta Hexosaminidase Release Assay 
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Figure 5.4: Release of 8-hexosaminidase through rodent FceRia. and 
huFceRla. transfected receptors in RBL-2H3 transfected with human 
huFcERla/y/y construct in response to antigenic stimulus 
Cells were cultured, harvested, resuspended at 0.5x106/ml in appropriate media with 
NIP-specific hulgE (SPE, 1/500)/ DNP-specific mlgE and plated into 96 well plates. 
Next days, cells were washed and activated with DNP-HSA/NIP-HSA cross-linking 
agent (0.1-1 0000ng/ml) for 20 minutes prior to incubation with P-hexosaminidase 
substrate for 2 hours. P-hexosaminidase release was assessed as described in section 
2.4. Data is presented as mean ± S.D. from three separate experiments performed in 
triplicate. 
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5.2.1.7: Intracellular Calcium Mobilisation 
Intracellular Ca2+ mobilization in RBL-2H3 transfected with huFceRia/y/y cDNA 
constructs brought about by antigenic stimulus (NIP/DNP) was assessed using the 
Ca2+ indicator Fluo-3AM (Section 2.8) (Aketani et al., 2001, Dearman et al., 2005). 
IgE sensitized cells loaded with Fluo-3AM were analysed using a F ACSort flow 
cytometer preset for Fluo-3AM studies. Data was recorded in the form of a density 
plot of mean fluorescence against time. After an initial background reading of 30-50 
seconds, samples were activated with the appropriate cross-linking agent (NIP/DNP 
1 00ng/ml) and in the event of no calcium mobilization the samples were challenged 
with a calcium ionophore (ionomycin) as a positive control to ensure that the cells 
have been loaded with Fluo-3AM. 
The RBL-2H3 transfected with huFceRia/yly cDNA constructs sensitized with mlgE 
exhibited an increase in mean fluorescence peaking at 26seconds after being activated 
by migE-specific DNP-HSA (figure 5.5a) and no calcium mobilization was observed 
on being sensitized with hulgE and activated by hulgE-specific NIP-HSA (figures 
5.5b ). The same transfected RB Ls on failure to elicit calcium mobilization with 
hulgE-specific NIP-HSA were activated by ionomycin as a positive control and 
exhibited an immediate increase in mean fluorescence which was maintained until a 
slow decrease occurred relating to a depletion of intracellular Ca2+ (figures 5.5b). 
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Fhmre 5.5: Assessment of Intracellular calcium level of RBLs 
transfected with huFceRia/y/y cDNA constructs followin2 activation 
in the absence of extracellular calcium 
RBL-2H3 cells transfected with the huFceRia/y/y cDNA constructs were sensitised 
with (Figures A) DNP-specific mlgE (SPE-7, 1/500) or (Figure B) NIP-specific hulgE 
(JW8, 1/500) for 16 hours. IgE sensitised cells were washed in BSS and harvested 
with CDS. Cells were loaded with Fluo 3-AM (5µM) for 30 minutes at room 
temperature in the dark. Samples were washed and resuspended at 2x 1.06 /ml in DPBS 
(without CaCh or MgCJi). After an initial background reading the cells were activated 
with appropriate cross-linking agent DNP (Figures A) and NIP (Figures B) at a 
concentration of 1 00ng/ml. Following excitation at 488nm emitted fluorescence was 
recorded at 525nm using a FACSort flow cytometer (BD biosciences). The cells were 
then activated with io_nomycin (1 0µM, Figure B). Results are representative of three 
separate experiments. 
5.2.1.8: Discussion 
The RBLs cell lines transfected with the huFceRia/y/y cDNA constructs (Section 
5 .2.1.4) were assessed for the cell surface expression of the huFceRla subunit and the 
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response to the antigenic stimulus by looking for degranulation and intracellular Ca2+ 
mobilisation. The results obtained showed the absence of huFceRla subunit 
expression on the surface of transfected cells as seen by flowcytometric studies 
(Section 5.2.1.5), P-hexosaminidase assays (Section 5.2.1.6) and intracellular calcium 
mobilsation studies (Section 5.2.1. 7). Similar results were obtained previously by 
Higginbottom in 1996 (PhD thesis). In contrast, a study by Repetto et al a afyly 
construct when stably transfected into RBL-2H3 cells lead to expression of the 
receptor which was able to exhibit all the signalling events similar to the native rat 
FceRI thus demonstrating the mandatory role of both the FceRicx EC domain and 
FcR-y CT domains (Repetto et al., 1996). It was expected that similar expression if 
achieved in the present study could lead to mutations being introduced in TM 
domains of the y that would provide insight into the intersubunit interactions. The 
huFceRla/y/y cDNA construct had the problem of presence of spurious point 
mutations, which needed correction. Similar problems were encountered in the 
generation and transfection of a!y/y cDNA constructs into RBL cells in a study by 
Higginbottom (1996). It is therefore surprising that the results published by Repetto 
and collaborators (1996) could not be reproduced in the present and previous study 
conducted by Higginbottom ( 1996). In the study by Repetto et al VIS expression 
vector (unavailable), which possesses a visna virus promoter for constitutive 
expression, was used for transfection into COS and RBL cell lines (Repetto et al., 
1996), While in the study by Higginbottom pMAMneo vector, which is an inducible 
vector, was employed for transfection of a!yly cDNA constructs into RBL cells 
(Higginbottom, 1996). In the present study constitutive expression pEE6 vector, 
which has been sucessfully used for the expression of wild-type and mutant huFceRlcx 
constructs into RBL-2H3 cell line, was used and the reason for the non-expression of 
huFcsRla/y/y cDNA constructs remains uncertain. 
The human-rodent chimeric receptors are assembled differently than the endogenous 
rodent receptors as seen in study in which COS 7 cells were transfected with 
human/rat chimeric complexes (Varin-Blank and Metzger, 1990). 
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5.3: RBL Gamma Chain Deficient Cell Line 
The RBL y-chain deficient cell line was generated by Draberova and Draber (1995) 
using chemical mutagenesis, which was reported to have resulted in a variant cell 
RBL cell line deficient in y subunit expression, and it is known that the y subunit is 
essential for the cell surface expression of FcsRI and FcyRIII (Kinet, 1992). The 
originators of the RBL y-chain deficient cell line transfected these cells with the 
rodent gamma construct (rFcERy) to enable the surface expression of FcERI, which 
was then challenged with antigen to assess the release of mediators after sensitising 
the transfected cells with mouse IgE and a successful outcome was published by Petr 
Bocek et al (1995). This work formed the basis for the next part of the project which 
was to use the site-directed mutation technique to introduce mutations into TM 
residue at position 22 (Thr22) of the gamma subunit and to assess their effect on the 
surface expression by carrying out stable transfection in the RBL y-chain deficient 
cell line. Two mutations were generated and introduced in place of threonine residue. 
One was alanine (T22A) and second was serine (T22S). The intention was to assess 
the effect of replacement of threonine with an almost similar-sized non-polar alanine 
and slightly smaller-sized polar serine residue on signal transduction. 
5.3.1: Subcloning to pEE6 
The already established wild-type and mutant rFcERy constructs (T22A and T22S) 
were present in the pUC18 cloning vector (figure 5.6). Sequencing (Cogenics) of the 
wild-type and mutant (T22A & T22S) rFcERy construct was carried out and cDNA 
constructs were subcloned into expression vector pEE6 for subsequent transfection 
into the RBL y-chain deficient cell line. The digested vector pEE6 and pUC18 with 
wild-type and mutant rFcERy constructs were resolved in parallel on 1 % T AE agarose 
gel (section 2.9.8.4). The desired bands i.e.260bp (wild-type and mutant rFcERy 
constructs) and 6200bp (pEE6) were excised from the agarose gel and purified using 
the Quantum Prep™ Freeze N Squeeze DNA gel extraction spin columns kit (Bio-
Rad) (section 2.9.8.4). The same procedure as described previously in section 3.6 was 
employed. The ligation reactions were transformed into XLI-Blue supercompetent 
cells (section 2.9.5). Qiagen DNA miniprep kit was employed for small scale DNA 
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extraction (section 2.9.6.1). Test digestion of 10µ1 miniprep plasmid DNA was carried 
out using the EcoRI and Hind III restriction enzymes (section 2.9.8.1) followed by 
resolving on TAE gel to confirm the presence of the desired fragment. The miniprep 
plasmid DNA was transformed into XLI-Blue competent cells (Section 2.9.5). 
QIAGEN Plasmid Midiprep Kit was employed for large scale DNA extraction 
(section 2.9.6.2). Test digestion of J OµI midiprep plasmid DNA was carried out using 
the EcoRI and Hind III restriction enzymes (section 2.9.8.1) followed by resolving on 
T AE gel to confirm the presence of the desired fragment (figure 5. 7). 
Puc18 (2686 bp) 
Gamma genes construct 
(260bp) 
1 M 
3000bp 
2500bp 
500bp 
250bp 
Figure 5.6 Test Digestion of Mini prep Plasmid DNA 
Test digestion of 1 OµI miniprep plasmid DNA was carried out using the EcoRI and 
Hind III restriction enzymes (Section 2.9.8.1) foJJowed by resolving on TAE gel to 
confirm the presence of the desired fragment. In Lane 1 two bands are visible 2686bp 
(pUC18) and 260bp (y construct) while lane M is the lKbp DNA marker 
(Section2.9. 7). 
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Figure 5. 7 Test Digestion of Midi prep Plasmid DNA 
pEE6 (6200 bp) 
Gamma gene construct 
(260bp) 
Test digestion of I 0µl midiprep plasmid DNA was carried out using the EcoRI and 
Hind III restriction enzymes (Section 2.9.8.1) followed by resolving on TAB gel to 
confim1 the presence of the desired fragment. In Lane 1 two bands are visible 6200bp 
(pEE6) and 260bp (y construct) while lane Mis the lKbp DNA marker (Section2.9. 7). 
5.3.2: Transfection into RBL Gamma Chain Deficient Cell Line 
Stable transfections were carried out usmg electroporation in the RBL y-chain 
deficient cells (Section2. l 0). In each case a negative control using water in place of 
DNA was setup alongside. The same procedure as described previously in section 
3.7.1 was employed. 
The transfected cells were then used to carry out flow cytometric studies (Section 2. 6) 
to ascertain the presence of the desired mouse FceRia receptors on the cell surface of 
RBL y-chain deficient cells. Fo11owing flow cytometric studies stocks of the 
transfected cells were prepared by cryogenic preservation (Section 2.3.2) and 
employed for release assays and intracellular calcium mobilisation studies (Section 
2.8). 
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5.3.3: Flow Cytometric Analysis of Transfected RBL y-chain 
Deficient cells for FctRla receptor subunits expression 
The RBL y-chain deficient cell line transfected with the rFceRy and mutant rFceRy 
cDNA constructs were assessed for clonal stability and highest FceRia expressing 
cells by employing the flowcytometry technique (Section 2.6). Cells were labelled in 
series with a combination of mlgE and FITC labelled anti-mouse IgE antibody. Data 
from the F ACS analysis of the transfected cell lines is shown in figure 5.8. Figure 
5.8A shows the unlabelled control. The data demonstrate the expression of FceRia 
receptor subunit on the cell surface of parental RBL y-chain deficient cells (figure 
5.8C) at a level lower as compared to RBL-2H3 cell line (figure 5.8B). The RBL y-
chain deficient cells transfected with wild-type rFceRy cDNA construct (RBL-y+) 
shows a reversion to expression of the FceRia receptor subunit to the same level 
(Figure 5.8E) as the parental RBL-2H3 cell line. The y-chain deficient cells 
transfected with mutant rFceRy cDNA construct (T22A and T22S) also shows a 
reversion to expression of the FceRia receptor subunit to the same level (figure 5.8F 
and G) as the parental RBL-2H3 cell line. FACS analysis of the sham transfection 
carried out showed the same level of FceRia receptor subunit expression (figure 
5.8D) as the parental y-chain deficient cells. 
5.3.4: J3-hexosaminidase Release Assays 
The parental RBL-2H3, RBL y-chain deficient cells and RBL y-chain deficient cells 
transfected with the wild-type and mutant rFceRy cDNA constructs were monitored 
for P-hexosaminidase release by sensitising them with mlgE specific DNP-HSA 
followed by antigenic challenge (Wilson et al., 1993, Aketani et al., 2001, Dearman et 
al., 2005). The parental RBL y-chain deficient cells and sham transfected cells 
demonstrated release in response to mlgE specific DNP-HSA which is much lower as 
compared to parental RBL-2H3 (figure 5.9). The transfected cell lines (RBL-y+, 
T22A and T22S) in response to mlgE specific DNP-HSA released at a higher level as 
compared to the parental RBL y-chain deficient cells (figure 5.9) but still much lower 
than the parental RBL-2H3 cells. 
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5.3.5: Intracellular Calcium Mobilisation 
Intracellular Ca2+ mobilization in parental RBL-2H3, RBL y-chain deficient cells and 
RBL y-chain deficient cells transfected with the wild-type and mutant rFceRy cDNA 
constructs cell lines brought about by antigenic stimulus (DNP-HSA) was assessed 
using the Ca2+ indicator Fluo-3AM (Section 2.8) (Wilson et al., 1993, Aketani et al., 
200 I, Dearman et al., 2005). lgE sensitized cells loaded with Fluo-3AM were 
analysed using a F ACSort flow cytometer preset for Fluo-3AM studies. Data were 
recorded in the form of a density plot of mean fluorescence against time. After an 
initial background reading of 30-50 seconds, cells were activated with the appropriate 
cross-linking agent (DNP I 00ng/ml) and in the event of no calcium mobilization 
being witnessed the samples were challenged with a calcium ionophore (ionomycin) 
to ensure that the cells had been loaded with Fluo-3AM. 
The RBL-2H3 cells sensitized with mlgE exhibited an increase in mean fluorescence 
peaking at 26 seconds after being activated by mlgE-specific DNP-HSA (figure 
S.1 OA). In case of RBL y-chain deficient cells and RBL y-chain deficient transfected 
cells no calcium mobilization could be observed on being sensitized with mlgE and 
activated by mlgE-specific DNP-HSA (figures 5.1 OB, C, D, E and F). The RBL y-
chain deficient cells and RBL y-chain deficient transfected cell lines on failure to 
elicit calcium mobilization with mlgE-specific DNP-HSA were activated by 
ionomycin and exhibited an immediate increase in mean fluorescence which was 
maintained until a slow decrease occurred relating to a depletion of intracellular Ca2+ 
(figures 5.1 OB, C, D, E and F). The RBL y-chain deficient cells and RBL y-chain 
deficient transfected cell lines support P-hexosaminidase release by challenging them 
with mlgE specific DNP-HSA but with the release being much lower as compared to 
parental RBL-2H3 cell line (Section 5.2.1.6). The methodology of assessing the 
intracellular calcium mobilization using the Ca2+ indicator Fluo-3AM (Section 2.8) in 
the RBL y-chain deficient cells and RBL y-chain deficient transfected cell lines after 
sensitising with mlgE and activating by mlgE-specific DNP-HSA indicated that these 
cell lines were incapable of supporting any intracellular calcium mobilisation. 
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Figure 5.8: Assessment of cell surface expression of mouse FcsRia receptors in 
RBL•2H3, RBL y-cbain deficient cell line, RBL y-chain defic_ient cell line 
transfected with wild type <RBL-y+) and mutant rFceRy constructs (T22A and 
T22S) and sham transfection by flowcytometry 
RBL-2H3 (5.8B), RBL y-chain deficient cells (5.8C), RBL y--chain deficient cells 
transfected with the rFceRy construct (RBL-y+) (5.8E), RBL y-cbain deficient cell 
line transfected with mutant rFceRy constructs (T22A and T22S) (5.8F and O 
respectively), and sham transfection (5.8D) were harvested labelJed in series with a 
combination of mouse IgE and anti-mouse FITC labelled IgE and assessed for mouse 
FceRia receptor expression. 
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Figure 5.9: Release of P-hexosaminidase in RBL-2H3, RBL y-chain deficient cell 
line, RBL y-cbain deficient cell line transfected with wild type (RBL-y+) and 
mutant rFcERy construct (T22A and T22S) and sham transfection in response to 
an IgE mediated antigenic stimulus 
Cells were cultured, harvested, re-suspended at 0.5xl06/ml in appropriate media with 
DNP-specific mlgE (SPE, 1/500) and plated into 96 well plates for 16h. Next day, 
cells were washed and activated with DNP-HSA cross-linking agent (0.1-
1 0000ng/ml) for 20 minutes prior to incubation with '3-hexosaminidase substrate for 2 
hours. '3-hexosaminidase release was assessed as described in section 2.4. Data are 
presented as mean± S.D. from three separate experiments performed in triplicate. 
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-Figure 5.1 O: Assesment of intracellular calcium level in RBL-2H3, RBL y-chain 
deficient cell line, RBL y-chain deficient cell line transfected with wild type 
(RBL-y+) and mutant rFcERy constructs (T22A and · T22S) and sham 
transfection following activation in the absence of extracellular calcium. 
RBL-2H3 (5. lOA), RBL y-chain deficient cell line (5.10B), RBL y-chain deficient cell 
linel transfected with the rFceRy construct (RBL-y+) (5.10D), RBL y-chain deficient 
cell line transfected with mutant rFceRy constructs (T22A and T22S) (5.IOE and F 
respectively), and sham transfection (5.IOC) were sensitised with DNP-specific mlgE 
(SPE-7, 1/500) for 16 hours. IgE sensitised cells were washed in BSS and harvested 
with CDS. Cells were loaded with Fluo 3-AM (5µM) for 30 min at room temperature 
in the dark. Samples were washed and re-suspended at 2x 106 /ml in DPBS (without 
CaCh or MgCb), After an initial background reading the cells were activated with 
DNP-HSA at a concentration of lOOng/ml. Following excitation at 488nm emitted 
fluorescence was recorded at 525nm using a F ACSort flow cytometer (BD 
biosciences). The cells were then activated with ionomycin (lOµM, Figures.JOB, C, 
D, E and F). Results are representative of three separate experiments. 
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5.3.6 Conclusions 
RBL y-chain deficient cell line exhibits a lower level of FccRia expression and 
degranulation in response to antigenic stimulus as compared to RBL cell line. 
Transfection of RBL y-chain deficient cells with the wild-type and mutant rFceRy 
constructs lead to restoration of FceRia expression in the transfected cell lines (RBL-
y+, T22A and T22S) to same levels as RBL cell line but the degranulation in 
response to antigenic stimulus although comparatively higher than the parental RBL 
y-chain deficient cell line was still significantly lower than RBL cells indicating a 
defective secretory response. The level of expression and degranulation in the 
transfected cell lines did not show much variation between the wild-type (RBL-y+) 
and mutant cell lines (T22A and T22S) indicating the necessity of carrying out further 
site-directed mutation studies (Section 6.4.1 ). 
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6.1: Introduction 
DISCUSSION 
The aim of the study was to understand the interaction between the subunits of high affinity 
immunoglobulin E receptor (FcERI) and its ability to mediate transmembrane signalling. 
Immunoglobulin E is key player in producing the allergic phenomena (lshizaka and Ishizaka, 
1967, Yazdanbakhsh et al., 2001, Maizels and Yazdanbakhsh, 2003) that is responsible for 
causing multiple debilitating allergic diseases which are being labelled as the epidemic of the 21 st 
century (lsolauri et al., 2004). FcERI is composed of ligand binding a-chain (Hakimi et al., 1990, 
Blank et al., 1991, Ra et al., 1993), signal-amplifying f3-chain (Scharenberg and Kinet, 1997, 
Kinet, 1999) and signal-transducing y subunits (Kinet, 1999). A model for the interaction was 
first described by Faber and Sears but rejected by our group on the basis of data obtained 
(Section 1.11) (Iodice, 2006) and the aim of the present study was to design experiments capable 
of assessing predictions made by the new molecular model structure. 
Firstly: Site-directed mutations ( Chapter3 and 4) were carried out in the D 194 residue within the 
TM domain of the hufcERla subunit which were then transfected into Rat Basophilic Cells 
(RBL-2H3. l) to produce rat/human chimeric receptors and assess the effect of the mutations on 
subsequent receptor expression and signalling. 
Secondly: Transfection into the RBL cell line (Chapter 5) of chimeric constructs created using 
the extracellular (EC) domain of the human high affinity lgE receptor alpha subunit (huFcERla) 
spliced onto the rodent gamma TM and cytoplasmic domain (CD) to achieve the surface 
expression of the huFcERla and activate them independent of the endogenous rodent FcERla. 
Thirdly : Assessment of a model system for studying the effects of mutations carried out in y 
subunits by using a gamma chain deficient RBL cell line (Bocek et al., 1995) and transfecting it 
with wild type (rFcERy) and mutant gamma constructs ( T22A and T22S). 
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6.2: Detection of huFcERI Expression and l\1ediator Release in Transfected 
RBL.2H3.1 Cells 
The RBL-2H3.l cells were transfected with the mutant huFcERla cDNA constructs (DI 94T, 
D1941, D194V, D194S and D194R) (Section3. 7.1) and assessed for the cell surface expression of 
the huFcERla subunit and the response to the antigenic stimulus employing measurements of 
mediator release, intracellular Ca2+ mobilisation, and phosphorylation of the y-subunit and Syk 
kinase as functional read-outs for signal propagation via the activator receptor complex. The 
results obtained showed that the mutation of the polar aspartic acid, at position 194 of the 
transmembrane domain of the huFcERla, to a slightly smaller polar threonine residue and 
subsequent transfection into parental RBL-2H3.1 cell line (D194T) resulted in a functional 
rat/human chimeric receptor, the huFcERla in association with the endogenous rodent FcR-P and 
FCR-y subunits, which was not only able to express the human receptor as shown by flow 
cytometric results (Section 4.2.1) but also degranulate in response to antigenic stimulus 
(huigE/NIP-HSA) as exhibited by P-hexosaminidase assay (Section 4.2.2) and intracellular 
calcium mobilsation studies (Section 4.2.3). 
In contrast the mutations to isoleucine (D1941), valine (D194V), serine (D194S) and arginine 
(D194R) and transfection into RBL-2H3.1 cells failed to create the assembly of a functional 
chimeric receptor complex as seen by flow cytometric studies (Section 4.2.1), P-hexosaminidase 
assays (Section 4.2.2) and intracellular calcium mobilsation studies (Section 4.2.3). This data 
harmonizes with the previous study by our group suggesting the importance of a polar residue at 
the 194 position (Iodice, 2006). 
Previous studies by our group showed that mutations to asparagine (D 194N) and leucine 
(D194L) lead to surface expression of the huFcERla subunit but it was only D194N which had a 
functionally viable receptor which was able to respond to antigenic stimulus, thus pointing to the 
importance of a polar residue at the 194 position as it is expected that the polar Asp serves to 
stabilise the receptor complex by forming side-chain/side-chain inter-helical hydrogen bonding 
with the other subunits (Iodice, 2006). It had already been shown that mutations to alanine 
(D194A), glutamic acid (D194E) and lysine (D194K) carried out previously failed to induce 
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huFc1::Rla expression in transfected cells. According to the model proposed (Section 1.9) the 
side-chain of residue 194 is placed in a closely packed central position at the interface between 
the transmembrane helices where there will be severe restraints as to which side chain can be 
accommodated. This is consistent with the results which demonstrates that the residue at 194 be 
a polar residue of medium size (Asp, Asn, Tor) computed of making two separate hydrogen 
bonds with the Thr22 residue in the two FcR-y subunits. The mutation to almost similar sized 
non-polar Ile (D1941) failed to exhibit surface expression as it is essentially different in polarity 
despite occupying similar space as Asp. The polar Tor mutation (D194T) is able to maintain 
receptor expression and function while the almost similar sized non-polar valine (D194V) is 
disfavoured as it is incapable of hydrogen bonding. It is evident that only slightly larger polar 
residues Glu (D194E) and polar Lys (D194K) and much larger sized polar Arg (D194R) were 
also not found to be suitable replacement although like Asp, Asn and Tor, the residues Glu, Lys, 
and Arg should also be capable of making the predicted hydrogen bonds thus reflecting the 
critical nature of the packing restraints at this position. Similarly the smaller sized residues non-
polar Ala (D194A) and polar Ser (D194S) also failed to act as a suitable substitution at the 194 
P?sition as no surface expression was witnessed in the D 194A and D 194S transfected cells. It is 
possible that in all the above-mentioned mutations the correct assembly of the three 
transmembrane helices is compromised and thus correct assembly at the cell surface does not 
take place. In studies on COS-7 cells by Varin-Blank and Metzger (1990) a polar to non-polar 
mutation (D195A, homologous residue to D194) TM mutation in the rat Fc1::Rla subunit resulted 
in marked reduction in cell surface expression. Similarly in another study by Gosse et al. (2005) 
a chimeria consisting of the EC domain of huFc1::Rla, TCR~ TM having a D15A mutation and 
CT domain exhibited a reduction in cell surface expression. 
These data point to the importance of the D 194 residue in receptor expression and downstream 
signalling as previously many studies have highlighted the importance of TM conserved residues 
of the immune receptors (TCR, BCR, IgA receptor, Fc1::RI) on receptor subunit assembly, 
expression and function (Varin-Blank and Metzger, 1990, Audoly and Breyer, 1997, Cain et al., 
2001, Kunjibettu et al., 2001, Gosse et al., 2005). 
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6.3: Transfection of RBL Gamma Chain Deficient Cell with Wild-
Type and Mutant rFcERy Constructs 
A mutant of the RBL-2H3 cell line with FcsRI deficient in they subunit, which is essential for 
the expression FcsRI, was employed in the study (Draberova and Draber, 1995) with the aim of 
assessing the FcsRia and y -chain interaction in transmembrane signalling. The RBL y-chain 
deficient cells were stably transfected with the wild-type and mutant rFcsRy cDNA constructs 
using electroporation technique (Section 5.3.2). The RBL y-chain deficient cells and RBL y-
chain deficient cells transfected with the wild-type and mutant rFcsRy cDNA constructs were 
assessed for the cell surface expression of the FcsRia subunit, the response to the IgE-mediated 
antigenic stimulus (DNP-HSA) by measuring the release of mediators during degranulation and 
intracellular Ca2+ mobilisation. 
Initial assessment of parental RBL y-chain deficient cell line for FcsRia expression by flow 
cytometry exhibited presence of FcsRia subunit at a level much lower than the parental RBL-
2H3 cell line, but not a complete deficiency (Section 5.3.3), and in response to antigenic stimulus 
degranulation was observed as seen by P-hexosaminidase release assay but at a level lower than 
in parental RBL-2H3 cells (Section 5.3.4). The RBL y-chain deficient cells transfected with the 
wild-type (rFcsRy) construct (RBL-y+) expressed the FcsRla at a level similar to RBL-2H3 cell 
line as shown by flow cytometric studies and in response to antigenic stimulus degranulation 
could be demonstrated as seen by (3-hexosaminidase release assay but at a level lower than in the 
parental RBL-2H3 cells. The results are similar to data obtained in a previous study carried out 
by Bocek et al (1995). 
After successfully demonstrating that by transfecting RBL y-chain deficient cells with rFcsRy 
construct reversion of full FcsRia can be obtained, the RBL y-chain deficient cells were 
transfected with mutant rFcsRy cDNA constructs in which the threonine residue at position 22 in 
the TM region of the rodent gamma subunit was replaced with polar serine (T22S) and non-polar 
alanine (T22A). RBL y-chain deficient cells transfected with mutant rFcsRy cDNA constructs 
expressed the FcsRia at a level similar to RBL-2H3 cell line as shown by flow cytometric 
studies (Section 5.3.3) and in response to antigenic stimulus J3-hexosaminidase release was 
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obtained although at a level significantly lower than RBL-2H3 cells but higher than the parental 
RBL -y-chain deficient cells (Section 5.3.4). The molecular basis for the lower level 13-
hexosaminidase release in the transfected cell lines (RBL--y+, T22A and T22S) as compared to 
the parental RBL-2H3 observed in the present study awaits further investigation but might be 
attributable to an incomplete assembly of the receptor complex resulting in inefficient signal 
propagation, a phenomenon commonly observed in RBL cells variants (Cohen-Dayag et al., 
1992). A sham transfection carried out did not support any increase in the FcERla expression 
(Section 5.3.3) in the parental RBL -y-chain deficient or increase in degranulation in response to 
antigenic stimulus (Section 5.3.4). The level of FcERla expression restoration is similar in all the 
three transfections (RBL--y+, T22A and T22S) carried out and the 13-hexosaminidase release was 
also of same level with no difference apparent between the wild-type and mutant rFcER-y cDNA 
constructs. 
The technique of Ca2+ imaging (Section 2.8) for assessing intracellular calcium mobilisation in 
response to antigenic stimulus did not prove sensitive enough in case of RBL -y-chain deficient 
cells and RBL -y-chain deficient cells transfected with the wild-type and mutant rFcERy cDNA 
constructs to detect any intracellular calcium mobilization, although it is known that the FcERl-
mediated pathway culminating in exocytosis requires Ca mobilization. 
6.4: Future Work 
The current study has provided assessment of a model system (RBL -y- chain deficient cell line) 
for studying the affect of mutagenesis in the gamma subunit along the same line as was carried 
out in the a-chain. Since they-chain deficient cell line still supported some FCERia expression, a 
meaningful interpretation of the changes in the interactions between a and -y-chain interactions in 
the FcERI at the molecular level requires further experimental analysis. 
6.4.1: Mutational Analysis of FcR-y Subunit 
Mutations were carried out in the Thr22 position of the gamma construct which were 
subsequently transfected into the RBL y-chain deficient cell line. The result obtained revealed no 
significant effect of the mutations (T22A and T22S) on the surface expression and degranulation 
levels as compared to the transfected wild-type cell line (RBL--y+ ). There is need to carry out 
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further mutations in the Thr22 (T22V) and other residues in the 'Y construct. A possible residue 
which can be targeted is the K29 (rat FceRI-y) as this has been suggested by Farber and Sears 
(1991) to be involved in interaction with the D203 residue of the rat FcyRIIIa (Section 1.9). The 
K29 residue is homologous to the K.30 residue of huFcR-y and D203 corresponds to D194 in 
huFceRia. 
6.4.2 Alternative Model System 
On the basis of data obtained in the current study the use of RBL y-chain deficient cell line as 
potential model system has been found to be associated with certain limitations including the 
continued expression of FceRI, even before transfection of the gamma constructs, and the 
defective secretory response to antigenic stimulus in the parental RBL y-chain deficient and the 
transfected RBL y-chain deficient cells. An alternative cell line which may be used is the COS-7. 
This cell line has been used for transfecting mutant FceRI subunits in previous studies (Varin-
Blank and Metzger, 1990, Kuster et al., 1990, Mao et al., 1993). If COS-7 cell line is co-
transfected with the gamma and huf ceRia constructs, used in the present study, together with co-
transfection of gene constructs encoding the FceRIP subunits it may provide an alternative means 
of assessing the effects of mutations in the a and 'Y subunits although the use of this line only 
allows the assessment of cell surface expression as they do not support mediator release (Varin-
Blank and Metzger, 1990, Kuster et al., 1990, Mao et al., 1993). 
6.5: Conclusions 
The present study provided further support for the importance of residue D 194 in the 
transmembrane region on surface expression and downstream signaling of FceRI. Various 
mutations carried out at the D 194 position showed that a polar residue of medium size (D 194T) 
Was required for cell surface expression of FceRI and successful downstream signalling leading 
to degranulation in response to antigenic stimulus. RBL-2H3 transfected with mutant hufceRia 
subunit cDNA constructs showed that mutations to almost similar sized non-polar Ile (D1941) 
and V (D194V), larger sized polar Arg (D194R), and smaller sized polar Ser (D194S) and non-
polar Ala (D194A) lead to loss of surface expression of huFceRia subunit and abrogation of 
downstream signalling as evidenced by loss of degranulation in response to an lgE-mediated 
antigenic stimulus. These data point towards D 194 residue as being a potential target for 
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developing future anti-allergy therapeutic strategies by inhibiting FcERI-mediated signalling 
along the same lines as T- cell receptor signalling inhibition and "molecular wedge" anti-cancer 
drugs (Section 1.9). Further research needs to be carried out with the aim of developing TM-
derived peptides sequence targeting D 194 residue. 
The current study also investigated the validity of RBL -y-chain deficient cell line (mutant of 
RBL-2H3 cell line) as a potential model system for assessing the effect of mutation in the -y-
chain to gain an improved understanding of a- and -y-chains interactions. A variant RBL-line 
proclaimed to be -y-chain deficient exhibited lower levels of FcERI expression and degranulation 
than the parental RBL-2H3 cells. Transfections of these cells with wild-type and mutant -y-chain 
cDNA constructs lead to restoration of FcERI expression to a similar level as seen in RBL-2H3 
cell line. Measurement of degranulation in response to antigenic stimulus in the transfected RBL 
y-chain deficient cells (RBL--y+, T22A and T22S) also showed an increased level as compared to 
the parental cells (RBL -y-chain deficient) but was still at a much lower level than RBL-2H3 cell 
line pointing to defective receptor assembly and downstream signal signaling resulting in a 
reduced secretory response commonly observed in variant RBL cells (Cohen-Dayag et al., 1992, 
Bocek et al., 1995). 
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Abstract 
The high-affinity receptor complex for IgE plays a pivotal role in allergic responses 
since cross-linking of the high affinity IgE receptor (FceRI) on target cells initiates a 
signaling cascade facilitating release of inflammatory mediators causing allergic 
responses. The transmembrane regions of the ligand binding domain of the high-
affinity lgE and low-affinity lgG receptors share an invariant motif (LFAVDTGL) 
containing a polar aspartate within a predominantly non-polar setting. The functional 
importance of this aspartate residue (D194) in FceRI-mediated receptor signaling was 
assessed by site-directed mutagenesis. Rat basophilic leukemia cells (RBL-2H3) 
transfected with the human IgE binding subunit (FceRla.), incorporating either 
asparagine (D194N) or threonine (D194T) polar substitutions, a functional rat/human 
chimeric receptor complex similar to wild type (D194) was formed. When activated 
via hulgE and antigen, mediator release, intracellular calcium mobilisation and 
tyrosine phosphorylation of y-chain and Syk kinase was obtained while a non-polar 
substitution (D194L) supported cell surface expression but failed to initiate 
downstream signaling. 
No cell surface expression of mutant huFceRla. gene constructs was observed when 
D194 was replaced with the non-polar Ile (D1941) residue of similar size, the larger 
positively charged Arg (D194R) or lysine (D194K) residues, the negatively charged 
glutamate (D194E) or the smaller polar Ser (D194S) non-polar Ala (D194A) and V 
(D194V). These observations highlight importance of both the size and charge of 
amino· acid residue at position 194 in determining lgE receptor subunit interactions, 
cell surface localization, distribution and signaling. 
148 
•· 
Appendix I 
Introduction 
The high-affinity IgE receptor (FcERI) is expressed as a tetrameric complex (aP12) on 
mast cells and basophils and consists of an extracellular Fc£Rla subunit that engages 
its ligand, a membrane spanning FcR-P subunit that acts to amplify signal 
transduction and a disulphide-linked FcR-y subunit homodimer that relays the 
activation signal intracellularly (Metzger, 1992). The FcR-y subunit is promiscuous 
and functions in homo- or hetero-dimeric forms in association with FcERI, FcyRIII, 
FcyRI, FcaRI and TCR (Kinet, 1999). Following cross-linking or aggregation of the 
receptor via an antigenic stimulus, FcR-P and FcR-y subunits become tyrosine 
phosphorylated within conserved immunoreceptor tyrosine-based activation motifs 
(ITAMs). Subsequent recruitment and activation of Syk kinase results in the initiation 
of numerous intracellular signaling pathways that culminate in the release of various 
preformed and de novo synthesized cellular mediators (Nadler et al., 2000). 
Several studies have demonstrated the importance of amino acid chemistry within 
transmembrane {TM) regions in the assembly, function and stability of numerous cell 
surface receptors. In earlier studies, COS-7 cells transfected with mutant subunits of 
the high-affinity lgE receptor showed that even minor changes within the TM regions 
could invoke major effects on receptor function and loss of cell surface expression 
(Varin-Blank and Metzger, 1990). More recently, chimeric receptors consisting of the 
extracellular human Fc£Rla (huFcERla), varying TM regions (wild-type and mutant 
TCR-t;, the IL-2 receptor a-chain Tac, transferrin and the phosphatases PTP-a and 
CD45) and TCR-~ cytoplasmic domains expressed in the RBL-2H3 cell line, 
demonstrated disparate effects on cell surface expression or subsequent signaling 
events depending on the source of the TM, thus substantiating an essential role for 
TM segments in FcR signaling (Gosse et al., 2005). The TCR consists of two 
extracellularly oriented heterodimeric glycoproteins {TCR-a and TCR-P) that are 
non-covalently linked to the CD3 complex (CD3-y, -8, -£ and -t;) (Samelson, 2002). 
Previous investigations have established the importance of conserved charged TM 
residues within the TCR as crucial for receptor assembly, cell surface expression and 
functional competence (Call et al., 2002). Similarly, a D to N substitution in the 
second TM domain of the C5a receptor abolished signaling while ligand binding was 
preserved (Monk et al., 1994). Furthermore, site-directed mutagenesis to investigate 
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the role of a conserved R in the TM domain of FcaRI demonstrated the requirement 
of a positively charged residue in mediating a functional association with the FcR-y 
subunit and consequent signal transduction (Morton et al., 1995). 
The identification of an invariant eight amino acid motif (LF A VDTGL) containing a 
polar aspartate residue within the TM domains of FcERia and FcyRIIIa from rat, mice 
and humans (Farber and Sears, 1991; Ravetch and Kinet, 1991) suggested a functional 
role in receptor mediated signalling. Subsequently, a model was proposed depicting 
possible TM domain helix-helix interactions between charged residues in rat FcyRIIIa 
and FcR-y, mediated in part by the negatively charged D and a corresponding 
positively charged K in the FcR-y, to allow optimal counterbalancing of electrostatic 
interactions. Furthermore, due to the conserved nature of the invariant TM motif, the 
authors proposed that their model was also applicable to FcERia and FcR-y TM 
domain helix-helix interactions (Farber and Sears, 1991). 
The aim of the present study was to examine the role of the D 194 residue within the 
TM domain of the huFcERla subunit on cell surface expression and FcERl-mediated 
signaling. In the current study, the parental rat basophilic leukemia (RBL-2H3.1) cell 
line (Bingham et al., 1994), referred to hereafter as RBL-2H3, was chosen as host for 
gene constructs encoding wild-type and mutant hufcERia subunits. Previous studies 
have shown that in RBL-2H3 cells the transfected huf cERia subunit forms a 
functional chimeric rat/human receptor complex with endogenous FcR-P and FcR-y 
subunits, which can be specifically activated via a human lgE (hulgE) mediated cross-
linking stimulus to mediate cell secretion (Gilfillan et al., 1992; Wilson et al., 1993). 
Our study demonstrates that cells transfected with wild-type (D194) and mutated 
variants (DI 94N, D194T and D194L) of the huFcERia subunit are expressed at the 
cell surface in association with endogenous FcR-P and FcR-y subunits. Cell 
transfection with other mutant hufcERia variants was attempted, but constructs 
encoding D194A, D194E, D194V, D194S, D1941, D194R and D194K failed to 
support cell surface expression. D194, D194T and D194N transfected cell lines 
demonstrated FcERI aggregation, tyrosine phosphorylation of FcR-y and Syk kinase, 
intracellular Ca2+ mobilization and mediator release in response to antigen-mediated 
150 
.. 
Appendix/ 
activation, analogous to that observed with the RBL-2H3 cell line. In contrast, RBL-
2H3 cells transfected with the mutant D194L gene construct supported cell surface 
expression but showed no evidence of FcERI-mediated signaling in response to the 
same antigenic stimulus. Based on these observations, we propose that interaction 
between D194 in FcERla and T22 in FcR-y TM domains is essential for expression of 
functional FcERI. 
Materials and Methods 
Reagents and immunoglobulins - Cell culture reagents were purchased from Sigma-
Aldrich (Dorset, UK) and fetal calf serum from Autogen Bioclear (Wilts, UK). All 
enzymes used for DNA manipulation and 'Complete Protease Inhibitor Cocktail' 
tablets were purchased from Roche Applied Science (Sussex, UK). DNA purification 
kits were purchased from Promega (Madison, USA) and Qiagen (Crawley, UK). DNA 
primers for PCR were synthesized in-house by Dr. A.J.G Moir in the Krebs Institute, 
University of Sheffield and VH Bio (Gateshead, UK). Dinitrophenol-human serum 
albumin (DNP-HSA) was obtained from Sigma-Aldrich and 4-hydroxy-3-iodo-5-
nitrophenylacetyl-human serum albumin (NIP-HSA) was prepared from NIP-OSu 
(Sigma-Genosys). NIP-specific human lgE (or hulgE, JW8, a chimeric mouse/human 
lgE with specificity for the hapten NIP) tissue culture supernatant was obtained in 
house by culturing transfected myeloma cells, as was DNP-specific mlgE ( or mlgE, 
SPE-7 supernatant). Human IgE and biotinylated goat anti-human lgE for F ACS was 
purchased from Serotec (Kidlington, Oxford, UK) and Vector Laboratories Ltd. 
(Peterborough, UK), respectively. Anti-phosphotyrosine, clone 4G 10 and anti-FcR-y 
subunit antibodies were purchased from Upstate Biotechnology (Lake Placid, USA). 
Monoclonal and polyclonal antibodies to Syk kinase were purchased from Abeam 
Ltd. (Cambridge, UK) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. 
Goat anti-mouse and anti-human IgE were both purchased as FITC conjugates from 
Bethyl Laboratories (Montgomery, USA). All other reagents and antibodies were 
obtained from Sigma-Aldrich, unless stated otherwise. 
Expression vector construction and cell transfection - cDNA for huFceRia, (a kind 
gift from Drs U. Blank and J-P. Kinet) was used as a template for PCR to generate 
. 
both the wild-type construct and constructs containing the targeted mutations of 
D194N, D194L, D194T, D194V, D194R, D194S, D194A, D194E, D194K and 
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D194I. Site directed mutagenesis by Overlap Extension PCR (Ho et al., 1989) or 
Quickchange Site- Directed Mutagenesis Kit (Stratagene, USA) was used to generate 
constructs. The following primers were generated: 
5' external 5'- ATCAAGCTTATGGCTCCTGCCATG-3' [1]; 3' external 5'-
ATGCTTGAATTCTCAGTTGTTTTTGGGGTT-3' [2]; Mutagenic pnmers; 
D194L5' 5'-GCTGTGCTCACAGAA-3' [3]; D194L3' 5'-TTGTGTGAGCACAGC-
3'[4]; D194N5' 5'-GCTGTGAACACAGGATTA-3'[5] D194N3' 5'-
T AA TCCTGTGTTCACAGC-3 '[6]; D 194T5' 5 ' - GGTGATTCTGTTTGCTGTG 
ACCACAGGCCTATTTATCTCAACTCAGCAG-3'[7]; D194T3' 5'- CTGCTG 
AGTTGAGAT AAA TAGGCCTGTGGTCACAGCAAACAGAATCACC-3 '[8]; 
D 194V5' 5 ' - GGTGATTCTGTTTGCTGTGGTCACAGGCCTATTTATCTCAACT 
CAGCAG-3 '[9]; D 194V3' 5 ' - CTGCTGAGTTGAGAT AAA TAGGCCTGTGAC 
CACAGCAAACAGAATCACC-3' [10]; D19415' 5'- GGTGATTCTGTTTGCT 
GTGATTACAGGCCTATTTATCTCAACTCAGCAG-3'[11]; D19413' 5' - CTG 
CTGAGTTGAGATAAATAGGCCTGT AATCACAGCAAACAGAATCACC-3' 
[12]. D194S5' 5'- GGTGATTCTGTTTGCTGTGTCCACAGGATTATTTATCTCA 
ACTCAGCAG-3'[13]; D194S3' 5' - CTGCTGAGTTGAGATAAATAATCCTGT 
GGACACAGCAAACAGAATCACC -3'[14]; D194R5' 5'- GGTGATTCTGTTT 
GCTGTGCGTACAGGATTATTTATCTCAACTCAGCAG-3'[15]; D194R3' 5' -
CTGCTGAGTTGAGATAAATAATCCTGTACGCACAGCAAACAGAATCACC-
3'[16]; D194A5' 5'- GCTGTGGCCACAGGATTA - 3' [17]; D194A3' 5'-
TAATCCTGTGGCCACAGC - 3' [18]; D194E5' 5'- GCTGTGGAAACAGGATTA 
- 3' [19]; D194E3' 5'- TAATCCTGTTTCCACAGC - 3' [20]; D194K5' 5'-
GCTGTGAAAACAGGATTA- 3' [21]; D194K3' 5'-TAATCCTGTTTTCACAGC -
3' [22]; 
The restriction sites Hind III and EcoRI were incorporated into primers to facilitate 
cloning into the pEE6 expression vector (Celltech, Slough, UK). An additional silent 
mutation in the form of Stu I was also incorporated in primers [7-12] to aid in 
assessing the presence of mutation with the help of restriction digestion with Stu I and 
resolution on TAE agarose gel. Reaction mix for PCR was as follows: 5µ1 lOX 
reaction buffer (supplied with enzyme), 50ng template, lµl dNTPs, primers 125ng 
each, ddH2O to a final volume of 50µ1 to which 1µ1 of PfuUltra HF DNA polymerase 
was added. The PCR cycling conditions were as follows: 95°C/30 s, 95°C/30 s, 
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55°C/60 s and 68°C for 60sec/kb of plasmid length, 12-18 cycles, according to 
manufacturer's instructions. The PCR products were resolved on 1 % TAE gels at 100 
mA/h, and the resulting bands purified using Wizard® PCR kits according to the 
manufacturer's instructions (Promega). The initial round of PCR was used to generate 
a template for the second round (Ho et al., 1989), which was again purified as 
described, and digested with the restriction endonucleases Hind III and EcoRI to 
facilitate cloning, initially into pUC18 and subsequently into the expression vector 
pEE6. Ligation was carried out at each step using T4 DNA ligase according to the 
manufacturer's instructions. Resulting DNA clones were sequenced for authenticity at 
each step using Cogenics (Takeley,UK) and results were then analysed using ALIGN, 
CHROMA and CLONE computer programmes to compare the sequence with 
genomic huFcsRia subunit and check mutations were 'in-frame'. The primers used 
for the sequencing were M13-48REV and M13For-40 to read the DNA from both 
ends. Transfection quality DNA was prepared using a commercial kit purchased from 
Qiagen. RBL-2H3 cells (107 cells/0.8ml) were transfected by electroporation (Bio-
Rad, Hercules, CA) using 20µg of DNA in a cuvette at 250V, 960 µFD according to 
the manufacturer's instructions. 24 h post-transfection, selection media was added 
(800µg/ml Geneticin, G-418 sulphate, lnvitrogen, Carlsbad, USA) for 5 days, after 
which a concentration of 400µg/ml Geneticin was maintained. Cells expressing high 
levels of the transfected receptor gene were sorted using flow cytometry. 
Flow Cytometry - Cells transfected with gene constructs encoding D194, D194N, 
D194T, D194V, D194R, D194S, D194I and D194L huFcsRia subunits were 
monitored and selected for highest receptor number expressing cells by flow 
cytometry. Briefly, cells (lx106-107/ml) were washed in PBS, harvested with a non-
enzymatic cell dissociation solution (Sigma-Aldrich) and resuspended in wash buffer 
(PBS containing 1 % fetal calf serum). Cells were incubated with huigE (1- lOµg, 
proportional to cell numbers) and biotinylated goat anti-human IgE (1/400 dilution) 
followed by a final incubation with streptavidin R-phycoerythrin (1/25 dilution). 
Samples were analysed using a FACsAria/ Facscalibur (BD Biosciences) or FASort/ 
FACS™ CYAN ADP flowcytometer (Dakocytomation). Following FACS sorting 
cells were grown and expanded for several generations and taken into suspension with 
cell dissociation medium prior to analysis. 
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Cell culture and activation - RBL-2H3 cell lines were maintained in culture as 
described previously (Bingham et al., 1994). D194, D194N, D194T, D194V, D194R, 
D194S, D1941 and D194L transfected cell lines were maintained in the same media 
supplemented with Geneticin (400 µg/ml). For receptor activation, RBL-2H3 and 
huFcERla transfected cell lines were sensitized for 16 h with either DNP-specific 
mlgE (1 ug/ml) or NIP-specific hulgE (1 ug/ml), respectively. Cells were harvested in 
cell dissociation solution and resuspended at 5x106/ml in a buffered solution (120mM 
NaCl, 5mM KCI, 25mM PIPES, 0.04mM MgC12, lmM CaCh, final pH 7.4). Cells 
were activated with the appropriate cross-linking agent (DNP or NIP coupled to HSA) 
at a final concentration of 1 00ng/ml and solubilized in RIP A lysis buffer ( 1 % NP-40, 
150mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 50 mM Tris, pH 7.4, 
supplemented with 1 mM Na3 VO4 and a Complete Protease Inhibitor Cocktail tablet). 
Post-nuclear supernatants (PNS) were obtained by centrifugation at 12000g for 15 
mm. 
P-hexosaminidase release assays - Cells were cultured, harvested, resuspended at 
0.5x106/ml in appropriate media with DNP specific mlgE/NIP specific hulgE (SPE, 
1/500) and plated 100µ1/well into 96 well plates. Next days, cells were washed with a 
buffered solution and activated with DNP-HSA/NIP-HSA cross-linking agent (0.1-
1 0000ng/ml) for 20 minutes prior to incubation with 50µ1 P-hexosaminidase substrate 
(p-nitrophenyl N-acetyl P-D-glucosaminide diluted to a final concentration of2mM in 
citrate buffer, pH 4.5) for 2-3 hours at 3 7°C. The reaction was stopped by addition of 
150µ1 lM TRIS-HCl, pH 9.0, and product absorbance visualized using an ELISA 
plate reader set to 405nm wavelength (Millenia Kinetic Analyser) against 
substrate/buffer blank. Total P-hexosaminadase cell content was obtained by cell 
disruption using Sirganian buffer supplemented with 1 % Triton-XlO0. Experiments 
were carried out in triplicate and mean values ± SD presented. 
Ca2+ mobilization - Cells were harvested in cell dissociation solution and washed in 
PBS. lx107 cells were resuspended in the appropriate media and incubated at 37°C for 
1 h with 1 0µg/mi of either DNP-specific mlgE or NIP-specific hulgE. Following 
incubation, cells were sedimented and resuspended at a density of 5x106/ml in a 
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buffered solution (120mM NaCl, 5mM KCl, 0.04mM MgC}i, lmM CaC}i, 25mM 
PIPES, final pH 7.4). The Ca2+ probe Fluo-3 AM was added at a final concentration 
of 5µM. Cells were incubated for 15 min at 37°C, after which aliquots of lx106 cells 
were analysed on a Facscalibur flow cytometer (BD Biosciences). After a baseline 
reading was taken, DNP-HSA or NIP-HSA was added as appropriate (l00nglml). In 
the unresponsive cell lines (D194L, D194V, D194R, D194S and D1941), ionomycin 
(1 0µM) was used as a positive control, demonstrating that the cells had been 
adequately loaded with Fluo-3 AM. 
lmmunoprecipitation and immunodetection - A standard Bradford assay (Bio-Rad, 
Hercules, USA) was performed with an aliquot of PNS to allow normalization 
between samples. Normalised PNS was incubated with respective antibodies (lµg/mg 
PNS) overnight at 4°C and precipitated with Protein A-agarose (Upstate 
Biotechnology, Lake Placid, USA) for 4 h. Immunoprecipitates were washed in ice-
cold RIPA lysis buffer and eluted in SDS sample buffer (50mM Tris, pH 6.8, 2% 
SDS, 10% glycerol and 100 mM DTT) prior to separation by 12.5% SDS-PAGE and 
subsequent electrophoretic transfer of protein to PVDF membranes (Amersham 
Biosciences). Membranes blocked either in 3% BSA (for anti-phosphotyrosine, clone 
4G10) or 5% non-fat milk (for all other primary antibodies) in PBS/Tween (0.1 %) 
were incubated with primary antibodies and HRP-conjugated secondary antibodies, as 
indicated, for I h each. Proteins were visualized by using the Enhanced 
Chemiluminescence (Amersham Biosciences). 
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Results 
(i) Cell surface expression of huFcdUa in transfected cell lines: Gene constructs 
encoding wild-type and mutant variants, where D 194 in the TM domain of the hulgE 
receptor ligand binding subunit has been replaced by codons specifying charged, polar 
and non-polar amino acids, were transfected into RBL-2H3 cells. Stable cell surface 
expression was observed following transfection of the wild-type gene and genes 
encoding replacement of D 194 by N, T or L, while variants encoding a substitution 
with A, E, V, I, S, R or K at this position showed no evidence of cell surface 
expression of mutant receptor subunits. Fig. 1 shows analysis of transfected cell lines 
by flow cytometry from a typical experiment demonstrating positive expression where 
stably transfected cell lines were subjected to repeated cell sorting to select for the 
highest expressing cells. Furthermore, co-immunoprecipitation studies confirmed 
expression of transfected huFcERla subunits in association with endogenous FcR-~ 
and FcR-y subunits in the transfected cell lines (Iodice, 2006). 
{ii) Downstream signaling P-hexosaminidase release: Antigen-mediated cross-linking 
of the high-affinity lgE receptor on mast cells results in the release of various 
mediators, including ~-hexosaminidase, thus providing a reliable system for assessing 
mast cell degranulation (Landegren, 1984). All cell lines were assessed for their 
ability to undergo degranulation in response to an lgE-mediated antigenic stimulus 
through endogenous FcERI and transfected huFcERla receptors (Fig. 2). The D194, 
D194T and D194N transfected cell lines exhibited ~-hexosaminidase release in 
response to hulgE/NIP-HSA (selectively activating cells sensitized via the transfected 
huFcERla receptor subunit). As expected the D194V, D194R, D194S, and D1941 
transfected cell lines, which show no surface expression of huFcERla by flow 
cytometry, did not support mediator release in response to a hulgE/NIP-HSA cross-
linking stimulus. In contrast, the D194L constructs, while supporting cell surface 
expressing of huFcERI, showed no release, indicating that this mutation at D194 
residue results in abrogation of receptor-mediated degranulation. 
(iii) Downstrea_m signaling Ca2+ mobilization: lgE/antigen-mediated activation of 
mast cells results in the production of the secondary mediator IP3 which promotes 
release of Ca2+ from ER localized stores to facilitate an increase in the concentration 
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of intracellular ca2+, a process essential to the degranulation response (Scharenberg 
and Kinet, 1998). Changes in intracellular Ca2+ levels were examined in all cell lines 
passively sensitized with the lgE for the appropriate species and subsequently loaded 
with Fluo 3-AM prior to challenge with the corresponding antigen. Ca2+ mobilization 
was assessed using flow cytometry. As shown in Fig. 3, cell lines showed an almost 
immediate increase in cellular Ca2+ levels following the addition of DNP-HSA, 
peaking around 20 s after stimulation. Similarly, the D194, D194T and D194N 
transfected cell lines demonstrated a significant increase in cellular Ca2+ levels 
following the addition of NIP-HSA. In contrast, the D194L, D194V, D194R, D194S, 
and D1941 transfected cell lines showed no increase in levels of intracellular Ca2+ 
following the addition of NIP-HSA. The Ca2+ ionophore ionomycin was used as a 
positive control in the unresponsive D194L, D194V, D194R, D194S, and D1941 
transfected cell lines demonstrating the capacity of the transfected cells to support 
Ca2+ mobilization (Fig. 3). 
(iv) Tyrosine phosphorylation of FcR-y and Syk kinase: Previously, we and others 
have established tyrosine phosphorylation of multiple proteins within 10-20 s of IgE-
receptor-mediated activation including the FcR-y subunit ITAMs and Syk kinase as a 
prerequisite to degranulation (Paolini et al., 1991 ). Immunoprecipitation studies 
demonstrated tyrosine phosphorylation of FcR-y subunits at ~14.3 kDa (Fig. 4) and 
Syk kinase at ~ 72kDa (Fig. 4) in response to antigen-mediated cross-linking of 
corresponding receptor subunits in the RBL-2H3, D194, D194T and D194N cell lines. 
In contrast, receptor activation of the D194L transfected cell line with NIP-HSA 
showed no evidence of tyrosine phosphorylation of either FcR-y or Syk kinase. To 
determine if the block in signal transduction and subsequent Ca2+ mobilization was 
due to defective receptor function caused by the D194L mutation within the huFc£Rla 
TM domain of this variant, the tyrosine phosphorylation status of FcR-y and Syk 
kinase was assessed following receptor-mediated activation. Receptor activation of 
D194L transfected cell line by NIP-HSA showed no evidence of tyrosine 
phosphorylation of either FcR- y or Syk kinase suggesting a medium sized polar 
residue at position 194 in Fc£RI facilitates receptor phosphorylation and subsequent 
signaling events leading to degranulation (Iodice, 2006). 
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Discussion 
• RBL-2H3 cells when transfected with wild-type (D194) and mutated variants 
(D194N, D194T and D194L) of the huFcERla subunit expressed at the cell surface in 
association with endogenous FcR-~ and FcR-y subunits. D194, D194T and D194N, 
but not D194L transfected cell lines, evidenced robust tyrosine phosphorylation of 
FcR-y subunits and Syk kinase, intracellular Ca2+ mobilization and degranulation in 
response to NIP-HSA. In contrast exchanging Asp with isoleucine (D1941), valine, 
(D194V) serine (D194S), alanine (D194A), glutamic acid (D194E), lysine (D194K) 
and arginine (D194R) failed to support cell surface expression of the mutant ligand 
binding domain. Interestingly we find that there is no correlation between lgE-
mediated, antigen induced levels of mediator release and levels of receptor expression 
confirming earlier observations (Sayers et al., 1998). This rules out that a reduction in 
the numbers of the ligand binding domain of the receptor complex can account for the 
failure of the mutant receptor subunit to induce downstream signalling and 
degranulation. 
Based on results obtained in the current study, a new structural model was developed 
~o account for interactions in the TM domain between the D194 residue and FcR-y 
subunits (Fig. 5). The model envisages the interaction between two FcR-y subunit TM 
helical segments (residues 6-26) which are arranged in a parallel conformation and 
restrained by forming the disulphide bond between cysteine residues (C7) in each 
subunit. A third helix corresponding to the FcERla TM sequence (residues 181-189) 
was orientated against these two helices in order to optimize interactions. D 194 is 
predicted to face into the interior of the three-helix bundle to form hydrogen-bonding 
interactions with T22 in both FcR-y subunits. Since the FcR-~ subunit is not essential 
for cell surface expression of human Fc&Rla and endogenous FcR-y subunits (Varin-
Blank and Metzger, 1990), this model addresses only the interaction between the 
minimal essential receptor subunits involved in FcERl-mediated signaling. The 
predicted interaction would stabilize all three residues in the interior of the TM helical 
bundle. The molecular model developed as a result of the current mutagenesis study 
differs significantly from that proposed previously (Farber and Sears, 1991), which 
suggested the negatively charged D203 (rat Fc-yRIIla) homologous to D 194 in the 
FcERla subunit, would interact with the positively charged K.29 (FcR-y). Our model 
predicts that K.29 occurs in the relatively hydrophilic sequence RLKIQV and places 
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its location into the cytoplasmic rather than in the TM region. In addition, the earlier 
study assumed a transmembrane 1:1 stoichiometry (Farber and Sears, 1991), rather 
than a 2:1 association of FcR-y and FcERla subunits, as envisaged in our model. 
Indeed, a recent study has implicated T22, along with other residues, in the formation 
of a central interface that is presumably involved collectively in interacting with the 
FcERla TM domain (Wines et al., 2006). 
According to the model proposed the side-chain of residue 194 is placed in a closely 
packed central position at the interface between the transmembrane helices where 
there will clearly be severe restraints as to which side chains can be accommodated. 
This is consistent with the results which demonstrates that the residue at 194 be a 
polar residue of medium size (Asp, Asn, Thr) capable of making two separate 
hydrogen bonds with the Thr22 residue in the two FcR-y subunits. The mutation to 
almost similar sized non-polar Ile (D1941) failed to exhibit surface expression as it is 
essentially different in polarity despite occupying a similar space as Asp. The polar 
Thr mutation (D194T) is able to maintain receptor expression and function while the 
almost similar sized non-polar valine (D194V) is disfavoured as it is incapable of 
hydrogen bonding. It is evident that only slightly larger polar residues Glu (D194E) 
and polar Lys (D194K) and much larger sized polar Arg (D194R) did not support cell 
surface expression, although like Asp, Asn and Thr, the residues Glu, Lys, and Arg 
should also be capable of making the predicted hydrogen bonds thus reflecting the 
critical nature of the packing restraints at this position. Similarly the smaller sized 
residues non-polar Ala (D194A) and polar Ser (D194S) failed to act as a suitable 
substitution at the 194 position as no surface expression was witnessed in the D194A 
and D 194S transfected cells. It is possible that in all the above-mentioned mutations 
the correct assembly of the three transmembrane helices is compromised and thus 
correct assembly at the cell surface does not take place. 
The D 194N mutation maintains receptor function as TM and downstream signaling 
are not affected, possibly due to the fact that N shares similar properties with D, even 
though there is a charge difference. The signaling properties of the variant receptor 
subunit are most likely to be maintained by virtue of similar polar properties of the 
residues as it is expected that the polar Asp serves to stabilise the receptor complex by 
forming side-chain/side-chain inter-helical hydrogen bonding with the other subunits. 
Although the amide side chain of N does not ionize, it is polar and can act as a 
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hydrogen bond donor and acceptor, suggesting the importance of polarity, rather than 
charge, of TM residues in the initiation of downstream signaling events. In contrast, a 
previous study showed that mutation of D-+N in the putative second TM domain of 
the C5 complement receptor (C5a) resulted in abrogation of intracellular signaling 
following transfection of the mutant receptor without affecting ligand binding (Monk 
et al., 1994). 
D and L essentially differ in polarity, and the latter non-polar substitution at residue 
194 is associated with a failure to transmit a cross-linking stimulus into a secretory 
response. The observed signaling defect could be due to a loss of polarity resulting 
from this substitution, compounded by a change in the size of the TM helix, which 
could affect the rotational and/or translational shift of the ligand binding subunit 
relative to other TM components that need to be in proper register to function co-
operatively. 
The model proposed for FceRialy chain interaction in the current study should be 
substantiated by probing the interaction with T22 in FceRiy. Using a variant of the 
RBL cell line described as FceRiy chain deficient, (gift of Prof. Draber, Univ of 
Prague) (Bocek et al., 1995) we still observed basal expression of the FceRI complex 
in these cells rendering them unsuitable for verifying the predictions made by the 
model developed in our study (Rashid, 2009). 
A more detailed understanding of the interaction between FceRICXi an9 FceRiy at the 
molecular level, may form the basis for the development of therapeutic agents aimed 
specifically at the inhibition of FceRI-mediated cell signaling in allergic disease 
linked to mast cell desensitization and should guide the development of 'molecular 
wedges', analogous to anti-cancer drugs, which inhibit neu oncogene receptor 
aggregation or T-cell receptor signaling (Lofts et al., 1993; Manolios et al., 1997) and 
may have wider applications for the development of selective inhibitors of 
immunoreceptor-mediated pathologies. These core peptides are not only anchor 
proteins but appear to function by inhibiting downstream signalling by blocking 
receptor subunit interactions in the membrane. The most interesting aspects of these 
peptides is their ability to internalize to many cell types without any apparent side 
effects. (Huynh et al., 2003) suggesting they may form the basis for a new class of 
anti-allergic drugs. 
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The abbreviations used are: DNP-HSA, dinitrophenol-human serum albumin; FcR-J3, FceRI beta 
subunit; FcR-y, FceRI gamma subunit; IP, immunoprecipitation; huFceRia., human FceRI alpha 
subunit; hulgE, human IgE; NIP-HSA, 4-hydroxy-3-iodo-5-nitrophenylacetyl-human serum 
albumin; PNS, post-nuclear supernatant; PVDF, polyvinylidene difluoride; RBL, rat basophilic 
leukemia; RIP A, radioimmunoprecipitation assay; Tac, IL-2 receptor a-chain; TM, 
transmembrane; WB, western blot. 
figure Legends 
fig. 1. Assessment of cell surface receptor expression in RBL-2H3 cells transfected with gene 
constructs encoding wild-type and mutant huFceRia subunits. Cells were harvested and labeled 
With human IgE, biotinylated goat anti-human IgE followed by streptavidin R-phycoerthrin. Cell 
Populations were assessed for huFcsRI transfected receptor expression by flow cytometry. Figure 
A shows control for B, C and D. Figure E shows control for F, G and H. Figure I shows control 
for J and K. 
Fig. 2. P-hexosaminidase secretion profiles of RBL-2H3 and transfected cell lines. Cells were 
harvested, sensitized for 16 hours with DNP-specific mlgE or NIP-specific hulgE and activated 
with the appropriate cross-linking agent i.e. DNP-HSA or NIP-HSA (0.1-lO000ng/ml) (16). 
Released J3-hexosaminidase is expressed as a percentage of total J3-hexosaminidase. Fig 2 shows 
cells activated through endogenous and transfected huFceRia. receptors with DNP-specific 
mlgE/DNP-HSA 3?d through transfected huFceRia. receptors with NIP-specific hulgE/NIP-
HSA. Data represent mean± S.D. from three separate experiments performed in triplicate. 
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fu:. ~ Ca2+ mobilization of RBL-2H3 and transfected cell lines in response to receptor 
activation. Cells were sensitized with DNP-specific mlgE (lµg/ml) (A) and NIP-specific hulgE 
(lµg/ml) (B-J). lgE-primed cells were loaded with Fluo-3 AM (5µM) and analyzed on a 
Facscalibur flowcytometer (BD Biosciences) (see Materials and Methods). A base reading was 
obtained prior to the addition of the appropriate cross-li~ing agents (lO0ng/ml DNP-HSA, NIP-
RSA or 1 0µM ionomycin). Data are representative of five separate experiments. (A) Cells 
sensitized with DNP-specific mlgE/ DNP-HSA as control (B) D194T (C) D194I (D) D194V (E) 
D194R (F) D194S (G) D194 (C) D194N (D) D194L (E) D194L sensitized with ionomycin 
(l0µM). 
fig. 4. Tyrosine phosphorylation of FcR-y and Syk kinase following aggregation of endogenous 
and transfected huFceRJa receptors. Cells sensitized overnight with DNP-specific mlgE (RBL-
2H3) or NIP-specific hulgE (D194, D194N, D194T and D194L) were harvested and activated 
With the appropriate cross-linking agent i.e. DNP-HSA or NIP-HSA (l00ng/ml) for 2 min. Cells 
Were lysed in RIP A buffer and immunoprecipitation of the PNS (RBL-2H3 cells ~3mg/ml and 
huFcERla transfectants ~6mg/ml) was performed either with anti-phosphotyrosine (clone 4GI0) 
or polyclonal anti-Syk antibodies. Immunoprecipitates were resolved by SDS-P AGE, transferred 
to PVDF membranes and probed with monoclonal anti-phosphotyrosine (clone 4G10), anti-Syk 
or polyclonal anti-FcR-y antibodies as indicated. FcR-y quantification was achieved by 
immunodetection of the PNS (taken prior to immunoprecipitation) with antibodies to the FcR- y 
subunit. _Data are representative of seven separate experiments. 
Figure 5. Modeling oftransmembrane helices. The transmembrane regions of both FcERla and 
FcR-y subunits were identified from NCBI annotation and confirmed by hydropathy plots (Kyte 
and Doolittle, 1982) . A model was constructed from two FcR-y subunit helices (linked by a 
disulphide bond between C7 in each FcR-y subunit) and one helix of the Fc(Rla subunit (centre), 
all with inter-helical angles of approximately -25°. This aimed at exposing the majority of 
hydrophobic side chains on the outside of the three-helix bundle, so as to permit favorable 
interactions with lipid tail groups in the membrane. The model positioned D194 of the FcERla 
subunit in hydrogen bonding distance from T22 residues present in both FcR-y subunits 
(indicated by ~ows). This model was then subjected to energy minimization using the X-PLOR 
program (Brunger et al., 1987) in order to improve stereochemistry and to optimize contacts. 
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